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I.1 Regulation of vascular smooth muscle tone 
In the cardiovascular system, the contractile tone of vascular smooth muscle cells plays a 
central role in the regulation of blood pressure and distribution of blood flow [1]. The heart 
continuously pumps blood throughout the body ensuring sufficient blood pressure and 
blood supply at the entrance of organs and tissues. However, local mechanisms will 
modulate blood flow within the tissues according to their metabolic and functional needs. 
This modulation depends on a wide range of extracellular signals including neuronal, 
humoral, ionic and mechanical forces. Besides the nervous system, also the endothelium, 
which covers the inner surface of all blood vessels, is very important as it releases various 
vasoactive factors in response to the external signals. A tightly regulated balance between 
contractile and relaxant factors eventually determines the level of smooth muscle tone and 
thus the diameter of the vessels, vascular resistance and blood flow within the organs. 
Furthermore, the mechanism of penile erection also relies on the contraction/relaxation 
balance of (vascular) smooth muscle cells [2]. Vasorelaxation is responsible for adequate 
blood supply in the penis which is necessary to induce erection. Contraction of the penile 
smooth muscle cells, on the other hand, initiates detumescence of the erected penis 
returning it to its flaccid state.  
 
Figure I.1: Influence of [Ca
2+
]i and RhoA on vascular smooth muscle tone and its regulation by cyclic 
nucleotide-dependent protein kinases. Green arrows stimulation and red arrows inhibition (adapted from [1]). 
I.1.1 Vascular contraction 
In general, vascular smooth muscle contraction occurs in response to elevated 
concentrations of intracellular Ca2+ ([Ca2+]i) either resulting from an electromechanical or a 
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pharmacomechanical coupling or a combination of both. A rise of [Ca2+]i by stimuli which 
depolarize the cell membrane (KCl, mechanical stretch), subsequently activating voltage-
operated Ca2+ channels (VOCC) and inducing Ca2+ influx, has been referred to as 
electromechanical coupling. In contrast, pharmacomechanical coupling depends on 
receptor-mediated stimuli activating G-protein signaling and generation of second 
messengers and is independent of direct changes in membrane potential [1,3,4]. Both 
pathways lead to Ca2+-dependent activation of myosin light chain kinase (MLCK) and actin-
myosin cross-bridging. Because of the increase in [Ca2+]i, free Ca
2+ will bind the protein 
calmodulin with formation of a Ca2+4-calmodulin complex (Ca-CaM) which removes the 
pseudo substrate domain from the catalytic core of MLCK. After resolving this auto-
inhibition, activated MLCK phosphorylates the 20 kDa myosin light chain (MLC) bound to the 
head–neck junction of the myosin heavy chains permitting actin access. Ultimately, vascular 
smooth muscle contraction will occur due to actin-induced activation of the myosin ATPase 
activity which leads to actin-myosin cross-bridge cycling in the presence of adenosine 
triphosphate (ATP) (Fig. I.1) [1,3,5-8].  
 
 
Figure I.2: Mechanisms involved in the increase and decrease of [Ca
2+
]i in vascular smooth muscle cells and 
regulation by cyclic nucleotide-dependent protein kinases. Green arrows stimulation and red arrows inhibition 
(adapted from [1]). 
 
Vascular contractile tone is mainly regulated by sympathetic neurons innervating the arterial 
wall. When an action potential reaches the terminal axon, the elevated open probability of 
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the plasmamembrane Ca2+ channels increases intraneuronal Ca2+ concentration triggering 
the release of norepinephrine (NOR) [9]. NOR will cross the neuromuscular junction to bind 
predominantly to α1-adrenergic receptors on the smooth muscle membrane [10]. 
Stimulation of the α1-receptor activates phospholipase C (PLC) which in turn catalyzes the 
conversion of phosphatidyl-inositol-4,5-biphosphate (PIP2) into two important second 
messengers: inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG) (Fig. I.2). IP3 induces 
the release of Ca2+ from intracellular stores by binding its receptors on the sarcoplasmic 
reticulum. DAG activates protein kinase C (PKC) which controls various cellular processes 
such as transmembrane Ca2+ transport and Ca2+ sensitivity of the myofilaments. Besides 
NOR, several other contractile agonists (tromboxane A2, vasopressine, endothelin, 
angiotensin II, etc.) elicit vascular contraction by the phosphatidyl-inositol pathway 
mentioned above after interaction with their respective G-protein coupled receptors 
[1,3,6,7]. 
 
 
Figure I.3: The RhoA-Rho kinase signaling pathway in which RhoA cycles between an inactive GDP-bound and 
an active GTP-bound conformation regulated by guanine nucleotide exchange factors (GEFs), GTPase-
activating proteins (GAPs) and guanine nucleotide dissociation inhibitors (GDIs) (adapted from [11]). 
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In addition to the initial smooth muscle contraction induced by [Ca2+]i-dependent activation 
of MLCK, further force generation relies on a Ca2+ sensitization mechanism modulating  
MLC phosphatase (MLCP) activity. MLCP, a heterotrimeric enzyme, regulates the 
MLC phosphorylation state by removing the high-energy phosphate. The RhoA-Rho kinase 
pathway inhibits MLCP altering the MLCK/MLCP activity ratio in favor of MLC 
phosphorylation which leads (indirectly) to smooth muscle contraction [6,7,12,13]. RhoA, a 
member of the Rho GTPase family, acts as a molecular switch, cycling between an inactive 
guanosine diphosphate (GDP)-bound and an active guanosine triphosphate (GTP)-bound 
form. This GDP-GTP cycling is controlled by several regulatory proteins, including guanine 
nucleotide exchange factors (GEFs), GTPase-activating proteins (GAPs) and guanine 
dissociation inhibitors (GDIs). Generally, the inactive GDP-bound form of RhoA is locked in 
the cytosol by GDI, which stabilizes the complex and prevents membrane translocation of 
RhoA. Agonist-induced activation of G-protein coupled receptors results in an interaction 
with Rho GEFs, catalyzing the exchange of GDP to GTP and the dissociation of GDI. Activation 
of RhoA is turned off by GAPs that enhance the intrinsic GTPase activity of the Rho protein, 
leading to the hydrolysis of GTP to GDP [11,14-17]. Activated RhoA-GTP directly interacts 
with Rho kinase inducing a conformational change which leads to activation of this 
serine/threonine kinase towards specific substrates [18]. One of these substrates is the 
regulatory myosin-binding subunit of MLCP, namely myosin phosphatase target subunit 
isoform 1 (MYPT-1). Phosphorylation of MYPT-1 at certain threonine residues inhibits MLCP 
activity [13,19-21]. Rho kinase also inhibits MLCP indirectly by phosphorylating CPI-17, which 
becomes a potent inhibitor of the catalytic subunit of MLCP [13-15,22]. Moreover,  
Rho kinase has been shown to directly phosphorylate MLC [23]. Taken together, the  
RhoA-Rho kinase pathway leads to an increase in MLC phosphorylation to promote smooth 
muscle contraction independent of changes in [Ca2+]i and MLCK activity, thereby causing 
Ca2+sensitization (Fig. I.3). 
I.1.2 Vascular relaxation 
Reduction of smooth muscle tone is evoked by various exogenous and endogenous 
vasodilators. These compounds elicit vascular relaxation by inhibiting synthesis of contractile 
agonists, by blocking receptors which mediate smooth muscle contraction and/or by 
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decreasing [Ca2+]i [1,24]. A decrease of [Ca
2+]i will occur at multiple cellular levels as a result 
of Ca2+ uptake and Ca2+ efflux as well as inhibition of Ca2+ release and Ca2+ influx. The 
sarcoplasmic reticulum Ca2+-ATPase (SERCA) can bind Ca2+ ions which are then transported 
over the sarcoplasmic membrane. This Ca2+ uptake into the sarcoplasmic reticulum is 
reversibly inhibited by phospholamban. Phosphorylation of phospholamban relieves its 
inhibitory effect, therefore increasing SERCA activity and the rate of Ca2+ uptake. The plasma 
membrane also contains Ca2+-ATPases (PMCA) leading to Ca2+ efflux into the extracellular 
space. Moreover, Na+/Ca2+-exchangers (NCX), located on the plasma membrane, contribute 
to the Ca2+ efflux driven by the transmembrane Na+ gradient which is maintained by the 
Na+/K+-ATPase pump. Ca2+ release from the sarcoplasmic reticulum is decreased by 
inhibition of IP3 formation and/or phosphorylation of the IP3 receptor blocking the  
Ca2+ mobilization in the initial phase of agonist-induced contraction [7,25]. Hyperpolarization 
of the smooth muscle membrane (indirectly) decreases [Ca2+]i. Activation of K
+ channels 
causes K+ efflux and membrane hyperpolarization, resulting in a reduced Ca2+ influx through 
VOCC and subsequent vascular relaxation [3]. Besides influencing [Ca2+]i, vasorelaxant agents 
can alter Ca2+ sensitivity of MLC phosphorylation. Upregulation of MLCP leads to enhanced 
MLC dephosphorylation whereas phosphorylated MLCK loses its affinity for Ca-CaM which 
decreases MLC phosphorylation, both shifting the balance towards inactive MLC and thus 
vasodilation [3,8,12].  
 
Figure I.4: Regulation of intracellular cyclic nucleotide concentrations and activation of their downstream 
effector protein kinases. Green arrows stimulation [1]. 
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Vasorelaxant agents often generate intracellular second messengers after interaction with 
specific receptors, which in turn triggers a cascade of molecular reactions. Two important 
pathways can be distinguished: the cyclic guanosine monophosphate (cGMP) pathway and 
the cyclic adenosine monophosphate (cAMP) pathway (Fig. I.4). cGMP can be synthesized by 
particulate guanylyl cyclase (pGC), present in the plasma membrane, which is activated by 
natriuretic peptides. However, the main mechanism of cGMP production is through nitric 
oxide (NO)-induced activation of soluble guanylyl cyclase (sGC) in the cytosol. cAMP is 
formed by adenylate cyclases (AC) in response to G-protein coupled receptor stimulation. 
The intracellular levels of cGMP and cAMP are also controlled by phosphodiesterases (PDE) 
converting both into their inactive metabolites 5’-guanosine monophosphate (5’-GMP) and 
5’-adenosine monophosphate (5’-AMP) respectively. cGMP exerts its vasorelaxant effect by 
activating protein kinase G (PKG) whereas cAMP activates protein kinase A (PKA). However, 
each cyclic nucleotide can act through both serine/threonine kinases. For instance, PKG can 
also be activated by cAMP, although it requires nearly a 10-fold-higher concentration of 
cAMP compared to cGMP to activate this kinase. Activated PKG will decrease [Ca2+]i by 
phosphorylation of phospholamban (thus SERCA activation and Ca2+ uptake), by activation of 
PMCA and NCX (thus Ca2+ efflux), by inhibition of IP3 synthesis and phosphorylation of the IP3 
receptor (thus inhibiting Ca2+ release) and by activation of K+ channels (thus blocking VOCC 
and Ca2+ influx). Moreover, PKG alters Ca2+ sensitization by phosphorylation of RhoA as well 
as phosphorylation of MYPT-1 at certain serine residues enhancing MLCP activity. Just like 
PKG, PKA can activate SERCA and NCX, block IP3 signaling, induce membrane 
hyperpolarization and increase MLCP activity. Furthermore, PKA also alters MLCK activity by 
phosphorylation of MLCK preventing interaction with Ca-CaM (Fig. I.1 and I.2) [1,3,24]. 
Various vasodilators such as prostaglandin E1, prostaglandin I2 (prostacyclin), substance P, 
calcitonin gene related peptide and others have been suggested to influence smooth muscle 
tone [26-28]. However, their actual contribution to vessel tone regulation remains at 
question. The principal mediator of vascular relaxation is by far NO released from the 
endothelial cells acting through activation of the sGC-cGMP-PKG pathway (Fig. I.5).  
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Figure I.5: Opposing actions of NO and vasoconstrictors on vascular smooth muscle tone. Full arrows 
vasoconstriction pathway and dotted arrows vasorelaxant pathway (based on [29]). 
I.1.3 Vascular (endothelial) dysfunction 
In the Western World, cardiovascular diseases such as atherosclerosis, heart failure and 
coronary heart disease are a major health problem. Despite the significant decline in 
cardiovascular mortality in Europe over the last three decades, cardiovascular diseases 
remain the primary cause of death accounting for over 4 million deaths in Europe annually 
and even 17.3 million deaths worldwide [30,31]. A growing list of risk factors, including 
hypertension, hypercholesterolemia, smoking and diabetes mellitus are associated with 
endothelial dysfunction [32,33]. In general, endothelial dysfunction is characterized by an 
imbalance of vasoconstrictive and vasodilatory compounds, with a shift towards 
vasoconstriction. In addition, various other endothelium-derived substances and endothelial 
functions are compromised with concomitant vascular smooth muscle proliferation, 
leukocyte adhesion and activation, vascular remodeling, platelet aggregation and thrombus 
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formation [34,35]. The pathophysiological mechanism of endothelial dysfunction is 
multifactorial, but the major outcome is an impaired NO signaling. NO plays a pivotal role in 
promoting endothelial homeostasis and maintaining healthy cardiovascular functioning. 
Therefore, any lowering of NO-bioavailability and/or responsiveness towards NO could result 
in endothelial dysfunction and thus cardiovascular disease [36]. 
Impairment of NO functioning can either be an immediate consequence of lowered NO 
generation or the result of accelerated NO degradation. Altered NO formation may occur 
due to a lack of substrate or cofactors as well as a reduction of the expression and/or 
function of NO synthase (NOS), which catalyzes the production of NO. On the other hand, 
indirect decrease of NO-bioavailability is caused by oxidative stress preventing NO to exert 
its effects [37,38]. Oxidative stress refers to a condition in which cells are exposed to 
excessive levels of chemical oxygen derivatives, the so called reactive oxygen species (ROS) 
[39]. ROS include free radicals such as superoxide (O2
•−), peroxynitrite (ONOO•−) and 
hydroxyl (OH•), and non-radicals such as hydrogen peroxide (H2O2) [40]. ROS formation 
generally begins with the one-electron reduction of molecular oxygen, giving rise to O2
•−. It 
has a half-life of only a few seconds and is rapidly converted into H2O2 either spontaneously 
or via the catalytic intervention of superoxide dismutase (SOD). Within mammalian cells, 
several enzyme systems are capable of transferring electrons to molecular oxygen producing 
O2
•−, such as nicotinamide-adenine-dinucleotide phosphate (NADPH) oxidases, the 
mitochondrial electron transport chain, xanthine oxidase, NOS, cyclooxygenases, 
lipoxygenases and cytochrome P450 reductases [41]. While all of these systems are 
important in various disease states, NADPH oxidases seem to play a central role in 
cardiovascular diseases [40]. OH• is generated from H2O2 in the presence of ferrous iron 
(Fe2+) by the Fenton reaction, but is also formed by the interaction between O2
•− and H2O2. 
Furthermore, O2
•− can also react with NO leading to the highly reactive ONOO•− and, even 
more importantly, reducing NO availability [40-42]. Hence, the pathological effects of ROS in 
the cardiovascular system (and O2
•− in particular) result from their ability to scavenge and 
remove several beneficial vasoprotective compounds such as NO, but also simultaneously 
result from their direct actions on vascular cell functions [43]. 
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I.1.4 Penile smooth muscle tone 
Just like vascular smooth muscle tone, cavernous smooth muscle tone heavily depends on 
the amount of intracellular free Ca2+. Contraction of the penile vessels and trabecular 
smooth muscle cells of the corpora cavernosa (CC) is controlled by [Ca2+]i and the Rho kinase 
signaling pathway. NOR released from adrenergic neurons interacts with α1 adrenoceptors 
on the smooth muscle membrane and elicits smooth muscle contraction as mentioned 
above in the paragraph ‘vascular contraction’. In addition, the Ca2+-sensitizing RhoA-Rho 
kinase pathway plays a synergistic role in cavernosal (vaso)constriction [44-46].  
 
Figure I.6: Regulation of cavernosal smooth muscle relaxation by NO released from the nitrergic nerves and 
sinusoidal endothelium. Stimulation of the endothelial cells and nitrergic nerves in the penis causes Ca2+ influx 
which promotes production of NO. Binding of NO on sGC in the cavernous smooth muscle catalyzes the 
conversion of GTP into cGMP. Due to activation of PKA and PKG, both high levels of cGMP and cAMP induce 
vasodilatation of the arteries and sinusoidal spaces of the corpus cavernosum by decreasing [Ca
2+
]i, which 
eventually leads to penile erection (adapted from [51]). 
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As with vascular relaxation, NO is the most important mediator of penile relaxation [47]. NO 
is liberated from the endothelial cells, lining the inner surface of the penile arteries and 
cavernous sinusoids, upon local neurogenic stimulation by acetylcholine and mechanical 
shear stress by the blood flow. However, in penile tissue an additional source of NO can be 
found. Electrical impulses in response to sexual stimuli induce the release of NO from 
noncholinergic parasympathetic neurons innervating the penis [48]. NO, produced by the 
endothelium as well as by these nitrergic nerves, diffuses into the neighboring smooth 
muscle cells and activates sGC to increase the intracellular cGMP concentration.  
cGMP-induced activation of PKG initiates various molecular mechanisms all leading to 
smooth muscle relaxation. Further, intracellular cGMP concentrations are managed by PDEs 
of which type 5 is the predominant form present in penile tissue (Fig. I.6) [2,46,49,50]. 
 
The smooth muscle cells of the CC and the arteriolar walls play a key role in the erectile 
process. These cells dynamically regulate the tone of the penile vasculature, and thus the 
arteriolar blood flow into the sinusoids. Ultimately, the balance between contraction and 
relaxation will determine the functional state of the penis. Under basal conditions, 
cavernosal (vaso)constriction allows constant minimal arterial blood flow, covering the 
nutritional needs and maintaining the penis in flaccid state [52-54]. Upon sexual stimulation, 
NO, released from nitrergic nerves and/or the endothelium, diffuses into the smooth 
muscles of the penile arteries and cavernous trabeculae. This activates the relaxant 
pathways subsequently leading to increased blood flow into the penile sinusoids. Expansion 
of the CC elicits mechanical pressure on the penile veins, minimizing venous outflow from 
the sinusoids. Furthermore, the limited elasticity of the tunica albuginea, a tight fibrous layer 
of connective tissue that surrounds the CC of the penis, causes a rapid increase of 
intracavernosal pressure and thus penile erection (Fig. I.7) [44,45]. Neurogenic 
parasympathetic NO release, associated with sexual stimuli, will initiate cavernous tissue 
relaxation, whereas NO produced by the endothelium will facilitate attainment and 
maintenance of full erection [48,55]. Physiological, sexually-induced erection is principally 
mediated through the NO-sGC-cGMP-PKG pathway. Detumescence and returning to basal 
conditions is carried out primarily through the degradation of cGMP by PDE type 5 [49]. 
Introduction 
 
13 
 
Figure I.7: Anatomy and hemodynamics of penile erection. In the flaccid state, inflow of blood via the 
constricted helicine arteries is minimal and there is free outflow through the venous plexus. During erection, 
relaxation of the trabecular smooth muscles and vasodilatation of the arterioles increase blood flow, expanding 
the cavernous sinusoids. This expansion of the sinusoids compresses the venous plexus reducing outflow of 
blood which contributes to the rapid increases of intracavernosal pressure [52]. 
 
I.1.5 Erectile dysfunction 
Penile erection is a complex neurovascular process depending on a tightly regulated balance 
between psychological, hormonal, neurological, vascular and cavernosal factors. Hence, any 
alteration in one or more of these factors and mechanisms may lead to erectile dysfunction 
(ED) [44]. Recent epidemiological studies in the US as well as in Europe reported an ED 
prevalence of approximately 30 %. With age being an important risk factor for ED, these 
numbers are expected to rise even further in our aging population [56,57]. ED is generally 
defined as the inability to achieve and/or maintain an erection for satisfactory sexual 
intercourse [58]. Even though ED is not life threatening, its influence on social interactions, 
general wellbeing and patients’ quality of life should not be underestimated [59]. In the past 
ED was mainly considered a psychological problem, but nowadays it is linked to different 
vascular, psychological, neurological and endocrinological disorders [44,60].  
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ED is predominantly a disease of vascular origin (approximately 75 % of the patients) and is 
therefore associated with multiple vascular risk factors such as atherosclerosis, 
hypertension, hypercholesterolemia, diabetes mellitus, obesity and smoking [58,59,61]. A 
number of both clinical and preclinical studies on hypertension, hypercholesterolemia, 
diabetes mellitus and aging have demonstrated endothelial dysfunction to be a critical factor 
in the development of vasculogenic ED [62]. Since NO is the main mediator of endothelium-
dependent penile smooth muscle relaxation, ED associated with endothelial dysfunction is 
often linked to impaired NO functioning. This can be directly by a reduced NO production 
and/or indirectly by a lowered NO-bioavailability due to oxidative stress [63,64]. However, 
there are also several NO-independent mechanisms involved in endothelial and erectile 
dysfunction. Alterations in prostaglandin synthesis and signaling may contribute to an 
imbalance of penile eicosanoid homeostasis resulting in (vaso)constriction of penile blood 
vessels and corporal smooth muscles. In addition, an increase of angiotensin II and 
endothelin-1 concentrations may further promote a vasoconstrictor effect and thus ED [64]. 
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I.2 Nitric oxide 
Since its discovery in the 1980s as being the endothelium-derived relaxing factor, NO rapidly 
gained interest and is nowadays regarded as one of the most important signaling molecules 
of various biological processes [65]. NO is the principle mediator in both the cardiovascular 
system and penile erection, promoting (vascular) smooth muscle relaxation.  
I.2.1 Endogenous NO production 
Biosynthesis of NO involves a two-step oxidation of L-arginine to L-citrulline, with 
concomitant production of NO. In a first step, L-arginine is hydroxylated by a standard mono-
oxygenation reaction forming the stable intermediate Nω-hydroxy-L-arginine (L-NOHA). In a 
second step, L-NOHA is further oxidized to L-citrulline and NO. Molecular oxygen and 
reduced NADPH are utilized as co-substrates, whereas flavin adenine dinucleotide (FAD), 
flavin mononucleotide (FMN) and tetrahydrobiopterin (BH4) serve as cofactors (Fig. I.8) 
[66,67].  
 
 
Figure I.8: Endogenous synthesis of NO from L-arginine. 
 
Endogenous NO production is catalyzed by a family of NOS enzymes. These dimeric enzymes 
consist of two identical monomers, which can be functionally divided into two major regions: 
a carboxy-terminal reductase domain and an amino-terminal oxygenase domain. Active NOS 
transfers electrons from NADPH, via the flavins FAD and FMN in the reductase domain, to 
the heme in the oxygenase domain. The oxygenase domain also binds the essential cofactor 
BH4, molecular oxygen and the substrate L-arginine. Between the two regions lies a 
calmodulin recognition site, which is important for both the structure and function of the 
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enzyme (Fig. I.9) [68,69]. Three quite distinct isoforms of NOS (eNOS, nNOS and iNOS) have 
been identified as products of different genes, with different localization, regulation, 
catalytic properties and inhibitor sensitivity [69]. Endothelial NOS (eNOS) is constitutively 
expressed mainly in (vascular) endothelial cells. Its enzymatic activity depends on a sufficient 
increase of [Ca2+]i which enhances calmodulin affinity to eNOS, facilitating the flow of 
electrons from NADPH in the reductase domain to the heme in the oxygenase domain. 
Neuronal NOS (nNOS) is also Ca2+- and calmodulin-dependent and is constitutively present 
throughout the brain as well as in the spinal cord and peripheral nervous system. Unlike 
eNOS and nNOS, inducible NOS (iNOS) already binds calmoduline at very low [Ca2+]i and can 
therefore be activated without the need for a Ca2+ increase. However, iNOS expression is 
highly regulated by cytokines, some of which promote and others inhibit induction of the 
enzyme. Although primarily identified in macrophages, expression of iNOS can be stimulated 
in virtually any cell or tissue, given that the appropriate inducing agents are provided 
[66,67,70].  
 
 
 
Figure I.9: Schematic representation of the overall reaction catalyzed by NOS (based on [69]). 
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I.2.2 NO-related therapy and drawbacks 
NO exerts various vasculoprotective roles in the cardiovascular system including inhibition of 
smooth muscle proliferation and apoptosis, stimulation of endothelial proliferation, 
suppression of platelet aggregation and prevention of vascular inflammation [71]. A 
quantitative and/or functional NO deficiency limiting NO-dependent signaling pathways has 
been implicated in a number of cardiovascular diseases. In these clinical conditions it would 
be an attractive therapeutic option to mimic endogenous NO functioning by administration 
of (low concentrations of) exogenous NO [70,72]. Because of the limited feasibility and short 
half-life of gaseous NO, NO donor molecules are being used for over a century to treat 
coronary artery disease (angina pectoris) and, to a lesser extent, as a therapy for congestive 
heart failure, myocardial infarction and hypertension [73]. To date, organic nitrates  
(e.g. glyceryl trinitrate/nitroglycerin: GTN) are still the NO donors most frequently used in 
clinical practice for the treatment of ischemic syndromes. These drugs mimic the actions of 
endogenous NO by bioconversion to NO or NO-related compounds [74]. Well-known side 
effects of nitrates are headache and hypotension as a result of (abrupt) systemic 
vasodilation. However, the major drawback of this NO replacement therapy is the 
occurrence of resistance and tolerance upon prolonged use [75]. Progressive attenuation of 
nitrate-induced vasodilation can result from an increased production of substances with 
contractile effects, such as catecholamines, angiotensin II and endothelin-1, and has been 
referred to as “pseudo”-tolerance. This phenomenon contributes to the rebound effects 
after discontinuation of nitrate therapy. Tolerance is also associated with a progressive 
impairment of the biochemical properties of nitrates. Although the underlying mechanisms 
remain complex, it has been reported that oxidative stress and the production of ROS seem 
to be involved. ROS may impair the bioconversion of the nitrates but also interferes with the 
NO signaling by scavenging NO, which reduces NO-bioavailability, and by oxidation of sGC 
towards a ferric- and eventually heme-free state, which makes it unresponsive to NO and 
thus NO donors [76-78]. Besides tolerance, (cGMP-independent) adverse effects occur, 
secondary to the non-specific interactions with other biological molecules. Indeed, NO does 
not only activate sGC but also other proteins by nitrosation or interaction with metals, which 
could induce beneficial as well as harmful effects [79]. 
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Because of its central role in the normal physiological erectile functioning, the NO pathway is 
an important target in the therapeutic strategies of vasculogenic ED associated with 
endothelial dysfunction. In the past, various NO-donating compounds have been tested in 
the context of ED and penile erection. Because of its vasodilatory capacity in cardiovascular 
diseases, GTN was evaluated as a treatment for ED. To avoid systemic cardiovascular effects, 
GTN was applied topically either by an ointment or transcutaneous patches. Studies showed 
that this transdermal GTN application could alter penile vascular diameter and enhance the 
quality of erection [80-84]. However, later on a placebo controlled clinical trial could not 
prove a significant effect of transcutaneous GTN. Nevertheless, the authors still 
recommended to try this penile application of GTN before starting with large-scale 
investigation or invasive treatment [85]. Another extensively studied NO donor is sodium 
nitroprusside (SNP). Intracavernosal as well as transurethral administration of SNP elicits 
penile erection associated with an increase of intracavernosal pressure and penile length 
[86-88]. However it was reported that the potency of SNP is lower compared to 
intracavernosal injection of papaverine and prostaglandin E1 [89,90]. Moreover, systemic 
hypotension often occurs as an undesired side effect [89-91]. The NO donor linsidomine 
chlorhydrate is also able to increase arterial blood flow and to relax penile smooth muscles 
thus leading to penile erection. Even so, this treatment strategy did not seem to be superior 
to intracavernosal injection of papaverine/phentolamine and prostaglandin E1 [92-95]. It has 
been suggested that sodium nitrite can act as a storage form of vasoactive NO. Although less 
potent than SNP, sodium nitrite increases intracavernosal pressure as a result of its 
conversion to NO by NOS and xanthine oxidoreductase [96]. However, sodium nitrite is not 
able to restore erectile functioning in aged rats [97]. Notwithstanding the sometimes 
promising results, all of the NO-donating molecules mentioned above are nowadays not 
available on the pharmaceutic market for the treatment of ED. This could probably be 
explained by to poor efficacy as compared to other available treatment strategies as well as 
the occurrence of adverse effects and/or the development of tolerance upon prolonged use 
[85,89-94,97,98]. 
Currently, PDE type 5 inhibitors are regarded as the first-line treatment of ED. The overall 
efficacy rate of these drugs is around 60 to 70% but is substantially lower in patients with 
severe neurological damage, ED after radical prostatectomy, diabetes or severe vascular 
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disease [99,100]. After all, for these drugs to work, a ‘critical’ amount of NO is necessary. 
Severe nerve damage and conditions in which expression or activity of NOS and/or release of 
NO is impaired, will negatively influence NO availability. Lack of adequate amounts of NO 
excludes sufficient sGC activation and subsequent cGMP formation undermining the 
mechanism of action of PDE type 5 inhibitors [101]. So although efficacy and safety of  
PDE type 5 inhibitors have been proven in large clinical trials, at least 30 to 35 % of the 
patients fail to respond [102]. Moreover, PDE type 5 inhibitors can potentiate the 
vasodilatory effect of nitrate therapy resulting in a potentially life-threatening hypotension. 
Hence, concomitant use of PDE type 5 inhibitors with nitrates, including occasional and 
short-acting administration, is contraindicated [103]. 
Development of tolerance, low bioavailability and adverse effects limit the therapeutic value 
of current NO replacement strategies. Moreover, although PDE type 5 inhibitors seem to be 
the most successful, they still remain ineffective in roughly 30% of ED patients, present 
various undesirable side effects and are only a short-term cure. Therefore the search for new 
alternative treatments is still at hand. Recently, oxime derivatives, bearing an oxime 
(C=NOH) functional group, were presented as new group of compounds with vasodilatory 
effects due to the release of NO. Furthermore, as a result of their interesting biochemical 
properties, a wide range of metallocomplexes have been developed which are capable of 
releasing NO (or CO) under certain conditions. 
I.2.3 Oximes 
As mentioned above, the first step of endogenous NO production is the formation of the 
stable intermediate L-NOHA which is specifically and exclusively catalyzed by NOS. Further 
oxidative cleavage of the C=NOH bond of L-NOHA will eventually lead to NO. Studies have 
demonstrated that oxidative cleavage of the C=N bond in the C=NOH functional group is not 
only mediated by NOS but also by other hemoproteins such as microsomal cytochromes 
P450 and peroxidases [104-106]. Because of their structural resemblance with L-NOHA, 
oxime derivatives, which also contain a C=NOH bond, gained interest as alternative  
NO-delivery strategy. Based on their structure and chemical composition, oxime derivatives 
can be subdivided into different groups including non-aromatic substituted oximes, aromatic 
amidoximes and aromatic ketoximes. It was established that oxidative cleavage of these 
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oximes, by hemoproteins other than NOS such as microsomal cytochromes P450, could lead 
to NO production [107-109]. This NOS-independent NO release could be of potential value, 
restoring NO deficiency in pathological conditions typified by endothelial (and in many cases 
also NOS-) dysfunction such as cardiovascular diseases and erectile dysfunction.  
 
 
 
Figure I.10: The chemical structure of formaldoxime (FAL), formamidoxime (FAM) and cinnamaldoxime 
(CAOx). 
 
 
However, as yet research on the effect of oximes on vessel tone and its underlying 
mechanism(s) is very limited [110-113]. In these few studies, formaldoxime (FAL) seemed to 
be the most potent compound to establish in vitro vasorelaxation of rat aortic ring segments 
(Fig. I.10). Chalupsky at al. demonstrated that the oxime-induced vasorelaxation does not 
occur from spontaneous NO release in the organ bath solution but rather from the 
production of NO in the smooth muscle layer. Since the cell-permeable NO scavenger PTIO 
could alter the oxime-induced relaxation, the production of NO as a result of oxime 
metabolization is held responsible for the oxime effect. This metabolization of oximes into 
NO seems to be mediated by 7-ER-sensitive NADPH-reductases whereas NOS and 
monoamine oxidases are not involved. The produced NO subsequently activates sGC and 
PKG as proven by the inhibitory effect of ODQ and Rp-8-Br-cGMPS respectively [110]. 
Furthermore in vivo experiments were performed with the oxime compounds in which 
formamidoxime (FAM) induced the most pronounced blood pressure lowering effect when 
endogenous NO formation was blocked (Fig. I.10). Jaros et al. reported that inhibition of sGC 
by methylene blue could almost completely prevent the blood pressure decrease elicited by 
the oximes which was believed to indicate a relative contribution of NO to the vasodilatory 
action of the oxime compounds [111]. In addition to the non-aromatic oximes FAL and FAM, 
the underlying mechanisms of the aromatic oxime cinnamaldoxime (CAOx) were elucidated 
in vitro on rat mesenteric artery (Fig. I.10). Again NO release seems to occur through 
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NADPH-dependent reductases, leading to the activation of the sGC-cGMP-PKG pathway. The 
vasorelaxant effect of CAOx is also associated with the activation of large-conductance Ca2+-
activated K+ channels [113]. Similar molecular pathways were also proven to underlay the 
vasorelaxing effect of other C=NOH bearing molecules such as L-NOHA and 4-chloro-
benzamidoxime [112].  
 
I.2.4 Ruthenium-based NO-donating molecules 
I.2.4.1 Ruthenium metallocomplexes 
Many metal ions play a crucial role in various biological processes. Hence, a potential role for 
metal-containing compounds as medicinal agents can be considered [114]. Preparations of 
iron, zinc, copper, gold, mercury and bismuth were used in medical practice throughout 
history. The use of metal compounds in medicine already dates back to 3000 BC when the 
Egyptians used copper to sterilize water. 3500 years ago gold was included in a variety of 
medicines in Arabia and China. Around 1500 BC different iron-based therapies were 
introduced in Egypt and zinc was found to promote wound healing. The Greek physician 
Hippocrates already used mercury in 400 BC and in the Renaissance period mercurous 
chloride was proposed as a diuretic [115-118]. 
The last five decades, metal complexes have attracted attention of many drug designers in 
the perpetual search for new therapeutic approaches. One of the oldest and best-known 
metallodrugs is the platinum-based anticancer drug cisplatin, which was discovered by 
accident in the 1960s [117,119]. Platinum belongs to the group of precious metals like gold 
and silver. Although in ancient times these metals were used because of their rare nature 
rather than its known medicinal activities, precious metals have been shown useful in a 
clinical setting. A wide range of platinum compounds are developed for cancer treatment, 
gold compounds are implemented in the treatment of rheumatoid arthritis and silver 
compounds present antimicrobial properties [115,116].  
More recently a less-known member of the precious metal class, namely ruthenium, entered 
drug research. Nowadays, ruthenium is already found in drugs with immunosuppressant 
[120], antimicrobial [121], antibiotic [122] and anticancer activity [123,124]. Over the years, 
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ruthenium became popular due to its interesting physico-chemical characteristics. First of 
all, the ability of ruthenium to coordinate ligands in a three dimensional configuration allows 
functionalization of these groups aiming at defined molecular targets. Moreover, rational 
ligand design provides control over the kinetic properties. In this way ruthenium complexes 
tend to slowly exchange its ligands when in contact with biological tissues in order to exert a 
biological effect. Secondly, ruthenium can access a range of oxidation states (II, III, IV) under 
physiological conditions. These oxidation states permit participation in biological redox 
chemistry influencing optimal dose and bioavailability. As a result of the reducing 
environment of diseased tissues, the more inert ruthenium(III) complexes are converted into 
active ruthenium(II) complexes which creates a certain selectivity causing minimal damage 
to healthy tissues. Thirdly, ruthenium shows a relatively low toxicity probably due its ability 
to mimic iron in binding different biomolecules, such as serum albumin and the iron 
transport protein transferrin [116,118,125]. 
 
 
Figure I.11: Overview of the main pathways involved in the vasorelaxation induced by ruthenium-based NO- or 
CO-donating molecules. (sGC = soluble guanylyl cyclase; PKG = cGMP-dependent protein kinase; [Ca
2+
]i = 
intracellular calcium concentration) 
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Besides their own possible therapeutic effect, metals can have a passive accompanying role 
in the delivery of drugs. The formation of a metal complex can modify toxicity, solubility and 
lipophilicity of the drugs, altering pharmacokinetics and pharmacodynamics [118,126]. 
Because of its favourable properties, ruthenium seems to be a perfect candidate for the 
design of such delivery agents. Recently, several NO-containing ruthenium compounds have 
been developed as an alternative delivery strategy of NO in disease states associated with an 
impaired NO functioning including cardiovascular diseases and erectile dysfunction. These 
ruthenium-based NO-complexes were tested on their ability to release NO but more 
importantly also their ability to relax (vascular) smooth muscle cells and the underlying 
mechanism(s) of effect were investigated (Fig. I.11 and Table I.1). 
Class 
NO 
species 
NO release Effect Mechanism Ref. 
[Ru(terpy)(bdq)NO]
3+ 
(TERPY) 
polypyridine NO
•
 / NO
-
 light irradiation 
vasorelaxation  
  (rat aorta/ mesenteric artery) 
blood pressure decrease  (rat) 
sGC 
K
+
 channels 
Ca
2+
-ATPase 
[127-136] 
trans-[RuCl([15]aneN4)NO]
2+ 
(15-ane)
 
macrocyclic NO
•
 / NO
-
 
chemical reduction 
light irradiation 
vasorelaxation  (rat aorta) 
blood pressure decrease  (rat) 
sGC 
KATP 
KCa 
Kv 
[137-143] 
cis-[RuCl(bpy)2NO](PF6) (RUNOCL) 
polypyridine not specified light irradiation 
vasorelaxation  (rat aorta) 
cytosolic [Ca
2+
] decrease 
   (rat aorta smooth muscle cells) 
sGC 
KCa 
[144,145] 
cis-[Ru(bpy)2(py)NO2](PF6) (RuBPY) 
polypyridine NO
•
 metabolization vasorelaxation  (rat aorta) 
sGC 
K
+ 
channels 
[146-148] 
trans-[Ru(NH3)4P(OEt)3NO](PF6)3 (RuNO) 
tetraamine NO
•
 chemical reduction blood pressure decrease  (rat) sGC [149-152] 
trans-[RuCl(cyclam)NO](PF6)2 (cyclam-NO) 
macrocyclic NO
•
 
chemical reduction 
light irradiation 
blood pressure decrease  (rat) sGC [153-155] 
 
Table I.1: Ruthenium-based NO complexes. (NO
•
 = free radical NO; NO
-
 = nitroxyl anion; sGC = soluble guanylyl 
cyclase; KATP = ATP-sensitive K
+
 channel; KCa = Ca
2+
-activated K
+ 
channel; Kv = voltage-dependent K
+
 channel) 
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I.2.4.2 [Ru(terpy)(bdq)NO]3+ 
To date [Ru(terpy)(bdq)NO]3+, abbreviated as TERPY, is the most extensively described 
ruthenium-based NO-releasing molecule in literature (Fig. I.12). This nitrosyl polypyridine 
ruthenium complex has been shown to induce smooth muscle cell relaxation of rat aortic 
rings due to the release of NO by light irradiation. The time to reach maximum relaxation in 
the dark was around 14 times longer as compared to the time it took under visible light 
irradiation [127]. Comparing the vasorelaxant effect of TERPY and the commonly used NO 
donor SNP led to some interesting insights in the underlying mechanisms of their effect. 
Although both compounds induce a pronounced relaxation of endothelium-denuded rat 
aorta, SNP seems to be more potent. The response to SNP only involves free radical NO, 
whereas both free radical NO and nitroxyl anions are involved in TERPY-induced relaxation. 
Moreover in contrast to SNP, activation of sarcoplasmic reticulum Ca2+-ATPase does not 
contribute to the vasorelaxation by TERPY. Taken together, these differences could explain 
the lower potency of TERPY when compared to SNP. However, the relaxing effect of both NO 
donors shows some similarities too. The effect of both compounds is mediated by 
stimulation of sGC and K+ channels as proven by the inhibitory effect of ODQ and 
tetraethylammonium (TEA) respectively [128,129]. In rat mesenteric resistance arteries, 
these pathways are also involved and even sarcoplasmic reticulum Ca2+-ATPase seems to 
contribute to the vascular relaxation induced by TERPY since thapsigargin blocked its effect 
[130]. 
Surprisingly, TERPY failed to relax rat basilar artery as a result of the absence of NO release. 
However this observation could be viewed as positive (lack of) effect since cerebral 
vasodilation is thought to be the major cause of NO donor-induced headache, which is the 
most common side effect of nitrovasodilator therapy [131]. Another interesting finding is the 
fact that TERPY exhibits a less potent vascular relaxation in the presence of intact 
endothelium by uncoupling endothelial NOS enhancing tissue O2
•− levels. Subsequent 
conversion of O2
•− to H2O2 or ONOO
•− activates the cyclooxygenase enzyme followed by the 
production of thromboxane A2 which negatively modulates the TERPY response. Keeping in 
mind that various disease states are characterized by impairment of the endothelium, the 
higher potency of TERPY in endothelium-denuded arteries could imply a higher effectiveness 
in patients suffering from endothelial dysfunction as compared to healthy individuals [132]. 
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Figure I.12: The chemical structures of the NO-donating ruthenium complexes. 
 
Nevertheless, the absence of functional endothelium associated with cardiovascular disease 
is not the only alteration that could modify TERPY responses. In a rat model of renal 
hypertension, the vasorelaxant effect of TERPY seemed to be lower in endothelium-denuded 
aorta ring segments of hypertensive rats as compared to normotensive control rats. This 
decreased vasodilatation in response to TERPY was attributed to impaired activation of K+ 
channels [133]. Moreover it was previously observed that the antioxidant vitamin C can 
normalize the altered TERPY effect on aorta’s of renal hypertensive rats, providing evidence 
for the involvement of O2
•− [136]. In contrast, TERPY-induced vasorelaxation was found 
similar in endothelium-denuded mesenteric resistance arteries of renal hypertensive and 
normotensive rats [130]. Furthermore the vasorelaxation by TERPY does not differ between 
normotensive and spontaneously hypertensive rats [129]. Recently, it was reported that the 
underlying mechanism of the latter observation involves uncoupling of endothelial NOS. In 
normotensive rats, TERPY leads to uncoupling of endothelial NOS reducing NOS expression 
and resulting in increased production of O2
•−. Subsequent interaction between NO and O2
•−, 
forming ONOO•−, lowers NO availability and therefore alters TERPY effect. In spontaneously 
hypertensive rats, NOS expression is low and O2
•− concentrations are already high altering 
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the TERPY-induced vasorelaxation. So both in normotensive and spontaneously hypertensive 
rats, the presence of O2
•−influences the vasorelaxation induced by TERPY resulting in an 
equally potent effect in both rat models [135].  
Although these seemingly contradictory in vitro results regarding the added value of TERPY 
in case of disease and in particular hypertension, TERPY showed promising blood pressure 
lowering effects in vivo. TERPY has a long-lasting dose-dependent hypotensive effect which 
is more pronounced in renal hypertensive rats than in normotensive rats [136]. In 
spontaneously hypertensive rats the hypotension induced by TERPY was also more potent 
than in normotensive controls. In addition this hypotensive effect does not lead to reflex 
tachycardia [129]. TERPY also presents a sexual dimorphism as its hypotensive effect is 
higher in male than in female spontaneously hypertensive rats. This phenomenon seems to 
be associated with oxidative stress and deficient superoxide dismutase activity in female 
spontaneously hypertensive rats, as the superoxide dismutase mimetic 4-hydroxy-2,2,6,6-
tetramethylpiperidine 1-oxyl (tempol) abolished the sexual dimorphism [134]. Overall, TERPY 
could represent a new therapeutic approach in the treatment of hypertension associated 
with vascular dysfunction. 
I.2.4.3 Trans-[RuCl([15]aneN4)NO]
2+ 
Trans-[RuCl([15]aneN4)NO]
2+ is a nitrosyl macrocyclic ruthenium complex which is 
occasionally abbreviated as 15-ane (Fig. I.12). This ruthenium complex is able to induce a 
pronounced vasorelaxation of NOR-contracted rat aortic rings. The time-course for maximal 
relaxation of 15-ane was up to 3 time longer than for SNP. Relaxation by 15-ane occurred 
through release of NO as proven by the complete abolishing effect of the NO scavenger 
oxyhemoglobin. When tissues are contracted with a high concentration of K+, instead of 
NOR, the relaxant effect of 15-ane disappears. This was partly explained by the participation 
of K+ channels in the 15-ane-induced relaxation. But more importantly this observation 
indicates that 15-ane needs a reducing agent, such as the catecholamines NOR and 
phenylephrine, to exert its effect [137,141]. Besides chemical reduction, photoinduction of 
15-ane by UV light irradiation is able to release NO from this ruthenium complex, 
subsequently leading to complete aorta relaxation [137-139]. 
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Just like with TERPY, the NO species contributing to the 15-ane relaxant responses are both 
nitroxyl anion and free radical NO. Elucidating the molecular pathways underling the 
relaxant effect of 15-ane, ODQ partially inhibited the vascular relaxation indicating the 
involvement of sGC activation followed by cGMP formation. cGMP-independent activation 
of K+ channels also seems to take place since co-incubation of ODQ with the non-selective  
K+ channel inhibitor TEA resulted in an additional inhibition. More specific, 15-ane is able to 
activate voltage-dependent, ATP-sensitive and Ca2+-activated K+-channels as its relaxation is 
impaired in the presence of respectively 4-aminopyridine, glibenclamide as well as apamin 
and iberiotoxin. Nevertheless, iberiotoxin-sensitive Ca2+-activated K+ channel showed to be 
the most prominent subtype involved in the vasorelaxation by 15-ane [143]. The deficient 
15-ane-induced relaxation in renal hypertensive rat aortas originates from an impaired 
functional activity of these K+ channels, further emphasizing their importance in the 15-ane 
effect [142]. Although the vasodilatory effect of 15-ane is lower in renal hypertensive rat 
aortas as compared to normotensive controls, 15-ane only establishes a significant and 
distinct blood pressure lowering effect in severe renal hypertensive rats. In moderate 
hypertensive rats the hypotensive effect of 15-ane was limited and dose-dependent, 
whereas in normotensive rats 15-ane did not present any effect at all [140]. 
I.2.4.4 Cis-[RuCl(bpy)2NO](PF6) 
Cis-[RuCl(bpy)2NO](PF6), also known as RUNOCL, is another polypyridine ruthenium complex 
which is only activated by irradiation, controlling its release of NO (Fig. I.12). Photoinduction 
of RUNOCL using a visible light system induces relaxation of phenylephrine-contracted rat 
aorta, independent of the presence of intact endothelium. Pretreatment of the aortic tissue 
with ODQ or with apamin and iberiotoxin, both inhibitors of the Ca2+-sensitive K+ channels, 
significantly altered the RUNOCL-induced relaxations, implying a role for sGC activation and 
stimulation of small- and large conductance Ca2+-activated K+ channels [145]. These 
observations are in agreement with the decrease of cytosolic Ca2+ concentration in vascular 
smooth muscle cells in response to RUNOCL. Also ODQ inhibits this reduction of cytosolic 
Ca2+. Moreover TEA is able to block the Ca2+ decrease by RUNOCL, hence an activation of  
K+ channels also seems to be involved [144]. 
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I.2.4.5 Cis-[Ru(bpy)2(py)NO2](PF6) 
A third polypyridine complex is the cis-[Ru(bpy)2(py)NO2](PF6) compound (= RuBPY) 
consisting of ruthenium, bipyridine ligands and a nitrite group (Fig. I.12). It was reported that 
the release of NO by RuBPY was attributed to a reduction process [146]. However later it 
was proven that RuBPY does not need to be chemically reduced nor does NO release occur 
upon photoinduction. On the contrary RuBPY-induced relaxations only depend on the 
presence of tissue [147]. Furthermore it was demonstrated that the complex RuBPY requires 
metabolization in order to elicit vasorelaxation. It was suggested that the nitrite group of 
RuBPY is converted into radicalar NO which appears to be catalyzed by the sGC enzyme 
[147,148]. RuBPY does not only activates sGC, but also induces hyperpolarization of the cell 
membrane and subsequent vasodilation which is blocked by TEA as well as by high  
K+ concentration [148]. 
I.2.4.6 Trans-[Ru(NH3)4P(OEt)3NO](PF6)3 
In light of its NO-delivering capacity, the potential hypotensive effect of the ruthenium 
tetraamine complex trans-[Ru(NH3)4P(OEt)3NO](PF6)3 (= RuNO) was tested (Fig.I.12) [149]. 
RuNO can establish a distinct decrease in mean arterial pressure in conscious rats due to NO 
release after activation by reducing agents. This blood pressure lowering effect of RuNO is 
completely blocked by the sGC inhibitor methylene blue and the NO scavenger carboxy-
PTIO, indicating that its mechanism of action is primarily through the NO-sGC-cGMP 
pathway. However, when in solution, RuNO rapidly loses its hypotensive properties. Addition 
of NaNO2 seemed to help maintain the stability of RuNO in physiological conditions. After all, 
co-administration of NaNO2 and RuNO helped to preserve the hypotensive effect of this 
ruthenium complex [150]. It was suggested that the nitrite ions could react with the reduced 
metabolite of RuNO yielding trans-[Ru(NH3)4P(OEt)3NO2]
+ and thus renewing the source of 
NO [151]. Furthermore, RuNO shows some promising results in different rat models of 
hypertension. The hypotensive response to RuNO was more pronounced in acute 
hypertension, induced by phenylephrine or angiotensin II, as well as in chronic 
spontaneously hypertensive rats compared to the normotensive controls. However, when 
hypertension was obtained by Nω-nitro-L-arginine methyl ester, no difference could be 
observed between the RuNO effect in hypertensive and normotensive animals [152]. 
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I.2.4.7 Trans-[RuCl(cyclam)NO](PF6)2 
Trans-[RuCl(cyclam)NO](PF6)2, which can be abbreviated as cyclam-NO, is a macrocyclic 
ruthenium complex (Fig. I.12). Like the macrocyclic 15-ane, NO release of cyclam-NO is 
controlled by light irradiation as well as chemical reduction [138]. Dissociation of NO occurs 
relatively slow in contrast to for instance RuNO which rapidly loses NO under physiological 
conditions. However, in this way cyclam-NO can deliver NO in a controlled manner, acting as 
a long-lasting, but less potent vasodilator [153,155]. Due to the release of NO following in 
situ reduction, cyclam-NO exhibits hypotensive properties. In phenylephrine-induced 
hypertensive rats cyclam-NO produces a reduction in blood pressure which is 3-fold larger 
than in normotensive rats. Moreover, this decrease of mean arterial pressure proceeds up to 
20-times longer than the SNP-mediated blood pressure drop. As suspected the hypotensive 
effect by cyclam-NO is mainly dependent on cGMP production as a result of sGC activation 
[154].  
I.2.4.8 Other ruthenium-based NO donors 
The ruthenium complex cis-[Ru(H-dcbpy-)2(Cl)NO
+], although more potent in terms of 
inducing vascular relaxation, is rapidly converted into the more stable cis-[Ru(H-dcbpy-
)2(Cl)NO2
-] nitrite analog. However, once converted, cis-[Ru(H-dcbpy-)2(Cl)NO2
-] does not act 
as a nitrite donor but rather as a NO generator due to fast conversion of the released nitrite 
to free radical NO. cis-[Ru(H-dcbpy-)2(Cl)NO2
-]-induced rat aorta relaxation, following a 
decrease in cytosolic Ca2+ concentration, primarily depends on sGC activation. Yet, in part, 
also activation of K+ channels takes place [156]. Similar to cis-[Ru(H-dcbpy-)2(Cl)NO
+], cis-
[Ru(NO2)(bpy)2NO](PF6)2 is converted to its more stable nitrite analog. Likewise, activation of 
sGC and K+ channels are the underlying mechanisms of Ca2+decrease and vasorelaxation. 
Moreover this stable configuration has shown to dose-dependently reduce blood pressure 
[157].   
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I.3 Carbon monoxide 
It has been shown that CO signaling may become relevant as some kind of rescue 
mechanism when NO-bioavailability is reduced [158,159]. Since the therapeutic value of NO 
replacement therapy is limited by the development of tolerance, CO administration has been 
suggested as an alternative treatment strategy. 
I.3.1 Endogenous CO production 
CO is generated physiologically, primarily (>85 %) as a side product from the oxidative 
degradation of heme by the heme oxygenase (HO) enzyme (Fig. I.13). HO catalyzes the 
cleavage of heme at the α-methene bridge carbon to generate biliverdin-IXα, which is 
accompanied by the release of ferrous iron and CO. This reaction requires three molecules of 
molecular oxygen as well as reducing agents from NADPH:cytochrome P450 reductase. 
Subsequently, biliverdin-IXα is rapidly converted to bilirubin by biliverdin reductase and iron 
is stored into ferritin [160,161]. The degradation of heme, and thus the endogenous 
formation of CO, is visible during the development of bruises [162].  
 
Figure I.13: Oxidative degradation of heme by heme oxygenase [163]. 
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Two major isoforms of the HO enzyme have been characterized, indicated as HO-1 and HO-2 
[160,164]. Under basal conditions, HO-2 is constitutively expressed in most human tissues. In 
contrast, HO-1 is an inducible isoform that may be induced through various conditions and 
agents including its substrate heme but also hypoxia and hyperoxia, smoking, 
metalloporphyrins, cytokines, growth factors, hormones and heavy metals. Moreover, HO-1 
gene transcription is induced by ROS and oxidative stress, suggesting that HO-1 could serve 
as an inducible defense mechanism against oxidative cellular stress [165-167]. Some studies 
also describe a third isoform, HO-3, which closely resembles HO-2 but with much lower 
catalytic activity. However, this isoform does not seem to be expressed in humans [164]. 
Just like NO, CO has been shown to act through the activation of sGC increasing cGMP 
concentrations [168,169]. CO is also able to regulate different classes of ion channels 
directly. [170] The most widely studied ion channel target of CO is the large-conductance, 
Ca2+-activated K+ channel which is activated by CO in smooth muscle cells [171]. Moreover, 
various other (heme-dependent) pathways have been described as CO targets such as the 
cytochrome P450 system [172]. Although the signaling pathway of CO shows some analogy 
with the NO pathway, CO also substantially differs from NO. The potency of CO to activate 
sGC is distinctively lower as compared to NO. Binding of NO stimulates sGC activity by  
100- to 200-fold, whereas CO only induces a 4-fold increase [173]. Furthermore, CO is 
essentially a stable molecule as it does not react with intracellular metabolites, unlike NO 
which is a highly reactive free radical susceptible to inactivation by O2
•− and other oxidative 
pathways [161].  
I.3.2 Ruthenium-based CO-releasing molecules 
The feasibility of inhaled CO gas as a therapy remains questionable due to its lack of 
specificity and its toxicity at high concentrations. After all, binding of CO to hemoglobin, 
forming carboxy-hemoglobin, concentration-dependently interferes with oxygen transport 
and -delivery. Additional inhibition of cytochrome C oxidase by CO contributes to the 
observed cell hypoxia. At high concentrations, CO is associated with various clinical 
symptoms including dizziness and lowered consciousness. Prolonged and excessive exposure 
could be even lethal [174]. Hence, CO-releasing molecules (CORMs) were developed to 
Chapter I 
 
32 
release CO locally in a safe and controlled way [175]. As with NO, ruthenium seemed a 
perfect fit for the creation of such metallocomplexes. Several of these ruthenium-based  
CO-donating compounds were tested on their capacity to relax smooth muscles as well as on 
their usefulness for the treatment of cardiovascular diseases and erectile dysfunction  
(Fig. I.14 and Table I.2). 
Solubility CO release Effect Mechanism Ref. 
[Ru(CO)3Cl2]2
 
(CORM-2) 
organic 
solvents 
ligand 
substitution 
vasorelaxation  
  (rat aorta/ renal arteriole 
   mice aorta/ femoral artery) 
blood pressure decrease (rat) 
corporal relaxation (mice) 
 
protection against   
    ischemia/reperfusion injury  
     (rat) 
sGC 
Kv 
 
 
 
 
p38 mitogen-activated protein kinase β  
protein kinase C  
phosphatidylinositol 3-kinase 
[24,42,73-82]
 
[Ru(CO)3Cl(glycinate)] (CORM-3) 
water 
ligand 
substitution 
 
water-gas shift 
vasorelaxation   (rat aorta) 
blood pressure decrease (rat) 
corporal relaxation (rat) 
 
positive inotropic (rat) 
anti-ischemic (rat) 
 
protection against   
    ischemia/reperfusion injury    
     (rat/mice) 
sGC 
KATP 
KCa 
 
sGC 
Na
+
/H
+
 exchange 
 
regulation of Na
+
, K
+
 and Ca
2+
 levels 
KATP 
[73,83-92]
 
 
Table I.2: Ruthenium-based CO complexes. (sGC = soluble guanylyl cyclase; Kv = voltage-dependent K
+
 channel;  
KATP = ATP-sensitive K
+
 channel; KCa = Ca
2+
-activated K
+
 channel) 
I.3.2.1 [Ru(CO)3Cl2]2 
[Ru(CO)3Cl2]2 (= CORM-2) is the first ruthenium-based CO-releasing molecule that has been 
developed (Fig. I.14). Since the solubility of CORM-2 is restricted to organic solvents, 
dimethyl sulfoxide has been used as vehicle to test this compound in vitro and in vivo. 
CORM-2 has shown to deliver CO in biological systems making it a useful tool to mimic the 
actions of the endogenous heme oxygenase pathway and to elucidate the effectiveness of 
CO under pathological conditions as well as its underlying pharmacological mechanism(s) 
[176]. It was proven that CORM-2 significantly relaxes isolated aortic ring segments and 
increases arteriolar diameter of afferent renal arterioles in a concentration-dependent 
manner [158,175,177,178]. In the presence of reduced myoglobin this vasorelaxing effect 
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was abolished, confirming that the pharmacological effect is mediated by liberation of CO 
[175]. The guanylyl cyclase inhibitor ODQ significantly attenuates the CORM-2 effect 
demonstrating, at least in part, the involvement of the sGC-cGMP pathway [176-178]. 
K+ channels also contributed to the CORM-2 induced vasodilation. Although it was published 
that CO is able to act directly on Ca2+-activated K+ channels, CORM-2 rather activates the 
voltage dependent K+ channels in mice thoracic aorta [171,178]. Co-inhibition of sGC and  
K+ channels did not produce a more pronounced inhibition of the CORM-2 relaxation 
providing indirect evidence for the involvement of an additional molecular mechanism [178]. 
 
Figure I.14: The chemical structure of [Ru(CO)3Cl2]2 (= CORM-2) and [Ru(CO)3Cl2(glycinate)] (= CORM-3).
 
 
The vasorelaxant capacity of CORM-2 potentially implies a blood pressure lowering effect in 
vivo. Intravenous administration of increasing CORM-2 concentrations elicits a transient 
decrease of blood pressure. Hence, it was hypothesized that CORM-2 could be beneficial in 
case of hypertension. In a rat model of acute hypertension, CORM-2 significantly 
counteracted L-NAME-induced pressor responses [175]. Although CORM-2 responses seem 
to be impaired during hypertension as compared to normotensive rats, CORM-2 is still able 
to induce a significant relaxation of thoracic aorta. Exercise training in hypertensive rats fully 
restores the impaired relaxant effects of CORM-2 due to an increased K+ channel activity 
[179]. 
In addition to its vasorelaxant effect, CORM-2 exhibits profound cardioprotection. Soni et al. 
demonstrated a significant concentration-dependent and endothelium-independent 
reduction of ischemia/reperfusion injury in perfused rat hearts [180]. Further research 
delineated the underlying mechanisms of this cardioprotective effect, being activation of the 
p38 mitogen-activated protein kinase β and protein kinase C pathways before ischemia and 
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the phosphatidylinositol 3-kinase pathway during reperfusion [181]. Moreover, CORM-2 
protects cardiomyocytes from ischemia/reperfusion-induced apoptosis most likely via 
inhibition of a mitochondrial apoptotic pathway and an improvement of the energy 
metabolism [182]. During the postresuscitation period CORM-2 also improves cardiac 
function by reducing the production of cardiac mitochondrial ROS, attenuating oxidative 
stress of the heart [183]. 
CORM-2 does not only relax vascular smooth muscles, but also relaxes mice CC. CO gas and 
CORM-2 are both able to concentration-dependently induce corporal smooth muscle 
relaxation offering a valuable treatment option for erectile dysfunction. The CO gas response 
seems to be partially mediated by the sGC-cGMP pathway. However, the underlying 
mechanism(s) of the CORM-2 effect on CC remain(s) as yet unknown [184].  
I.3.2.2 [Ru(CO)3Cl(glycinate)] 
Due to its poor water solubility, the compatibility of CORM-2 with biological systems is 
relatively low limiting its pharmacological value. Therefore a new series of ruthenium 
carbonyls were developed by attaching different amino acid groups to the metal core. After 
screening these compounds for their potency to release CO and to mediate vasorelaxation, 
[Ru(CO)3Cl2(glycinate)] (= CORM-3) was identified as most promising agent (Fig. I.14) [176]. 
Just like CORM-2, CORM-3 readily releases CO in a biological milieu. Its vasoactive properties 
in isolated vessel ring segments were tested, showing a profound aortic relaxation within a 
few minutes after addition to the organ bath. The lack of response to iCORM-3 (inactivated 
CORM-3 which is depleted of CO) demonstrates that CO is directly responsible for the 
vascular effects of CORM-3. Blocking the ATP-dependent K+ channels with glibenclamide or 
the sGC activity with ODQ considerably reduced CORM-3-dependent relaxation, confirming 
that K+ channel activation and cGMP partly mediate the CORM-3 effect. CORM-3-induced 
vasorelaxation was significantly lower in endothelium-denuded vessels as well as after 
inhibition of NOS activity. Three possible underlying reasons were proposed: (1) a 
synergistic/permissive role of an endothelial factor augmenting the vasodilatory activity of 
CO, (2) the production of a substance in the endothelium such as NO which interacts with 
the ruthenium core of CORM-3 facilitating CO release or (3) displacement of NO from an 
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intracellular storage pool by CO [185]. However, Alshehri et al. proved that the 
aforementioned hypotheses are unlikely to explain the endothelium- and cGMP-dependent 
relaxant effect of CORM-3. They suggested that this effect results from a stimulation of NOS. 
Furthermore, they found that CORM-3 also produces relaxation independent of the 
endothelium and sGC by direct activation of smooth muscle K+ channels [186]. 
Besides its vasorelaxant activities in vitro, CORM-3 also elicits vasorelaxation in vivo leading 
to a rapid decrease in mean arterial pressure. This blood pressure lowering effect was 
further enhanced in the presence of YC-1, which is known to sensitize sGC to activation by 
CO, confirming the involvement of sGC [185,187]. To look further into the actions of CORM-3 
in the cardiovascular system during hypertension, the effect of CORM-3 was investigated on 
aortas of normotensive and spontaneously hypertensive rats. Pretreatment with ODQ or 
charybdotoxin reduced the CORM-3 relaxation in both strains, indicating a contribution of 
sGC and Ca2+-activated K+ channels respectively. In contrast to the NO donor S-Nitroso-N-
Acetyl-D,L-Penicillamin, the CORM-3 mediated vascular relaxation was conserved in 
spontaneously hypertensive rat aortas. Hence, CORM-3 could serve as a potential alternative 
for the treatment of hypertension, when response to NO donor therapy turns out to be sub-
optimal or absent [188]. 
The vasodilatory properties of CORM-3 are associated with positive inotropic and anti-
ischemic effects observed in cardiac tissue. CO release from CORM-3 exerts a direct positive 
inotropic effect on isolated perfused rat heart in which both cGMP and stimulation of  
Na+/H+ exchange appear to be involved [189]. Many research groups studied the 
cardioprotective effect of CORM-3 on myocardial ischemia/reperfusion injury. CORM-3 
improves haemodynamic, biochemical and histological parameters of isolated hearts 
subjected to ischemia/reperfusion by the activation of mitochondrial ATP-dependent K+ 
channels. CORM-3 has a beneficial effect on myocardial perfusion and contractility, reduces 
the release of myocardial creatine kinase (a specific marker of cardiac tissue injury) and 
attenuates infarct size [190]. CORM-3 reduces the incidence of reperfusion-induced 
ventricular fibrillation and tachycardia by regulating Na+, K+ and Ca2+ levels. Normally, 
myocardial ischemia/reperfusion injury is associated with cellular loss of K+ as well as 
increased intracellular concentrations of Na+ and Ca2+. When hearts are treated with CORM-
3, significant decreases in cellular Na+/Ca2+ gains and K+ loss occur resulting in antiarrhythmic 
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protection and associated reduction in infarct size. However, the direct mechanism(s) 
underlying this normalization of ion balance remain(s) to be fully identified. CORM-3 also 
diminishes myocardial infarct size in vivo when given just before reperfusion [191,192]. Even 
more important is the fact that CORM-3 has been shown to induce cardioprotection not only 
when administered at the time of reperfusion but also when given 24 or 72 h prior to 
coronary occlusion. This sustained cardioprotective influence of CORM-3 may be useful as 
prevention in patients at risk for myocardial infarction [193]. 
Since erectile dysfunction is often attributed to a decrease in cGMP content, CORM-3 has 
been investigated to see if it could alter cavernous cGMP content due to its release of CO 
and subsequent activation of sGC. Intracavernosal injection of CORM-3 increased cGMP by 
twofold compared with the inactive negative control. Moreover it increased endogenous 
heme oxygenase-1 protein. Hence, CORM-3 seems feasible to compensate for the lowered 
cGMP content in erectile dysfunction [194].  
I.3.2.3 Other ruthenium-based CO donors 
Besides the two prototypic ruthenium-based CORMs described above, a few other  
CO-delivery agents were developed, with ruthenium being the metal core, such as 
ruthenium imidazole oxime carbonyls [195]. Although previously most studies with CORMs 
were performed with the commercially available CORM-2 and CORM-3, nowadays the 
potential usefulness of both compounds is a matter of debate. Researchers have tried to 
elucidate the chemistry and mechanisms of both CORMs, however the exact mode of action 
remains obscure [196]. CORM-2 and CORM-3 formerly accepted as fast CO-releasers 
recently appear to require a reducing agent in order to release CO at an appropriate rate. 
More importantly there seem to be some discrepancies between CORM effects, CO gas 
effect and heme oxygenase induction, although all three strategies aim to increase CO 
concentrations [178,197]. Furthermore these CORMs have shown to elicit effects 
independently of CO-release [170,198]. Even though in most cases these CO-independent 
effects seem to be beneficial, possible undesired side effects should be kept in mind. Romao 
et al. presented a model for the rational design of CORMs with the appropriate 
pharmaceutical properties [199]. Based on the principles of this model, new complexes with 
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improved properties were developed. [RuCl2-thiogalactopyranoside(CO)3], abbreviated as 
ALF492, showed some improved druglike properties as well as modified CO-release profiles 
[200]. Moreover alternative CORM-delivery strategies are being tested in which for instance 
CORMs are combined with a micellar system [201]. However, to date none of these newer 
“next-generation” ruthenium-based CORMs were tested in the context of smooth muscle 
relaxation or as potential therapeutics for cardiovascular diseases and/or erectile 
dysfunction.  
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I.4 Soluble guanylyl cyclase 
sGC is the principal physiological target of NO (and CO), playing a pivotal role in vascular as 
well as penile smooth muscle relaxation. Therefore, exploring the involvement of sGC in the 
relaxant effect of new alternative (NO-related) treatment strategies is inevitable.  
I.4.1 Guanylyl cyclases 
cGMP was first identified and purified in rat urine in 1963 [202]. A few years later, the 
enzymes responsible for the conversion of GTP into cGMP were discovered [203-205]. Over 
time it became clear that these so called guanylyl cyclases (GC) are ubiquitous enzymes 
regulating critical functions in vivo. In mammals, 7 different membrane-bound/particulate 
GCs (pGC) and 2 physiologically relevant cytosolic/soluble GCs (sGC) exist. Although pGCs 
and sGCs show certain sequence homology and structural resemblance, their function and 
regulation is substantially different. sGC is a heterodimeric protein regulated by the gaseous 
molecules NO and CO [206]. In contrast, pGC is generally expressed as homodimer serving as 
a receptor for peptide ligands including the atrial, brain and C-type natriuretic peptides 
(resp. ANP, BNP and CNP) [207,208]. The natriuretic peptide family is primarily involved in 
the regulation of cardiovascular homeostasis. ANP and BNP are both produced 
predominantly in the heart and seem to bind to the same signaling receptor (NPR-A). CNP is 
expressed in (vascular) endothelial cells and has its own receptor (NPR-B). Being a potent 
inhibitor of smooth muscle proliferation, CNP acts as an antagonist for a variety of growth 
factors [209].  
I.4.2 Structure and isoforms 
Isolation of sGC from the cytosol has proven that the soluble isoforms of GC exist as 
heterodimers composed of two homologous subunits, α and β, with a molecular mass of 
∼73-82 kDa and ∼70 kDa respectively [212]. Expression of both subunits is required for 
catalytic activity [213]. In mammals, for each subunit two isoforms are identified (α1/α2 and 
β1/β2). The isoforms of α-subunits are highly homologous with ∼48% sequence identity 
whereas β-subunits have an overall sequence identity of ∼41% [214]. Both the α1 and β1 
subunit are found in most tissues opposed to the α2 subunit which is only highly expressed in 
the brain, lung, colon, heart, spleen, uterus, and placenta. Unlike β1, the β2 isoform is not 
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ubiquitously expressed and is primarily found in the kidney [215]. The best-characterized 
and physiologically relevant heterodimers are the α1/β1 and the α2/β1 forms. Although the 
primary structure of both α-isoforms substantially differs, no difference could be observed 
when comparing the kinetic and pharmacological properties of the α1/β1 and α2/β1 
heterodimers [216]. For the β2 subunit it was found that it does not exhibit cyclase activity 
when expressed with α1 or α2. In vitro, β2 seems to be active in the absence of an α-subunit, 
suggesting that it can function as a homodimer. However, to date the physiological role of β2 
in cGMP signaling remains unclear [217].  
 
Figure I.15: Schematic structure of the heterodimeric sGC enzyme (based on [210] and [211]) 
 
Each subunit consists of three functional domains: an amino-terminal heme-binding 
regulatory domain, a central dimerization domain and a carboxy-terminal catalytic domain 
(Fig. I.15) [211]. Compared to the central and catalytic domains, the regulatory region of sGC 
subunits exhibits lower homology between isoforms and across species. However, this 
regulatory amino-terminal domain plays a critical role in the sGC function as it binds heme 
which is required for the activation of sGC by NO [215]. sGC binds 1 molecule of heme per 
heterodimer which is sandwiched between the two subunits [218]. The central dimerization 
region is involved in the formation of the heterodimeric structure, which is also necessary 
for the sGC enzyme to exhibit catalytic activity [213]. The carboxy-terminal domain of the 
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sGC subunits is the most conserved region of these proteins sharing a substantial sequence 
homology with the corresponding domains in pGCs and adenylyl cyclases. This domain is 
responsible for substrate recognition and the catalytic activity of sGC [211,215]. 
 
Figure I.16: Schematic representation of NO and CO binding to the prosthetic heme moiety of sGC [219]. 
 
The prosthetic heme group of sGC is a five-membered nitrogen-containing porphyrinic ring 
in which four nitrogen atoms are coordinated with a central ferrous (Fe2+) iron (Fig. I.16). The 
axial ligand of the penta-coordinated iron center is histidine at position 105 (His105) in the 
amino terminus of the β subunit [220]. Binding of NO results in the formation of a transient 
hexa-coordinated histidine-heme-NO intermediate. By breaking the bond between the axial 
histidine and iron, this intermediate is rapidly converted into a penta-coordinated ring with 
NO in the fifth position, displacing the iron from the plane of the porphyrinic ring. Activation 
of sGC by binding of NO and subsequent conformational change will increase basal catalytic 
activity up to 200 fold [221]. His105 is the essential amino acid required for binding the 
prosthetic heme moiety in the β subunit. Mutation of His105 results in the inability of sGC to 
bind heme and produces an enzyme that is unresponsive to NO [222,223]. Moreover, 
oxidation of the heme group to the ferric iron (Fe3+) state also prevents both binding and 
activation by NO and is even often associated with a complete loss of the heme moiety from 
the protein [224]. Besides NO, sGC can bind CO at its heme group, yielding a hexa-
coordinated complex. Leaving the iron-histidine bond intact, interaction between CO and 
sGC leads only to a 4-fold increase of catalytic activity [225]. When compared to other 
hemoproteins, such as hemoglobin and myoglobin, sGC is unique because it preferentially 
binds NO (or CO) rather than oxygen forming a ferrous-nitrosyl species even under aerobic 
conditions. This peculiar characteristic of sGC is important for its function as NO sensor since 
in vivo oxygen is present at much higher levels than NO [211,214]. 
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It is generally accepted that NO act as an essential gaseous neurotransmitter in the human 
body. In the cardiovascular system NO regulates normal blood pressure, blood flow and 
vascular resistance [1]. Moreover, NO plays a crucial role in the mechanism of penile 
erection [2]. Therefore it is reasonable that impairment of NO-bioavailability results in 
various disease states, including hypertension and erectile dysfunction (ED) [3,4]. Because of 
the limitations and adverse effects of current NO-related therapies, the search for new and 
better alternatives still remains [5,6]. In this continuous urge for improvement, oxime 
derivatives have been put forward due to their NO-releasing capacities [7]. Furthermore, 
(ruthenium-based) metallocomplexes have been suggested as delivery agents of (gaseous) 
molecules such as NO and CO [8]. By compensating the loss of normal NO functioning, both 
oximes and ruthenium-based NO/CO-releasing molecules potentially offer some (new) 
therapeutic perspectives.  
 
Oxime derivatives had already shown to induce vascular relaxation of rat aorta ring 
segments as a result of their NO-release [7]. This vasorelaxant effect could also be of value in 
the context of penile erection and ED. Hence, in our first study, described in Chapter IV, we 
examined the ability of the oximes FAL and FAM to relax isolated mice corpora cavernosa 
(CC) by performing in vitro tension measurements. We also aimed to elucidate the 
underlying mechanisms of the oxime effects in vitro, without the influence of counteracting 
neuronal, humoral and hemodynamic factors seen in in vivo conditions. 
 
However, in order to find out the physiological relevance of our in vitro results, we also 
carried out some in vivo experiments. In this second study, we aimed to monitor the changes 
in mean arterial pressure (MAP) and intracavernosal pressure (ICP) after intravenous and 
intracavernosal injection of the oxime compounds respectively. Furthermore, we tried to 
confirm the importance of sGC as the main target of FAL-/FAM-induced effects, both in vitro 
and in vivo, by using genetically modified sGCα1 knock-out mice (sGCα1
-/-). The results of this 
study are presented in Chapter V. 
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An important factor responsible for the lowered NO functioning in ED is the presence of 
reactive oxygen species [9]. Oxidative stress and the associated production of reactive 
oxygen species, such as superoxide, diminish the available effective NO concentrations by 
forming peroxynitrite, thus impairing NO-mediated relaxations. So in additional in vitro 
experiments, we tested the influence of oxidative stress on (NO-mediated) corporal 
relaxations with special attention to the effect on FAL-/FAM-induced responses. The results 
are also presented in Chapter V. 
 
Over the years, various ruthenium-containing metallocomplexes were developed for the 
safe and controlled release of NO and CO. Since NO and CO are able to induce 
vasorelaxation, these ruthenium-based compounds were also expected to present a 
vasorelaxing effect which was already reported various times in literature [8]. However, 
some ambiguous results regarding the correlation between the CO-release from CO-
releasing molecule-2 (CORM-2) and its vascular effects, made us wonder if ruthenium itself 
could influence vascular tone [10]. Therefore, we designed a study to explore the 
vasorelaxing effect of different ruthenium-containing compounds on mice aorta ring 
segments. In addition, former studies had demonstrated that CORM-2 and its water soluble 
alternative CORM-3 attenuate NO donor-induced vasorelaxation [11,12]. To evaluate the 
influence of ruthenium as such on exogenous and endogenous NO-mediated signaling, we 
performed in vitro experiments with some ruthenium-containing compounds. The results of 
the ruthenium experiments are described in Chapter VI. 
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III.1 In vitro tension measurements 
In vitro tension measurements are a sensitive technique to evaluate the mechanical 
responses of isolated vascular ring segments and corpora cavernosa (CC). It allows complete 
control over the experimental conditions without the interference of competing or 
compensating regulatory in vivo mechanisms. This technique, using freshly isolated tissues, 
is the golden standard to investigate the influence of molecules on vascular tone and makes 
it possible to determine the underlying molecular pathways.  
III.1.1 The experimental setup 
The changes in tissue tension were measured by a myograph constructed by the technical 
staff of our laboratory (Fig. III.1 and Fig. III.2) [1]. This myograph consists of a 10 ml organ 
bath containing two holders to fix the isolated tissue preparations. One of the holders is 
connected to a micrometer which allows adjustment of the distance between the two 
holders. While maintaining this distance and therefore the length of the mounted tissues 
constant, isometric tension changes are recorded by a force transducer which is connected 
to the other holder. Subsequently, the measured force is transformed into an electrical 
signal which is amplified and registered by a reading system. In order to create in vivo-like 
conditions the myograph was placed on a heating plate at 37°C and carbogen gas (95 % O2 
en 5 % CO2) was supplied continuously. The organ bath solutions were also preheated in a 
warm water bath at 37°C and bubbled with carbogen gas.  
 
 
Figure III.1: Myograph with (1) force transducer, (2) organ bath and (3) micrometer. 
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Figure III.2: Overview of the experimental in vitro setup. (1) myograph (2) heating plate (3) carbogen gas 
supply (4) warm water bath (5) thermoregulator (6) amplifier (7) reading system. 
 
III.1.2 Mice models 
Most experiments were performed with mature (age 8-12 weeks) male Swiss mice which 
were obtained from Janvier (Saint-Berthevin, France). For determining the role of sGC in the 
molecular pathway of the studied vasorelaxant compounds, transgenic sGCα1 knock-out 
mice (sGCα1
-/-) and sGCβ1 knock-in mice (sGCβ1
ki/ki) as well as their wild type controls 
(129SvJ) were used. These transgenic mice were generated, genotyped and bred in the 
Department of Biomedical Molecular Biology (Ghent University) at the Laboratory of 
Molecular Pathology and Experimental Therapy (Inflammation Research Center, VIB, Ghent, 
Belgium). The genotyping of the mice was carried out prior to the experiments by PCR and 
Southern blot analysis. All animals were treated in accordance with the Guide for the Care 
and Use of Laboratory Animals published by the US National Institutes of Health. Food and 
water were provided ad libitum and the animals were kept in a 12h/12h day/night cycle. All 
experiments were also approved by the local ethical committee for animal experiments  
(ECD 10/42, Ghent University, 14/02/2011 and ECD 14/48, Ghent University, 14/07/2014). 
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III.1.2.1 sGCα1
-/- 
The sGCα1 knock-out mice (sGCα1
-/-) were developed by a targeted deletion of exon 6 of the 
sGCα1 gene. Deletion of exon 6, which codes for a conserved region of the catalytic domain, 
does not cause a frame shift but results in a mutant protein. When co-expressed with sGCβ1, 
this mutant protein is able to form a heterodimer, which is however found to be inactive and 
could not be stimulated by NO. Hence, the sGCα1
-/- mice lack a functional sGCα1β1 isoform 
which is the predominant form in vascular smooth muscle cells. However, the sGCα2β1 
activity still remains. Quantitative RT–PCR experiments and immunoblot techniques have 
also indicated that sGCα2β1 does not compensate for the loss of cGMP production by 
sGCα1β1 [2]. 
III.1.2.2 sGCβ1
ki/ki 
Transgenic sGCβ1 knock-in mice (sGCβ1
ki/ki) were generated by replacing exon 5 of the 
endogenous Gucy1b3 gene with a mutant exon 5 carrying a point mutation of the histidine 
105 residue. Normally, this histidine 105 is responsible for ligation of the heme-group to 
sGC. However, replacement of the histidine residue with phenylalanine results in the 
expression of heme-free sGC. Although basal activity is preserved, the heme-free sGC can no 
longer be activated by NO [3]. This modification of the β1 subunit is generally considered as a 
global alteration of sGC activity because both sGCα1β1 and sGCα2β1 are affected and the  
α1 and α2 subunits do not form functional heterodimers with the β2 subunit (as mentioned in 
Chapter I.4). 
III.1.3 Tissue preparation 
At the day of the experiment, the tissues were dissected from the mice after cervical 
dislocation (Fig. III.3). The thoracic part of the aorta was isolated from the thoracic cavity 
alongside the spine and displaced in fresh, cold Krebs-Ringer bicarbonate (KRB) solution. 
Remaining adherent connective tissue as well as surrounding adipose tissue were carefully 
removed. In the upper leg, the femoral artery was separated from the femoral vein and 
nerve. Furthermore, the CC were cleansed from surrounding connective and adipose tissue 
and the dorsal arteries, dorsal veins, glans penis, corpus spongiosum as well as the urethra 
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were removed. The CC were separated and excised at the base. After excision of the femoral 
artery and CC, the isolated tissues were also transferred in cold KRB solution. Isolation of the 
tissues has to be done with precision and great care in order to preserve intact smooth 
muscle contraction and functionality of the endothelium. 
 
Figure III.3: Isolation of mice (1) aorta, (2) femoral artery and (3) corpora cavernosa. 
III.1.4 Tissue mounting 
After isolation, the tissues were mounted into the organ bath of the myograph by fixing 
them between two holders (Fig. III.4). The arterial ring segments were mounted by passing 
two wires through the lumen of the vessels whereas the CC strips were clamped between 
the holders. 
 
Figure III.4: Organ bath with half-moon shaped holders for mounting arterial ring segments (left)  
and holders for clamping CC strips (right).  
III.1.4.1 Arterial ring segments 
The isolated thoracic aorta and femoral artery were cut into ring segments of around 2.5 
mm in length. Under a microscope, these arterial ring segments were then mounted in an 
organ bath between a pair of holders by guiding two thin stainless steel wires (40 µm) 
through the lumen.  
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First, one wire was clamped between the holders by turning the micrometer (Fig. III.5.2). The 
wire was fixed on the top corner of the left holder with a screw keeping the free end pointed 
towards the operator (Fig. III.5.3). Next, the arterial ring segment was gently pulled over the 
wire using a forceps (Fig. III.5.4). Slowly, the ring segment was slided towards the center of 
the holders and the wire was tightened with a screw (Fig. III.5.5). In the following step, a 
second wire was guided through the arterial lumen and again clamped between the holders 
by turning the micrometer (Fig. III.5.6). The second wire was screwed to the top and bottom 
corner of the right holder (Fig. III.5.7). Finally, the remaining loose ends of the wires were cut 
off to avoid interference the experiments (Fig. III.5.8). This mounting procedure has to be 
done with due diligence to remain the endothelium intact. 
 
Figure III.5: Schematic overview of the mounting procedure of arterial ring segments. 
III.1.4.2. CC strips 
In contrast to the small arterial ring segments, mounting the CC strips is much easier. Each 
CC was mounted longitudinal as a whole. Instead of the half-moon shaped holders for the 
arterial tissues, the holders for the corporal tissue consist of two blocks in between which 
the CC can be pressed. Both ends of the CC were clamped between the two holders and 
tightened with two screws. Because of the relatively larger size, this procedure can be done 
without the need for a microscope. 
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III.1.5 Preliminary Protocol 
After mounting, the tissue preparations were left to equilibrate for 30 minutes in KRB 
solution (37 °C; pH 7.4) and continuously oxygenated with carbogen gas. In order to obtain 
maximal, stable contractions and relaxations, each type of tissue was subjected to a slightly 
different preliminary protocol before starting with the actual experiments.  
III.1.5.1 Aortic ring segments 
The mounted aortic tissues were gradually stretched by turning the micrometer until a fixed 
stable preload of 4.905 mN was obtained, as it has been shown that this results in a maximal 
response. It takes around 30 minutes to reach a stable equilibrium during which the aortic 
ring segments spontaneously lose part of their tension. Therefore regular adjustment is 
necessary until the tension remains stable. Every 10 minutes the KRB solution in the organ 
bath was refreshed with new, preheated and oxygenated KRB solution. After submitting the 
preload, the aortic rings were maximally contracted for 20 minutes by replacing the KRB 
solution with an adjusted high K+ (120 mmol/L) KRB solution and concomitant addition of  
5 µmol/L norepinephrine (NOR). Afterwards, the aortic tissues were rinsed with KRB solution 
until they returned to basal tone. Subsequently, functionality of the endothelium was tested 
by first contracting the aortic ring segments with 5 µmol/L NOR. When a stable plateau was 
reached, 10 µmol/L acetylcholine (ACh) was added. The endothelium was considered intact 
in tissues that relaxed more than 50 % of the obtained contraction level after addition of 
ACh. The preparations were intensively washed and ready to start with the actual 
experiments when basal tone was reached again. 
III.1.5.2 Femoral artery ring segments 
In small arteries, such as the femoral artery, the optimal internal diameter for maximal 
active force production was determined by using a normalization procedure [1,4]. Gradually 
stretching the femoral ring segments influences the length of the circumferentially oriented 
smooth muscle cells. At a certain internal circumference or diameter, which correlates with a 
specific length of the smooth muscle cells, the force development reaches a maximum. 
Therefore, optimal experimental conditions can be obtained by calculating the position of 
the holders corresponding to the vessels’ ideal internal circumference which has been found 
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to be 0.9 times the internal diameter a vessel would have in situ when relaxed and under a 
transmural pressure of 100 mmHg. After normalizing the femoral artery ring segments to 
their optimal diameter, precontraction of the tissues was induced with high K+ KRB solution 
and 10 µmol/L NOR. To have a maximal contraction response during the experiments, this 
precontraction step was repeated twice. After each precontraction the femoral artery rings 
were washed to obtain basal tissue tension. The presence of intact endothelium was 
checked by addition of 10 µmol/L ACh when the rings segments reached a stable plateau 
with 10 µmol/L NOR. When the contraction level dropped more than 50 % after ACh 
addition, the endothelium was considered fully functional. Afterwards the tissues were 
rinsed again. 
III.1.5.3. CC strips 
Just like with the aortic tissues, the CC were gradually stretched to offer nearly maximal 
reactivity during the experiments. After 60 minutes of regular tension adjustment, a stable 
preload of 4.415 mN was reached. Then, the CC were precontracted two times by adding 
only 5 µmol/L NOR since the use of a high K+ KRB solution does not result in stable 
contractions. When a plateau was reached after approximately 10 minutes, the CC strips 
were extensively rinsed until they returned to their basal tension level. Control of the 
endothelial functioning was performed by contraction with 5 µmol/L NOR and subsequent 
relaxation with 1 µmol/L ACh. To consider the endothelium intact, a relaxation of at least  
50 % was required again. Afterwards the tissues were washed to basal tone. 
III.1.6 Mechanistic studies 
In the different in vitro studies presented in this thesis, various pharmacological agents were 
used because of their specific effects when incubating the isolated tissues with these 
substances. An overview of the compounds used can be found in Table III.1. Various 
pharmacological inhibitors were added to elucidate the underlying molecular pathways 
involved in the FAL- and FAM-induced relaxations. Hydroquinone and DETCA were used to 
create an in vitro model for oxidative stress. L-ascorbic acid and N-acetyl L-cysteine were 
applied in the in vitro experiments with RuCl3 because of their antioxidant capacities. 
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For the arterial tissues, experiments were performed in parallel (unpaired observations). A 
concentration-response curve was performed in a ring segment, while at the same time in 
another, parallel ring segment the concentration-response curve was performed in the 
presence of an antagonist. In contrast, the corporal strips were each used as their own 
control (paired observations). A concentration-response curve was established on a corporal 
strip and after a washout period, the concentration-response curve was repeated on the 
same corporal strip in the presence of an antagonist. 
Abbr. (Chemical) Name Effect Conc.  
Incubation 
Time  
ODQ 
1H-[1,2,4]oxadiazolo 
[4,3-a]quinoxalin-1-one 
sGC inhibition 10 µmol/L 10 min 
DPI diphenyliodonium chloride Flavoprotein inhibition 10 µmol/L 30 min 
7-ER 7-ethoxyresorufin 
NADPH-dependent 
reductases inhibition 
 
CYP450 1A1 inhibition 
10 µmol/L 20 min 
apocynin 
4’-hydroxy-3’-
methoxyacetophenone 
NADPH oxidases 
inhibition  
300 µmol/L 20 min 
miconazole 
1-[2-(2,4-Dichlorobenzyloxy)-2-(2,4-
dichlorophenyl)ethyl]-1H-imidazole 
CYP450 inhibition 10 µmol/L 20 min 
L-NNA Nω-Nitro-L-arginine NOS inhibition 100 µmol/L 20 min 
TEA tetraethylammoniumchloride K
+
 channels inhibition 3 mmol/L 20 min 
apamin apamin 
Small conductance 
calcium activated 
K
+
 channel inhibition 
1 µmol/L 20 min 
SQ 22,536 
9-(Tetrahydro-2-furanyl)- 
9H-purin-6-amine 
Adenylate cyclase 
inhibition 
100 µmol/L 20 min 
compound C 
6-[4-(2-Piperidin-1-ylethoxy)phenyl]-
3-pyridin-4-ylpyrazolo 
[1,5-a]pyrimidine 
AMP-activated protein 
kinase inhibition 
10 µmol/L 20 min 
hydroquinone 1,4-Dihydroxybenzene 
Superoxide generation 
 
Free radical scavenging 
50 µmol/L 20 min 
DETCA diethyldithiocarbamic acid 
Superoxide dismutase 
inhibition  
8 mmol/L 20 min 
L-ascorbic acid L-ascorbic acid Antioxidant 100 µmol/L 20 min 
N-acetyl 
 L-cysteine 
N-acetyl L-cysteine Antioxidant 1 mmol/L 20 min 
 
Table III.1: Overview the pharmacological molecules used in the in vitro experiments, their main effect(s), 
the concentration used and the duration of tissue incubation before inducing contraction with 
norepinephrine or phenylephrine.  
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III.1.7 Electrical Field Stimulation 
Neurogenic-mediated relaxations of the CC were examined by applying electrical field 
stimulation (EFS; parameters: train duration 40 s; frequency 1, 2, 4 and 8 Hz; pulse duration 
5 ms; 80 V). When a stable contraction was obtained with phenylephrine (5 µmol/L),  
two parallel platinum electrodes were lowered into the organ baths using a lever (Fig. III.6). 
The L-shaped electrodes are placed at the level of the mounted CC in a way that the CC strip 
is located in-between both ends of the electrodes (Fig. III.6). The electrodes are connected 
to a Grass stimulator (80 V). The CC strips were stimulated with consecutive frequencies of 
1, 2, 4 and 8 Hz. Each stimulus was applied for 40 seconds with a pulse duration of 5 ms. 
 
Figure III.6: Overview of the experimental setup for the in vitro electrical field stimulation (left) showing the 
lever (1) and electrode holder (2). Close up of the organ bath (right) showing the position of the L-shaped 
platinum electrodes (3) relative to the mounted CC strip (4).  
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III.2 In vivo pressure measurements 
Although in vitro tension measurements are well suited for elucidating the molecular 
mechanisms of contractile and relaxant compounds, it is not necessarily correlated to 
relevant in vivo effects. Therefore, additional in vivo experiments were performed evaluating 
simultaneously blood pressure and intracavernosal pressure (Fig. III.7). 
 
 
Figure III.7: Overview of the experimental in vivo setup. (1) heated blanket (2) pressure sensor (3) microscope  
(4) recording system (5) mean arterial pressure (MAP) monitoring (6) intracavernosal pressure (ICP) 
monitoring. 
 
III.2.1 Mouse preparation 
The mice were anesthetized with an intraperitoneal injection of ketamine (100 mg/kg) and 
xylazine (10 mg/kg) prior to the experiments. To maintain their body temperature at 37 °C, 
the mice were placed on a heated blanket in supine position. During anesthesia, the mice 
breathed spontaneously without the need for additional oxygen supply. 
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III.2.2 Blood pressure and intracavernosal pressure measurements 
To evaluate systemic blood pressure, a polyethylene (PE-10) tube was inserted into the left 
carotid artery and connected to a pressure transducer (Fig. III.7). To avoid blood clotting, the 
PE-10 catheter was filled with heparinized saline (25 U/mL). Using the Powerlab recording 
system (AD instruments), the mean arterial pressure (MAP) was recorded on a computer 
with the LabChart software (AD instruments). To monitor penile hemodynamics, 
intracavernosal pressure (ICP) was assessed simultaneously with the MAP [5]. For that, a  
30-G needle attached to another PE-10 tube, filled with heparinized saline, was introduced 
into the right CC (Fig. III.8). Again this catheter was connected to a pressure transducer and 
ICP was registered on a computer through the Powerlab system and LabChart software. 
 
 
Figure III.8: Photograph of an anesthetized mouse in which 4 catheters are inserted: a catheter in the left 
carotid artery connected to a pressure sensor to monitor MAP (right upper corner), a catheter in the right 
jugular vein for intravenous injection (left upper corner), a catheter in the right CC connected to a pressure 
sensor to monitor ICP (left lower corner) and a catheter in the left CC for intracorporeal injection (right lower 
corner). 
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III.2.3 Intravenous and intracavernosal injection  
To study the effect of pharmacological agents on blood pressure and intracavernosal 
pressure, the compounds where administered through intravenous and intracavernosal 
injection respectively. For intravenous bolus injection, the right jugular vein was catheterized 
with a PE-10 tube, again filled with heparinized saline (Fig. III.7). Only small amounts of fluid 
could be injected to avoid volume-induced alteration of blood pressure. Moreover, the 
injection volume was standardized to 10 µL in order to interpret the dose-response relation 
correctly, independent from potential volume-related effects. Intracavernosal administration 
was obtained via a separate catheter inserted into the left CC (Fig. III.7). As a catheter,  
a 30-G needle attached to a PE-10 tube was used which was also filled with heparinized 
saline. Because of the limited volume expansion of the CC, the intracavernosal injection 
volume was standardized to 5 µL. For each compound tested, either after intravenous or 
after intracavernosal injection, a dose-response curve was established. Between each 
injected dose, the injection catheter was flushed several times with heparinized saline to 
remove all residual agent.  
 
III.3 Data analysis and statistical procedures 
Data are presented as mean values ± standard error of the mean; N represents the number 
of preparations. For the in vitro experiments, the relaxations are expressed as the 
percentage decrease in contraction level. The level of NOR-induced contraction is presented 
in mN. For the in vivo experiments, blood pressure changes are shown as absolute changes 
in MAP (mmHg) whereas the ICP effects are calculated as the ICP adjusted for the MAP, 
expressed in percentage (ICP/MAP x 100). Statistical significance was evaluated using the 
nonparametric test for paired (Wilcoxon: CC strips), unpaired (Mann-Withney U: arterial ring 
segments) and multiple unpaired (Kruskal-Wallis with Bonferroni-corrected pairwise 
comparison: analysis of the different ruthenium-containing compounds on aorta ring 
segments) observations when appropriate (SPSS, version 18; IBM Corporation, Armonk, NY, 
USA). Data were considered statistically significant when P<0.05. 
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IV.1 Abstract 
INTRODUCTION: Erectile dysfunction (ED) as well as many cardiovascular diseases are 
associated with impaired NO-bioavailability. Recently, oxime derivatives have emerged as 
vasodilators due to their NO-donating capacities. However, whether these oximes offer 
therapeutic perspectives as alternative NO-delivery strategy for the treatment of ED is 
unexplored.  
AIMS: This study aims to analyze the influence of formaldoxime (FAL), formamidoxime (FAM) 
and cinnamaldoxime (CAOx) on corporal tension and to elucidate the underlying molecular 
mechanisms. 
METHODS: Organ bath studies were carried out measuring isometric tension on isolated 
mice corpora cavernosa (CC), thoracic aorta and femoral artery. After contraction with 
norepinephrine (NOR), cumulative concentration-response curves of FAL, FAM and CAOx 
(100 nmol/L – 1 mmol/L) were performed.  
MAIN OUTCOME MEASURES: FAL-/FAM-induced relaxations were evaluated in the 
absence/presence of various inhibitors of different molecular pathways.  
RESULTS: FAL, FAM and CAOx relax isolated CC as well as aorta and femoral artery from 
mice. ODQ (sGC inhibitor), diphenyliodonium chloride (nonselective flavoprotein inhibitor) 
and 7-ethoxyresorufin (inhibitor of CYP450 1A1 and NADPH-dependent reductases) 
substantially blocked the FAL-/FAM-induced relaxation in the arteries, but not in CC. Only a 
small inhibition of the FAM response was observed with ODQ.  
CONCLUSIONS: This study shows for the first time that NO-donating oximes relax mice CC. 
Therefore oximes are a new group of molecules with potential for the treatment of ED. 
However, the underlying mechanism(s) of the FAL-/FAM-induced corporal relaxation clearly 
differ(s) from the one(s) involved in arterial vasorelaxation.  
Keywords: Corpora cavernosa; oxime; formaldoxime; formamidoxime; cinnamaldoxime; 
erectile function 
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IV.2 Introduction 
Over the past decades nitric oxide (NO) has evolved as an important (patho)physiological 
signaling molecule with therapeutic potential. The endogenous production occurs via NO 
synthase (NOS) that hydroxylates L-arginine to the stable intermediate Nω-hydroxy-L-
arginine (L-NOHA). L-NOHA is further oxidized to L-citrulline and NO [1]. NO acts as the 
principle mediator of penile erection and is also the best known vasodilator in the 
cardiovascular system. Several disease states such as erectile dysfunction (ED) and 
hypertension are associated with impaired NO-mediated relaxations due to loss of 
endothelial and/or neuronal production of and/or response to NO [2,3]. To compensate for 
this loss, some oxime derivatives have been presented as new NO donor molecules, 
mimicking the action of endogenous NO by their bioconversion to NO or NO-related 
compounds [4,5]. In the past, the NO-donating capacities of oximes were demonstrated both 
by direct (electron paramagnetic resonance spectroscopy) and indirect (NO-scavenging with 
PTIO) strategies [4-6]. In rat aorta both formaldoxime (FAL) and formamidoxime (FAM) have 
been shown to induce a substantial vasorelaxant effect [4]. Moreover, participation of the 
NO pathway in the cinnamaldoxime (CAOx)-induced relaxation has been demonstrated in rat 
mesenteric artery [5]. As proven vasodilators of arteries, oximes could also be of value in the 
treatment of ED. However, no studies support this hypothesis yet.  
 
 
IV.3 Aims 
In our study we examined the ability of FAL, FAM and CAOx to relax isolated mice corpora 
cavernosa (CC). Furthermore, the mechanisms underlying this effect were examined and 
compared with the mechanisms involved in the relaxation of mice aorta and femoral artery. 
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IV.4 Materials and methods 
IV.4.1 Animals 
Mature (age 8-12 weeks) male Swiss mice were obtained from Janvier (Saint-Berthevin, 
France). Food and water were provided ad libitum and all animals were treated in 
accordance with the Guide for the Care and Use of Laboratory Animals published by the  
US National Institutes of Health. This study was approved by the local Ethical Committee for 
Animal Experiments.  
IV.4.2 Tissue preparations and mounting 
After cervical dislocation thoracic aorta, femoral artery and corpora cavernosa (CC) were 
carefully isolated, displaced in cold Krebs-Ringer bicarbonate (KRB) solution, mounted into 
10 ml organ baths from a myograph for isometric tension measurements as previously 
described [7,8] and left to equilibrate for 30 minutes in KRB solution (37°C; pH 7.4, bubbled 
with 95% O2 – 5% CO2). 
IV.4.3 Preliminary protocol 
Before starting with the actual experiments, each tissue was subjected to a slightly different 
preliminary protocol in order to obtain maximal, stable contractions and relaxations as 
previously described [7-9]. To test the functionality of the endothelium, 5 µmol/L (aorta and 
CC) or 10 µmol/L (femoral artery) norepinephrine (NOR) was used to induce contraction and 
when a stable plateau was reached, 10 µmol/L (arteries) or 1 µmol/L (CC) acetylcholine 
(ACh) was added. Thereafter, preparations were washed until basal tone was obtained.  
IV.4.4 Experimental protocol 
All preparations were contracted with NOR, and when a stable plateau was obtained, 
cumulative concentration-response curves for FAL, FAM and CAOx (100 nmol/L – 1 mmol/L) 
were established. The molecular pathways involved in these effects were tested using 
different inhibitors. In some experiments, the endothelium of aortic or femoral artery 
segments was removed by gently rubbing the intimal surface with a rough polyethylene tube 
or small hair respectively, while the CC were carefully squeezed between 2 fingers for  
30 seconds. The absence of functional endothelium was evaluated by the loss of response to 
ACh.  
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IV.4.5 Drugs, chemicals and reagents 
The experiments were performed in a KRB solution with the following composition 
(mmol/L): NaCl, 135; KCl, 5; NaHCO3, 20; glucose, 10; CaCl2, 2.5; MgSO4, 1.3; KH2PO4, 1.2 and 
EDTA, 0.026 in H2O. Norepinephrine bitartrate (NOR), dimethylsulfoxide (DMSO), 
acetylcholine chloride (ACh), formaldoxime trimer hydrochloride (FAL), formamidoxime 
(FAM), cinnamaldoxime (CAOx), 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ),  
4’-hydroxy-3’-methoxyacetophenone (apocynin), diphenyliodonium chloride (DPI),  
7-ethoxyresorufin (7-ER), miconazole nitrate, Nω-Nitro-L-arginine (L-NNA), 
tetraethylammoniumchloride (TEA), apamin, SQ 22,536, and compound C were obtained 
from Sigma-Aldrich (St.Louis, MO, USA). DPI, apocynin, 7-ER, miconazole and compound C 
were dissolved in DMSO and ODQ in ethanol. All other drugs were dissolved in distilled 
water. Incubation with ODQ, 7-ER and L-NNA elicited a significant increase in the  
NOR-induced contraction of the arterial ring segments, whereas DPI and miconazole evoked 
a substantial decrease. However, these experiments were also performed on ring segments 
of mice with a 129SvJ background in which the contraction level was not/barely influenced. 
These results led to the same conclusions as compared to our results with the Swiss mice. 
The final concentrations of vehicle solution in the organ bath never exceeded 0.1 %. 
IV.4.6 Data analysis and statistical procedures 
Data are presented as mean values ± SEM; N represents the number of preparations. The 
relaxations are expressed as the percentage decrease in contraction level. Statistical 
significance was evaluated by using the Mann-Withney U-test (aorta and femoral artery) and 
Wilcoxon test (CC) (SPSS, version 18; IBM Corporation, Armonk, NY, USA). P<0.05 was 
considered as significant.  
 
 
IV.5 Main outcome measures 
FAL- and FAM-induced concentration-response curves were evaluated in the absence and 
presence of different inhibitors.  
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IV.6 Results 
IV.6.1 Effect of FAL, FAM and CAOx 
In precontracted corporal strips FAL, FAM and CAOx (100 nmol/L – 1 mmol/L) elicited a 
concentration-dependent relaxant effect (Fig. IV.1). However, FAM induced a substantially 
smaller relaxation than FAL and CAOx (maximal effect FAL: 73.26% ± 5.62 –  
FAM: 40.52% ± 4.59 – CAOx: 92.6% ± 6.42 – control: 4.17% ± 6.42). The onset of FAL 
relaxation was relatively fast, while the FAM and CAOx relaxations were rather gradual  
(Fig. IV.1). After intensive washout, a similar NOR-induced contraction level is obtained when 
compared to the first contraction with NOR. This illustrates the reversibility of the 
relaxations induced by oximes. Moreover, the concentration-response curves of FAL, FAM 
and CAOx could be reproduced on the same preparation (data not shown). FAL, FAM and 
CAOx also elicited a concentration-dependent relaxation in precontracted aorta and femoral 
artery rings. The FAL-/FAM-induced relaxations were quite similar, while CAOx induced a 
more pronounced relaxation at the highest concentrations in both aorta (maximal effect 
FAL: 71.13% ± 4.34 – FAM: 80.4% ± 3.2 – CAOx: 104.7% ± 1.76 – control: -4.65% ± 1.09) and 
femoral artery (maximal effect FAL: 61.89% ± 5.18 – FAM: 88.16% ± 6.7 –  
CAOx: 103.84% ± 1.29 – control: 9.06% ± 4.46).  
 
Figure IV.1: Original tracings showing a concentration-response curve to formaldoxime (FAL) (-log mol/L) (A); 
formamidoxime (FAM) (-log mol/L) (B) and cinnamaldoxime (CAOx) (-log mol/L) (C) in mice CC precontracted 
with NOR. 
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IV.6.2 Involvement of sGC 
CC incubated with the soluble guanylyl cyclase (sGC) inhibitor ODQ (10 µmol/L, 10 min) 
showed a somewhat smaller relaxation with FAM (Fig. IV.2F) but not with FAL (Fig. IV.2E). 
However, ODQ significantly decreased the FAL effects in aorta as well as femoral artery  
(Fig. IV.2A and C) and almost abolished FAM-induced relaxations (Fig. IV.2B and D).  
 
Figure IV.2: The effect of formaldoxime (FAL) and formamidoxime (FAM) in the absence () or presence () of  
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) (10 µmol/L incubated during 10 minutes) in thoracic aorta 
(A and B); in femoral artery (C and D) and in CC (E and F). Data are expressed as % relaxation of the NOR-
induced tone (N = 5-6); *P<0.05 and #P<0.01 
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IV.6.3 Involvement of NADPH oxidase/reductase and CYP450 
The nonselective flavoprotein inhibitor DPI (10 µmol/L, 30 min) caused a very small 
inhibition only at the highest concentration of FAL and FAM in CC (Fig. IV.3E and F). In 
contrast, a strong inhibition of the FAL-/FAM-induced relaxations occurred in aortic and 
femoral artery rings after incubation with DPI (Fig. IV.3A–D).  
 
Figure IV.3: The effect of formaldoxime (FAL) and formamidoxime (FAM) in the absence () or presence () of 
diphenyliodonium chloride (DPI) (10 µmol/L incubated during 30 minutes) in thoracic aorta (A and B); in 
femoral artery (C and D) and in CC (E and F). Data are expressed as % relaxation of the NOR-induced tone  
(N = 5-9); *P<0.05 and #P<0.01 
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In the CC FAL-/FAM-induced relaxations were not influenced in the presence of apocynin  
(300 µmol/L, 20 min), a specific blocker of NADPH oxidases (Fig. IV.4E and F). Moreover, 
apocynin did not affect the FAL response in the arteries (Fig. IV.4A and C) but significantly 
diminished the vasorelaxant effect of FAM (Fig. IV.4B and D). 
 
Figure IV.4: The effect of formaldoxime (FAL) and formamidoxime (FAM) in the absence () or presence () of 
apocynin (300 µmol/L incubated during 20 minutes) in thoracic aorta (A and B); in femoral artery (C and D) and 
in CC (E and F). Data are expressed as % relaxation of the NOR-induced tone (N = 6-9); *P<0.05 and #P< 0.01 
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7-ER (10 µmol/L, 20 min), an inhibitor of NADPH-dependent reductases and CYP450 1A1, 
failed to inhibit the FAL-/FAM-responses in CC (Fig. IV.5E and F), but significantly diminished 
the FAL effect and even abolished the FAM relaxation in arteries (Fig. IV.5A–D). The CYP450-
inhibitor miconazole (10 µmol/L, 20 min) did not modify the FAL-/FAM-induced relaxation 
neither in the CC nor in the arteries (data not shown).  
 
Figure IV.5: The effect of formaldoxime (FAL) and formamidoxime (FAM) in the absence () or presence () of  
7-ethoxyresorufin (7-ER) (10 µmol/L incubated during 20 minutes) in thoracic aorta (A and B); in femoral artery 
(C and D) and in CC (E and F). Data are expressed as % relaxation of the NOR-induced tone (N = 5-7); *P<0.05 
and #P<0.01 
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IV.6.4 Involvement of NOS and the endothelium 
The NOS inhibitor L-NNA (100 µmol/L, 20 min) did not alter the FAL-/FAM-induced responses 
in the CC (Fig. IV.6E and F). Surprisingly, in the arteries the relaxant effect of FAL was 
substantially enhanced (Fig. IV.6A and C), whereas the FAM-induced relaxations showed only 
a very small increasing trend at higher concentrations (Fig. IV.6B and D).  
 
Figure IV.6: The effect of formaldoxime (FAL) and formamidoxime (FAM) in the absence () or presence () of  
Nω-Nitro-L-arginine (L-NNA) (100 µmol/L incubated during 20 minutes) in thoracic aorta (A and B); in femoral 
artery (C and D) and in CC (E and F). Data are expressed as % relaxation of the NOR-induced tone (N = 6-8); 
*P<0.05 and #P<0.01 
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Removal of the endothelium did not modify the FAL-/FAM-effects in the CC (Fig. IV.7E and 
F). In endothelium-denuded aorta a significantly enhanced relaxation of FAL was seen, 
whereas in femoral artery this enhancement was limited to one concentration. (Fig. IV.7A 
and C). Removal of the endothelium elicited only a limited, but statistically significant, 
increase of the FAM response in aortic rings but had no effect in femoral artery (Fig. IV.7B 
and D). 
 
Figure IV.7: The effect of formaldoxime (FAL) and formamidoxime (FAM) in the presence () or absence () of 
the endothelium in thoracic aorta (A and B); in femoral artery (C and D) and in CC (E and F). Data are expressed 
as % relaxation of the NOR-induced tone (N = 6-9); *P<0.05 and #P<0.01 
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IV.6.5 Involvement of other pathways 
To explore the role of alternative pathways in the FAL-/FAM-induced corporal relaxation, the 
K+ channel blocker TEA (3 mmol/L, 20 min), the small-conductance Ca2+-activated K+ channel 
blocker apamin (1 µmol/L, 20 min), the adenylyl cyclase inhibitor SQ 22,536 (100 µmol/L, 20 
min) and the AMP kinase inhibitor compound C (10 µmol/L, 20 min) were used. None of 
these inhibitors influenced the FAL-/FAM-related responses in the CC (data not shown). 
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IV.7 Discussion 
In this study, we show for the first time that oximes such as FAL, FAM and CAOx relax mice 
corporal tissue and thus may be of interest in the treatment of ED. Surprisingly, the 
mechanism(s) underlying this relaxant effect differ(s) considerably from the one(s) involved 
in the oxime-induced relaxation of arteries. 
In the search for NO donor drugs, oxime derivatives have been presented as a new group. 
Oximes have attracted attention because of their close resemblance with L-NOHA, the stable 
intermediate in the endogenous NO production [10]. Since L-NOHA elicits a concentration-
dependent vasodilation, the presence of a C=NOH bond in oxime derivatives raised the 
question whether they also could serve as an alternative NO-delivery strategy [11]. The 
relaxant effect of different substituted non-aromatic oximes, including FAL and FAM, as well 
as the aromatic CAOx has already been demonstrated in isolated rat aorta and mesenteric 
artery respectively [4,5]. In our study, we tested these compounds in the context of penile 
erection and demonstrated that FAL, FAM and CAOx indeed elicit a pronounced relaxation of 
mice CC. Parallel experiments on mice aorta and femoral artery were performed in which 
their profound vasorelaxing capacity was confirmed. However, the CAOx-related effect was 
not entirely concentration-dependent and required higher concentrations in comparison 
with the gradual FAL-/FAM-induced relaxations. Moreover, the very poor solubility in water 
and the strong arterial relaxant (side)effects would limit the therapeutic value of CAOx for 
the treatment of ED. Therefore, we focused on the FAL-/FAM-induced relaxations. 
The main endogenous target of NO is sGC which stimulates various (vaso)relaxing pathways 
through the formation of cGMP. Obviously, the sGC/cGMP-pathway should, at least in part, 
be involved in the effect of any possible NO donor. Hence, an activation of sGC was 
implicated in the vasorelaxation by L-NOHA and other compounds bearing a C=NOH function 
[5,6,12,13]. Even more specifically for FAL and FAM, it was proven on rat aorta that their 
effect was strongly diminished when sGC was inhibited by ODQ [4]. Also we found that ODQ 
substantially decreased the FAL vasorelaxation in the mice arteries and the FAM response 
was even completely abolished, definitely supporting the importance of the sGC/cGMP 
pathway. Surprisingly, our results in the CC only revealed a small inhibition of the FAM 
relaxation by ODQ, whereas ODQ had even no influence at all on the FAL effect.  
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As oxime-induced relaxation does not result from spontaneous NO release, but rather occurs 
via biotransformation within the tissue, we were interested in the underlying metabolization 
pathway(s) [4]. It was reported that diphenyleneiodonium, an analog of the non-specific 
flavoprotein inhibitor DPI, inhibited the metabolic activation of glyceryl trinitrate (GTN) 
which is considered as the prototypic NO donor through enzymatic biotransformation 
[14,15]. Besides for GTN, flavoproteins are involved in the rat aorta relaxation of L-NOHA 
and 4-chloro-benzamidoxime, which also possess a C=NOH function, as DPI could block their 
effect [6]. Also in our experiments, DPI almost abolished FAL-/FAM-related responses in 
aorta and femoral artery, clearly indicating the participation of (a) flavoprotein-based 
mechanism(s). However, this was not the case for the FAL-/FAM-induced relaxations in the 
CC.  
Diphenyleneiodonium and DPI are frequently used for the nonselective inhibition of NADPH 
oxidase [16]. Though apocynin, the best known NADPH oxidase inhibitor, did not modify the 
FAL-induced relaxations and caused only a limited inhibition of the FAM response in the 
arteries. These results suggest that not NADPH oxidase inhibition, but other mechanisms are 
responsible for the strong inhibition of the FAL-/FAM-related effects in the presence of DPI. 
Besides NADPH oxidase, diphenyleneiodonium and DPI block multiple other enzyme systems 
including NOS, glucose phosphate dehydrogenase, xanthine oxidase, mitochondrial electron 
transport, aldehyde dehydrogenase-2, aldehyde oxidase, and NADPH-CYP450 reductase  
[15-17]. In terms of oxime-induced relaxations NADPH-CYP450 reductase seems to be of 
particular interest. Several studies demonstrated the importance of the CYP450/NADPH-
CYP450 reductase system in the NO-mediated responses of ACh, GTN and sodium 
nitroprusside [18,19]. Furthermore 7-ER, an inhibitor NADPH-dependent reductases and 
CYP450 1A1, diminished the relaxations induced by L-NOHA, 4-chloro-benzamidoxime, FAL, 
FAM and other oxime derivatives [4-6,12,20]. Unfortunately in our mouse model no 
decrease of the FAL-/FAM-induced relaxations by 7-ER could be observed in the CC. At the 
same time, a pronounced inhibition of the FAL response occurred in the aorta and femoral 
artery whereas the FAM effect was even completely blocked. So in the arteries  
7-ER-sensitive mechanisms, e.g. CYP 450 and/or NADPH-dependent reductases, do seem to 
be involved. However, miconazole had no influence on either FAL-/FAM-induced relaxations, 
ruling out the significance of CYP450. This is in accordance with the failure of the CYP450-
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inhibitors proadifen, 17-ODYA and/or miconazole to inhibit the vasorelaxing effect of  
L-NOHA and some oximes [4,6,11-13]. In contrast, for some other oxime derivatives it was 
reported that NO formation was mediated by CYP450 [21,22]. 
The combined results of 7-ER and miconazole are pointing towards a contribution of NADPH-
dependent reductases in the FAL-/FAM-induced relaxation. Because of their structural and 
functional resemblance it is not surprising that besides NADPH-CYP450 reductase also the 
NADPH-dependent reductase domain of NOS can be blocked by 7-ER [19,23,24]. The 
oxidative cleavage of the C=NOH function can occur through NOS-dependent pathways [8], 
but the relaxant effect of various oximes is NOS-independent [4-6]. In correspondence  
L-NNA had no effect on the FAL-/FAM-induced responses in the CC as well as the FAM 
response in the arteries. Surprisingly, L-NNA strongly enhanced the FAL-induced 
vasorelaxation. Previously, a similar but non-significant trend for the FAL relaxation in rat 
aorta was noticed [4]. An explanation for the enhanced response after NOS-inhibition 
remains to be found, but this phenomenon can be associated with some in vivo 
experiments. In one study oxime derivatives, including FAL and FAM, elicited only an acute 
systemic vasodilation in vivo when the endogenous NO production was blocked [25]. L-NNA 
only blocks the endogenous NO formation, but other (endothelial) pathways, such as the 
endothelium-derived hyperpolarizing factor and vasodilatory prostanoids, are preserved and 
should be considered. Nevertheless, in our study, endothelium-denuded preparations 
exhibited analogous results. The FAM effect remained unchanged after removal of the 
endothelium. In contrast, the FAL-induced vasorelaxation was even more pronounced in the 
absence of the endothelium. This partially correlates with experiments on rat aorta in which 
no difference was observed in FAL-/FAM-related responses between tissues with or without 
endothelium [4]. So although addition of L-NNA and removal of the endothelium do not 
affect the exact same molecular mechanisms, their effect on our FAL and FAM results 
reflects that there exists some kind of overlap. The results with L-NNA as well as with 
endothelium removal indicate that an absence of endogenous NO and/or endothelium 
promotes FAL-induced relaxation. A possible explanation for these enigmatic observations is 
that the absence of functional NOS shifts breakdown of the oximes to other mechanisms 
leading to vasorelaxing metabolites. Nevertheless, elimination of these endogenous systems 
would entail a stronger efficacy of FAL, which could be beneficial under pathological 
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conditions. After all, different types of ED as well as multiple cardiovascular diseases are 
linked to endothelial dysfunction which is mainly related to a decreased NO formation 
and/or lowered NO responsiveness [2,26]. The more pronounced relaxant effect of FAL and 
FAM in the absence of NOS and the endothelium could therefore compensate for this 
diminished NO and reduce the deleterious consequences of impaired NOS activity.  
Our study reveals a clear difference between arteries and CC. Although both FAL and FAM 
elicit corporal smooth muscle relaxation as well as arterial vasorelaxation, the pathways 
activated by FAL and FAM in the arteries are more evident than those in the CC. In the 
arteries, a pronounced inhibition with ODQ proves the importance of the sGC/cGMP-
pathway. Since both miconazole and L-NNA fail to influence the FAL-/FAM-induced 
responses, inhibition by 7-ER implicates the involvement of NADPH-CYP450 reductase. This 
observation is further supported by the fact that DPI blocked the FAL-/FAM-related effects 
to the same extent as 7-ER. The NO donor capacities of FAL and FAM were previously 
demonstrated by electron paramagnetic resonance spectroscopy and by the blunting of 
their vasorelaxing effect by the NO-scavenger PTIO [4]. Taking this into account we assume 
that the underlying mechanism of FAL-/FAM-induced vasorelaxation involves the metabolic 
conversion of the C=NOH function to NO or NO-related compound by (a) NOS- and 
endothelium-independent, but NADPH-CYP450 reductase-dependent mechanism(s) and 
subsequent activation of the sGC/cGMP pathway. One should keep in mind that this 
pathway does not cover the complete FAL response because ODQ, 7-ER and DPI only have a 
partial inhibitory effect. So (an) other (NO-independent) mechanism(s) take(s) part in the 
FAL-induced relaxation. Recently, an analogous pathway was suggested for CAOx [5]. 
Concerning the FAM-induced vasorelaxation, a small role can be addressed to NADPH 
oxidase. The surprising enhancement of FAL responses in the absence of endogenous NO 
and/or endothelium offers therapeutic perspectives in several disease states. 
On the contrary, in the CC the exact mechanism of action remains elusive. NOS, NADPH 
oxidase, NADPH-dependent reductases, CYP450, AMP kinase, adenylate cyclase and  
K+ channels do not appear to be involved. Only a limited involvement of the sGC/cGMP 
pathway in the FAM response is found. Because of the sGC/cGMP participation, FAM could 
be beneficial in combination with PDE5-inhibitors, since in many ED variants lack of sufficient 
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amounts of cGMP undermines the efficacy of PDE5-inhibitors [27-29]. Besides that, the  
NOS- and endothelium-independency of the FAL-/FAM-related responses makes them still 
valuable in ED associated with endothelial dysfunction.  
 
IV.8 Conclusion 
In conclusion, this study shows for the first time that FAL, FAM and CAOx elicit relaxation in 
mice CC. The mechanism(s) involved in the FAL-/FAM-induced relaxations are clearly 
different from the mechanism(s) underlying their arterial vasorelaxing effect. In the CC  
NOS- and endothelium-independency could be demonstrated. In the arteries NADPH-
CYP450 reductase and the sGC/cGMP pathway seem to mediate the vasorelaxation elicited 
by FAM and partially by FAL. NADPH oxidase also plays a limited role in the FAM 
vasorelaxation. In addition, when functional NOS and/or endothelium are absent FAL-
induced vasorelaxation is stronger. Thus, oximes can further be considered as alternative 
NO-donating drugs for the treatment of ED. 
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V.1 Abstract 
INTRODUCTION: Because of their NO-donating capacities, oxime derivatives have shown to 
offer some therapeutic perspective for the treatment of erectile dysfunction (ED) as well as 
cardiovascular diseases. However, to date the in vivo effect of these oximes on erectile 
function remains unknown. In many disease states oxidative stress occurs, impairing  
NO-mediated relaxations. Hence the influence of oxidative stress on oxime-induced effects is 
also of interest.  
AIMS: This study aimed to evaluate the in vivo effect of formaldoxime (FAL) and 
formamidoxime (FAM) on blood pressure and intracavernosal pressure (ICP); and to examine 
the role of sGC and the influence of oxidative stress on the FAL and FAM responses. 
METHODS: Blood pressure and intracavernosal pressure were monitored in vivo after resp. 
intravenous or intracavernosal injection of FAL and FAM. Moreover isometric tension was 
measured in vitro on isolated mice corpora cavernosa (CC), thoracic aorta and femoral artery 
in organ baths. The role of sGC was investigated by using transgenic mice lacking the alpha 1 
subunit of sGC.  
MAIN OUTCOME MEASURES: Mean arterial pressure (MAP) and intracavernosal pressure 
(ICP) were measured after FAL/FAM injection. In vitro relaxation of CC strips was evaluated 
in response to addition of FAL/FAM.  
RESULTS: In vivo both FAL and FAM elicit a dose-dependent lowering of blood pressure 
(maximal ΔMAP: 33.66 ± 4.07mmHg (FAL) and 20.43 ± 2.06mmHg (FAM)) as well as an 
increase of intracavernosal pressure (maximal increase of ICP/MAP: 70.29 ± 2.88% (FAL) and 
52.91 ± 8.61% (FAM)). The FAL/FAM effect is significantly lower in knockout versus wild-type 
mice. Oxidative stress has an inhibitory effect on corporal NO-mediated relaxations induced 
by electrical field stimulation (EFS), acetylcholine (ACh) and sodium nitroprusside (SNP) 
whereas the responses to 8-(4-chlorophenylthio)-guanosine 3’,5’-cyclic monophosphate 
sodium salt, FAL and FAM were not influenced.  
CONCLUSIONS: Oximes induce erection which is mediated by sGC. The oxime-induced 
relaxations are resistant to oxidative stress, which increases their therapeutic potential for 
the treatment of ED.  
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V.2 Introduction 
The nitric oxide(NO)/soluble guanylyl cyclase(sGC)/cyclic guanosine monophosphate(cGMP)-
pathway plays a pivotal role in the normal regulation of penile erection as well as in the 
complex balance of vascular tone. Consequently, any profound lowering in NO production 
and/or decreased response to endogenously formed NO can result in erectile dysfunction 
(ED) and/or various cardiovascular diseases [1]. NO-donors have been used for several years 
to compensate for lost NO-bioavailability. Recently, oxime compounds such as formaldoxime 
(FAL) and formamidoxime (FAM) (Fig. V.1) have been presented as a new class of  
NO-donating molecules because of their structural resemblance with Nω-hydroxy-L-arginine 
(L-NOHA), a stable intermediate in the endogenous NO production. These oximes relax 
vascular tissues as well as mice corpora cavernosa (CC) through metabolization within the 
tissue [2-4]. Furthermore, oxime derivatives show a distinct blood pressure-lowering effect 
in rats after inhibition of the endogenous NO synthesis [5]. However, so far the in vivo effect 
of oximes on intracavernosal pressure (ICP) and their ability to induce erection is not studied 
yet. 
The lowered NO functioning in ED often results from an increased production of reactive 
oxygen species, diminishing the effective NO concentration for cavernosal smooth muscle 
relaxation [6]. Therefore oxidative stress associated with hypertension [7], diabetes [8,9], 
aging [10,11], hypercholesterolemia [12] and radiation damage [13] can lead to ED. It was 
reported that oxidative stress impairs NO-mediated relaxations of mice CC [14]. Hence, we 
were interested if oxidative stress also has an influence on the FAL-/FAM-induced corporal 
relaxations, as an impairment would limit their therapeutic relevance. 
 
 
Figure V.1: The chemical structure of formaldoxime (FAL) and formamidoxime (FAM). 
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V.3 Aims 
In our study, we examined the in vivo effect of FAL and FAM on blood pressure and ICP. The 
importance of sGC in the FAL-/FAM-induced effects was characterized both in vitro and in 
vivo. Moreover the influence of oxidative stress on (NO-mediated) corporal relaxation was 
evaluated in vitro.  
 
V.4 Materials and methods 
V.4.1 Animals 
For our in vitro and in vivo experiments mature (8-14 weeks) male soluble guanylyl cyclase 
alpha 1 knockout (sGCα1
-/-) mice and sGCα1
+/+ mice (129SvJ) were used [15]. All animals were 
bred in the SPF facility of the Department of Molecular Biomedical Research (VIB, Ghent, 
Belgium) and were treated in accordance with the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health. This study was also approved by 
the local Ethical Committee for Animal Experiments (Faculty of Medicine and Health 
Sciences, Ghent University, Belgium).  
V.4.2 In vitro study 
V.4.2.1 Tissue preparations and mounting 
Thoracic aorta, femoral artery as well as CC were isolated from the animals after cervical 
dislocation. The tissues were then mounted into 10 ml organ baths from a myograph for 
isometric tension measurements as previously described [16,17]. The mounted tissues were 
left to equilibrate for30 minutes in Krebs-Ringer bicarbonate (KRB) solution at 37°C (pH 7.4) 
and continuously bubbled with carbogen gas (95% O2 – 5% CO2). 
V.4.2.2 Preliminary protocol 
In order to obtain maximal, stable contractions and relaxations during the actual 
experiments, each tissue was subjected to a slightly different preliminary protocol as 
previously described [16-18]. Functionality of the endothelium was tested by addition of  
10 µmol/L (arteries) or 1 µmol/L (CC) acetylcholine (ACh) to the organ baths after 
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contraction with 5 µmol/L (aorta and CC) or 10 µmol/L (femoral artery) norepinephrine 
(NOR). Afterwards the preparations were rinsed extensively until they returned to their basal 
tension level.  
V.4.2.3 Experimental protocol 
In a first series of experiments both the effect of FAL and FAM was tested in sGCα1
-/- and 
compared to their effect in the wild-type control mice (sGCα1
+/+). All preparations were 
contracted with NOR and when a stable plateau was obtained cumulative concentration-
response curves for FAL and FAM (100 nmol/L – 1 mmol/L) were established. In a second 
series of experiments the influence of oxidative stress on corporal relaxations was evaluated. 
CC were incubated with the superoxide generator/free radical scavenger hydroquinone  
(50 µmol/L) and the superoxide dismutase inhibitor diethyldithiocarbamic acid (DETCA)  
(8 mmol/L) for 20 minutes. After reaching a stable contraction with phenylephrine  
(5 µmol/L), electrical field stimulation (EFS; train duration 40s; frequency 1, 2, 4 and 8 Hz; 
pulse duration 5ms; 80V) as well as cumulative concentration response curves for ACh, 
sodium nitroprusside (SNP), 8-(4-chlorophenylthio)-guanosine 3’,5’-cyclic monophosphate 
sodium salt (8-pCPT-cGMP), FAL and FAM were performed. 
V.4.3 In vivo study 
Mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and placed on a 
heated blanket maintaining their body temperature at 37°C. A PE-10 tube filled with 
heparinized saline (25 U/mL) was inserted into the carotid artery and connected to a 
pressure transducer to monitor the mean arterial pressure (MAP). A 30-gauge needle 
attached to another PE-10 tube was introduced into the right CC and also connected to a 
pressure transducer to measure the intracavernosal pressure (ICP). The effect of FAL and 
FAM (1–8 mg/kg) on blood pressure was evaluated after intravenous injection via a PE-10 
tube inserted into the jugular vein (standardized injection volume of 10 µL). In a second set 
of experiments, the ICP response to FAL and FAM (1–8 mg/kg) was investigated through 
intracavernosal administration via a separate cannula (30-gauge needle attached to a PE-10 
tube) inserted into the left CC (standardized injection volume of 5 µL). Between each 
injected dose the cannulas were flushed several times with heparinized saline to remove 
residual agent. 
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V.4.4 Drugs, chemicals and reagents 
The experiments were performed in a KRB solution with the following composition 
(mmol/L): NaCl, 135; KCl, 5; NaHCO3, 20; glucose, 10; CaCl2, 2.5; MgSO4, 1.3; KH2PO4, 1.2 and 
EDTA, 0.026 in H2O. NOR bitartrate, ACh, FAL hydrochloride, FAM, SNP, 8-pCPT-cGMP, 
hydroquinone, DETCA sodium salt and phenylephrine hydrochloride were obtained from 
Sigma-Aldrich (St.Louis, MO, USA). All drugs were dissolved in water (in vitro) or heparinized 
saline (25 U/mL) (in vivo). Concentrations are expressed as final molar concentrations in the 
organ bath experiments, while for the in vivo study the amount of agent injected is given as 
mg/kg.  
V.4.5 Data analysis and statistical procedures 
Data are presented as mean values ± SEM; N represents the number of preparations. For the 
in vitro experiments, relaxations are expressed as the percentage decrease in contraction 
level. For the in vivo study, blood pressure effects are shown as absolute changes in MAP 
whereas the intracavernosal pressure results are calculated as the ICP adjusted for the MAP, 
expressed in percentage (ICP/MAP x 100). Statistical significance was evaluated by using the 
non-parametric tests for paired (Wilcoxon) and unpaired (Mann-Withney U) observations 
when appropriate (SPSS, version 18; IBM Corporation, Armonk, NY, USA). P<0.05 was 
considered as significant.  
 
V.5 Main outcome measures 
MAP and ICP were measured in vivo after respectively intravenous and intracavernosal 
FAL/FAM injection. In vitro relaxation of CC strips was evaluated in response to addition of 
FAL/FAM. The results of the wild-type control mice were compared to the effects in the 
knockout mice to assess the role of sGC. The influence of oxidative stress was determined 
after generation of superoxide and inhibition of superoxide dismutase.  
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V.6 Results 
V.6.1 Role of sGC in vitro 
Both FAL and FAM (100 nmol/L – 1 mmol/l) relaxed the different tissues of sGCα1
-/- and 
sGCα1
+/+ mice in a concentration-dependent manner. The responses in sGCα1
-/- preparations 
of aorta and femoral artery were significantly reduced but not completely abolished  
(Fig. V.2A-D). Moreover, FAM induced a lower effect in sGCα1
-/- CC compared to the wild-
type control strips (Fig. V.2F). In contrast, FAL elicited identical concentration-dependent 
relaxations of both sGCα1
-/- and sGCα1
+/+ CC (Fig. V.2E).  
 
Figure V.2: The effect of formaldoxime (FAL) and formamidoxime (FAM) in thoracic aorta (A and B); in femoral 
artery (C and D) and in corpora cavernosa (E and F) from sGCα1
+/+
 () and sGCα1
-/-
 () mice. Data are 
expressed as % relaxation of the norepinephrine (NOR)-induced tone (N = 4-6); *P<0.05 and #P<0.01 
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V.6.2 Role of sGC in vivo 
V.6.2.1 Blood pressure 
Basal MAP of sGCα1
+/+ mice (134 mmHg ± 2.28; N=31) was significantly (P < 0.001) lower 
compared to the basal MAP of sGCα1
-/- mice (157 mmHg ± 1.75; N=36) as previously 
described [15]. Intravenous injection of both FAL and FAM decreased MAP of sGCα1
-/- and 
sGCα1
+/+ mice dose-dependently (Fig. V.3A). However this MAP decrease was significantly 
less pronounced in the sGCα1
-/- mice. In contrast, the effects of vehicle control solutions did 
not differ between the sGCα1
-/- and sGCα1
+/+ mice. The characteristics of this MAP decrease 
seem to differ between FAL and FAM. Intravenous administration of FAL induces a biphasic 
response: a very fast blood pressure drop followed by a fast rise in blood pressure. Injection 
of FAM on the other hand elicits a more slow and maintained lowering of MAP, followed by 
a gradual recovery to the basal blood pressure level (Fig. V.3B).  
 
Figure V.3: (A) The changes in mean arterial pressure (MAP) after intravenous administration of formaldoxime 
(FAL) and formamidoxime (FAM) in sGCα1
+/+
 versus sGCα1
-/-
 mice. (ΔMAP = MAPafter – MAPbefore); (N = 6-10); 
*P<0.05 and #P<0.01. (B) Original tracings showing the change in mean arterial pressure (MAP) after 
intravenous (I.V.) administration of FAL and FAM (8 mg/kg) in sGCα1
+/+
 mice.  
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V.6.2.2 ICP 
Intracavernosal injection of increasing amounts FAL and FAM resulted in a dose-dependent 
increase in ICP of sGCα1
-/- as well as sGCα1
+/+ mice. Basal ICP, when adjusted for the MAP, as 
well as vehicle controls did not differ between both groups. On the contrary, the  
FAL-induced rise in ICP/MAP was significantly lower in sGCα1
-/- mice compared to sGCα1
+/+ 
mice. Moreover, in sGCα1
-/- mice the effect of FAM on ICP was almost completely abolished 
(Fig. V.4A). Intracavernosal injection of both FAL and FAM also induces a small and transient 
decrease in MAP (Fig. V.4B). 
 
Figure V.4: (A) The intracavernosal pressure/mean arterial pressure (ICP/MAP) ratio (in %) after 
intracavernosal administration of formaldoxime (FAL) and formamidoxime (FAM) in sGCα1
+/+
 versus sGCα1
-/-
 
mice. (N = 6-9); *P<0.05 and #P<0.01. (B) Original tracings showing the change in intracavernosal pressure 
(ICP) as well as mean arterial pressure (MAP) after intracavernosal (I.C.) administration of FAL and FAM  
(8 mg/kg) in sGCα1
+/+ 
mice. 
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V.6.3 Influence of oxidative stress on corporal relaxations 
Incubation with the superoxide generator hydroquinone (50 µmol/L) and the superoxide 
dismutase inhibitor DETCA (8 mmol/L) strongly inhibited NO-mediated relaxations induced 
by EFS, ACh and SNP (Fig. V.5A-C) in isolated CC. In contrast, the corporal relaxation by  
8-pCPT-cGMP, FAL and FAM remained unaffected (Fig. V.5D-F). 
 
Figure V.5: The influence of hydroquinone (50 µmol/L) and diethyldithiocarbamic acid (DETCA) (8 mmol/L) on 
relaxations of isolated corpora cavernosa induced by electrical field stimulation (EFS) (A); acetylcholine (ACh) 
(B); sodium nitroprusside (SNP) (C); 8-(4-chlorophenylthio)-guanosine 3′,5′-cyclic monophosphate  
(8-pCPT-cGMP) (D); formaldoxime (FAL) (E) and formamidoxime (FAM) (F) in corpora cavernosa (CC) of sGCα1
+/+
 
mice. Data are expressed as % relaxation of the phenylephrine-induced tone (N = 5-8); *P<0.05  
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V.7 Discussion 
Our results show for the first time that the oxime compounds FAL and FAM are able to 
induce erection in vivo. The blood pressure lowering effect of FAL and FAM as well as the 
importance of sGC in their responses were confirmed. Furthermore we demonstrated that 
both FAL and FAM seem to be resistant to oxidative stress offering some perspective as a 
potential new treatment strategy for ED. 
Oxime compounds were proposed as a new class of NO-donating molecules which can 
compensate the impaired NO functioning in various disease states. It was reported that 
metabolization of oxime compounds occurs through (a) 7-ethoxyresorufin sensitive 
pathway(s), resulting in the release of NO. Subsequently NO interacts with its main target 
sGC, eventually leading to smooth muscle relaxation [2-4]. A previous study in our lab 
already established the importance of sGC in both FAL- and FAM-mediated relaxations on 
isolated preparations. The sGC inhibitor 1H-[1,2,4]oxadiazolo[4,3-a] quinoxalin-1-one (ODQ) 
blocked FAL-induced vasorelaxation in mice aorta and femoral artery ring segments whereas 
the effect of FAM was even completely abolished. In contrast, ODQ had no influence on the 
FAL response in the isolated mice CC and only a limited involvement of sGC was 
demonstrated for the FAM effect [4]. Besides a pharmacological approach, the role of sGC in 
the  
FAL-/FAM-induced relaxations can further be characterized by a genetic approach using 
transgenic mice. After all ODQ lacks specificity as there are reports indicating that ODQ also 
influences the redox state of other heme-containing proteins than sGC such as cytochrome 
P450 [19]. Moreover, the use of genetically modified mice enables to differentiate between 
the different isoforms of sGC elucidating their individual role in the FAL/FAM responses. sGC 
is a αβ-heterodimer of which two isoforms exist for each subunit (α1/α2 and β1/β2), but only 
the sGCα1β1 and sGCα2β1 heterodimers are catalytically active [20]. In the sGCα1
-/- mice a 
deletion in the catalytic domain of the α1 subunit results in a selective loss of activity of the 
sGCα1β1 isoform [15]. Both FAL- and FAM-induced relaxations are significantly lower in the 
aorta and femoral artery ring segments of sGCα1
-/- mice compared to the wild-type control 
mice, implicating a role for the sGCα1β1 isoform in these responses. Also the FAM-effect in 
the CC seems to be mediated by the activation of the sGCα1β1 isoform, while this was not 
the case for the FAL-response. Remarkably, in our genetically modified sGCα1
-/- mice only a 
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limited lowering of the FAL-/FAM-induced relaxations of aorta and femoral artery occurred 
whereas ODQ almost abolished their responses, especially the FAM-response [4]. This can be 
explained by the fact that ODQ is able to inhibit both sGC isoforms. In the sGCα1
-/- mice on 
the other hand only the sGCα1β1 isoform is catalytically inactive while the sGCα2β1 isoform 
maintains its functionality. Thus the remaining sGCα2β1 activity could be responsible for the 
FAL-/FAM-induced vasorelaxation which is still seen in the sGCα1
-/- mice. In general we can 
say that sGC plays an important role in the FAL-/FAM-mediated relaxations. However, sGC 
does not appear to take part in the FAL-induced corporal relaxation which is in correlation 
with our previous in vitro study [4]. 
In contrast to our findings, FAL and FAM do not elicit a blood pressure lowering effect in 
control rats. However, a blood pressure drop could be demonstrated after inhibition of 
endogenous NO synthesis and this blood pressure drop was further enhanced when also the 
arterial baroreflex was interrupted [5]. Our in vivo experiments demonstrate that both FAL 
and FAM induce a dose-dependent blood pressure reduction in mice even without blockade 
of endogenous NO synthesis. This blood pressure lowering is at least in part mediated by the 
activation of sGC since the in vivo FAL-/FAM-response is significantly lower in sGCα1
-/- mice 
compared to their wild-type controls, which corresponds with our in vitro results. Jaros et al. 
[5] also reported an involvement of sGC in the blood pressure lowering effect of FAL and 
FAM in rats by using methylene blue, which is however a non-specific sGC inhibitor and also 
has redox effects. 
As yet, nothing is known about the effect of FAL and FAM on erectile function in vivo. In our 
study both compounds were administered through intracavernosal injection. This resulted in 
a dose-dependent increase of ICP. So, FAL and FAM not only relax corporal smooth muscles 
in vitro, but also in vivo, leading to a rise of ICP and ultimately erection. However, this ICP 
rise is less pronounced when compared to standard NO-donors such as SNP and Spermine-
NO. Lower doses of these NO-donors (µg/kg instead of mg/kg range) give even higher ICP 
values [21]. In accordance with the in vitro results in the CC, sGC is involved in the effect of 
FAM on ICP as its response was almost completely abolished in the sGCα1
-/- mice. 
Surprisingly sGC also plays a limited role in the FAL-induced ICP rise whereas in vitro no sGC-
involvement could be demonstrated in the corporal FAL-relaxation. 
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Various disease states are characterized by oxidative stress due to an increased production 
of reactive oxygen species, including superoxide. Excessive levels of superoxide lower  
NO-bioavailability by forming peroxynitrite [22]. The interaction between NO and superoxide 
is one of the important pathophysiological mechanisms implicated in ED [6]. In 
steptozotocin-induced diabetes in rats it was proven that antioxidant therapy improves  
NO-mediated neurogenic (EFS) and endothelium-dependent (ACh) corporal relaxation [23]. 
Lowered ICP values after cavernosal nerve stimulation in diabetic rats could be restored by 
treatment with the superoxide dismutase mimetic tempol [24] and adenoviral gene transfer 
of extracellular superoxide dismutase [25]. Furthermore, experiments on human CC and 
penile resistance arteries showed that antioxidant therapy ameliorates impaired  
NO-mediated relaxations (both ACh and EFS) in diabetic patients with ED [26]. Oxidative 
stress alters NO-mediated relaxations in mice CC, as the combination of the superoxide 
generator LY 83583 and the superoxide dismutase inhibitor DETCA inhibited corporal 
relaxations induced by EFS, ACh and acidified sodium nitrite [14]. In our model of oxidative 
stress we increased superoxide concentrations by using the superoxide generator (free 
radical scavenger) hydroquinone [27,28] in combination with DETCA, an irreversible inhibitor 
of the Cu2+/Zn2+-containing superoxide dismutase [29]. The combination of hydroquinone 
and DETCA significantly lowered EFS-, ACh- and SNP-induced corporal relaxations. This 
confirms that oxidative stress influences respectively neuronal, endothelial as well as 
exogenous NO-mediated responses in CC. As expected oxidative stress had no effect on the  
8-pCPT-cGMP, an analog of cGMP, which causes NO-independent corporal relaxation. 
Surprisingly both FAL and FAM responses were unaffected by oxidative stress as the 
combination of hydroquinone and DETCA had no influence on the FAL-/FAM-induced 
relaxations. However, in our previous study we could not elucidate the underlying 
mechanism of corporal FAL-/FAM-effect [4]. So it is possible that in the CC FAL and FAM elicit 
relaxation mainly through (a) NO-independent mechanism(s), which could explain the lack of 
sensitivity towards oxidative stress. Moreover, it was already reported that superoxide leads 
to the production of nitrites from glyceryl trinitrate whereas FAL was resistant to its action 
[30].  
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The pathophysiology of ED is multifactorial, but is often linked to impaired NO functioning. 
This can be caused either directly by a lowered NO production because of altered NO 
synthase expression, NO synthase function and endothelial dysfunction [31] or indirectly by 
a decreased NO-bioavailability due to oxidative stress [6]. Previously we already showed that 
the FAL-/FAM-induced corporal relaxations are independent of NO synthase and the 
endothelium [4]. In this study we demonstrated that FAL and FAM are not susceptible to 
oxidative stress. Moreover we could also prove that FAL and FAM induce erection in vivo. 
Taken together, all these results point out that oximes such as FAL and FAM should be 
considered as potential new and alternative drugs for the treatment of ED. 
 
V.8 Conclusion 
In this study we showed for the first time that both FAL and FAM induce a concentration-
dependent erectile effect in vivo. However, the in vivo ICP increase seems to be mediated by 
(a) different mechanism(s) than the FAL-/FAM-induced in vitro corporal relaxations. 
Moreover, both compounds elicit a distinct blood pressure lowering effect. Activation of sGC 
plays an important role in the FAL-/FAM-effect on blood pressure as well as on ICP, but FAL 
and FAM could partially exert their effects by different mechanisms. In addition, FAL-/FAM-
induced corporal relaxations seem to be unaffected by oxidative stress. Overall, oximes offer 
favourable perspectives for the treatment of ED. 
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VI.1 Abstract 
OBJECTIVES: Over the past few years ruthenium became under the attention for 
development of organometallic drugs with various therapeutic applications. Because of its 
favorable characteristics ruthenium is perfectly suitable for drug design. Ruthenium-
containing complexes exert a wide range of biological effects. However, so far the influence 
of ruthenium itself on vascular tone has never been studied.  
METHODS: The effect of ruthenium was analyzed through organ bath studies measuring 
isometric tension on mice thoracic aorta. After obtaining a stable contraction plateau, 
cumulative concentration-response curves of the ruthenium-compounds (RuCl3, Ruthenium 
Red, [RuCl2(CO)3]2 and RuCl2(DMSO)4) (30 – 600 µmol/L) were performed. The effect of RuCl3 
after contraction with different contractile agents was evaluated. Furthermore the influence 
of ruthenium-containing molecules on endogenous (ACh) and exogenous (SNP)  
NO-mediated relaxations was determined.  
KEY FINDINGS: All studied ruthenium-compounds elicit to some extent a decrease of the 
contraction level. Looking further into the underlying mechanism we found that RuCl3 
relaxes aortic rings only when contracted with norepinephrine (NOR). This RuCl3-induced 
relaxation can be prevented by the antioxidants ascorbic acid and N-acetyl L-cysteine. In 
addition ruthenium-compounds may diminish acetylcholine (ACh)- and/or sodium 
nitroprusside (SNP)-induced relaxations. 
CONCLUSIONS: Ruthenium-containing molecules can influence vascular tone induced by 
NOR due to oxidative inactivation. Moreover they can undermine NO-mediated responses. 
This should be considered when developing ruthenium-containing drugs. 
 
Keywords: Aorta; ascorbic acid; carbon monoxide-releasing molecule; nitric oxide; 
ruthenium  
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VI.2 Introduction 
Ruthenium is a precious metal with some intriguing properties making it useful for various 
pharmacological applications. In the past, precious metals have already been successful for 
drug development, such as platinum compounds for cancer treatment, silver compounds as 
antimicrobial agents and gold compounds in the treatment of rheumatoid arthritis [1]. 
Nowadays ruthenium can be found in drugs with immunosuppressant, antimicrobial, 
antibiotic and anticancer activity [2-5]. Over the years ruthenium became popular for drug 
designers as it has interesting characteristics. First of all, ruthenium complexes exchange 
ligands when in contact with biological tissues, which is often necessary to exert biological 
effects. Another important property is that ruthenium shows different oxidation states 
under physiological conditions namely Ru(II), Ru(III) and Ru(IV) with Ru(III)-complexes being 
biological more inert. Hypoxic conditions, which occur in multiple disease states, lead to a 
reductive environment reducing the relatively inert Ru(III)-complexes to active  
Ru(II)-complexes. This activation-by-reduction mechanism creates certain selectivity towards 
the hypoxic, diseased tissues [1,6]. Another advantage of ruthenium is its low toxicity due to 
the ability of ruthenium to mimic iron in binding to biomolecules, including serum transferrin 
and albumin, resulting in effective biodistribution and minimum systemic toxicity [1,7].  
Based on its beneficial characteristics several ruthenium-containing drugs were developed 
for safe and controlled delivery of carbon monoxide (CO) and nitric oxide (NO) in tissues. 
Since CO and NO induce vasorelaxation, these CO- and NO-releasing ruthenium-complexes 
were tested for their vasorelaxing effect. Many of them indeed elicit vasorelaxation which is 
then attributed to the release of CO or NO [8-11]. However, in a recent study using the 
ruthenium-containing CO-releasing molecule [RuCl2(CO)3]2 (= CORM-2) we found that its 
vasorelaxing effect could not completely be explained by CO-release as CORM-2 showed a 
stronger relaxation than CO as such. Moreover, tissues that do no relax in response to CO do 
so in response to CORM-2 [12]. Therefore we wondered if the ruthenium-core of CORM-2 
could be responsible for this enigmatic observation. As far, the influence of ruthenium itself 
on vascular tone has never been studied. 
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Some ruthenium-containing compounds can rapidly and strongly bind NO and this could be 
useful for the treatment of diseases involving NO overproduction such as septic shock  
[13-15]. However, this mechanism can be considered as an undesired side-effect of 
ruthenium-compounds in disease states with a compromised NO-bioavailability.  
CO-releasing ruthenium-drugs are often proposed as compensating therapy to overcome 
loss in endogenous NO functioning. Hence, scavenging of the already low NO-levels by 
ruthenium-based drugs would seriously counteract their beneficial effect. It was already 
demonstrated that CORM-2 attenuates NO donor-induced relaxations and that the water-
soluble ruthenium-based CO-releasing molecule RuCl(CO)3-glycinate (= CORM-3) inhibits 
endothelium- and NO-dependent relaxations [16,17]. However, the influence of ruthenium 
itself on NO-mediated signalling is not completely explored. 
 
VI.3 Aims 
The present study was designed to elucidate the vasorelaxing effect of different ruthenium-
containing compounds on isolated mice aortic ring segments. Furthermore, the influence of 
these compounds on endogenous as well as exogenous NO-mediated relaxations was 
evaluated. 
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VI.4 Materials and methods 
VI.4.1 Animals 
For this study mature (age 8-12 weeks) male Swiss mice were obtained from Janvier  
(Saint-Berthevin, France). All animals were treated in accordance with the Guide for the Care 
and Use of Laboratory Animals published by the US National Institutes of Health. Food and 
water were provided ad libitum and animals were kept in a 12h/12h day/night cycle. All 
experiments were approved by the local Ethical Committee for Animal Experiments  
(Ghent University, 14/02/2011, ECD 10/42).  
VI.4.2 Tissue preparations and mounting 
After cervical dislocation thoracic aorta was carefully isolated from surrounding tissues and 
displaced in cold Krebs-Ringer bicarbonate (KRB) solution. Aortic ring segments were 
mounted into 10 ml organ baths from a wire myograph for isometric tension recordings as 
previously described [12,18]. The mounted aortic rings were then left to equilibrate for  
30 minutes in KRB solution (37°C; pH 7.4, bubbled with 95% O2 – 5% CO2). 
VI.4.3 Preliminary protocol 
To obtain maximal, stable contractions and relaxations of the aortic ring segments, a 
preliminary protocol was performed as previously described [12]. Subsequently, the tissues 
were contracted with 5 µmol/L NOR. When a stable plateau was reached 10 µmol/L ACh was 
added to test the functionality of the endothelium. The endothelium was considered intact 
when ACh induced more than 50 % tissue relaxation. Preparations were washed until they 
returned to basal tone before starting with the actual experiments.  
VI.4.4 Experimental protocol 
In a first set of experiments the effect of various ruthenium-containing molecules was 
tested. Aortic rings were contracted with 5 µmol/L NOR and when a stable plateau was 
obtained cumulative concentration-response curves for RuCl3, Ruthenium Red, [RuCl2(CO)3]2 
and RuCl2(DMSO)4 (30 – 100 – 300 – 600 µmol/L) were established. Furthermore the 
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responses to RuCl3 were evaluated after contraction with different contractile agents. The 
RuCl3 responses after NOR-induced contraction were compared with those after contraction 
with K+30, serotonin (1 µmol/L), 9,11-dideoxy-11α,9α-epoxy-methanoprostaglandin F2α 
(U46619; 5 nmol/L), prostaglandin F2α (PGF2α; 1.5 µmol/L) and phenylephrine (1 µmol/L). In 
another series of experiments the influence of ascorbic acid and N-acetyl L-cysteine on the 
RuCl3-induced effects were analysed. First, tissues were incubated with vehicle, RuCl3  
(200 µmol/L) or RuCl3 (200 µmol/L) + ascorbic acid (100 µmol/L) before inducing contraction 
with 5 µmol/L NOR. In a second experiment, the effect of ascorbic acid (100 µmol/L) and N-
acetyl L-cysteine (1 mmol/L) on the cumulative concentration-response curve for RuCl3 was 
determined. In a third experiment, the organ bath solution was replaced by either 10 mL 
KRB + NOR (5 µmol/L) or 10 mL KRB + NOR (5 µmol/L) + RuCl3 (200 µmol/L) or 10 mL KRB + 
NOR (5 µmol/L) + RuCl3 (200 µmol/L) + ascorbic acid (100 µmol/L), which were first left at 
37°C and continuously bubbled with 95% O2 – 5% CO2 for 1 hour. In a last series of 
experiments aortic ring segments were incubated with 200 µmol/L of either RuCl3, 
RuCl2(DMSO)4 or [RuCl2(CO)3]2 and contracted with 1.5 µmol/L PGF2α. After obtaining a 
stable plateau cumulative concentration-response curves for ACh and SNP  
(1 nmol/L – 10 µmol/L) were performed.  
VI.4.5 Drugs, chemicals and reagents 
The experiments were performed in a KRB solution with the following composition 
(mmol/L): NaCl, 135; KCl, 5; NaHCO3, 20; glucose, 10; CaCl2, 2.5; MgSO4, 1.3; KH2PO4, 1.2 and 
EDTA, 0.026 in H2O. K
+
30 was made as modified KRB solution containing 30 mmol/L K
+ 
(changes in the KCl concentration of the KRB solution were compensated by equimolar 
adjustment of the NaCl concentration). Norepinephrine bitartrate (NOR), dimethylsulfoxide 
(DMSO), acetylcholine chloride (ACh), sodium nitroprusside (SNP), RuCl3, Ruthenium Red, 
[RuCl2(CO)3]2 (CORM-2), RuCl2(DMSO)4, U46619, serotonin, L-phenylephrine hydrochloride, 
L-ascorbic acid and N-acetyl L-cysteine were obtained from Sigma-Aldrich (St.Louis, MO). 
PGF2α (Dinolytic®) was acquired from Pfizer (Puurs, Belgium). All stock solutions were 
prepared in distilled water, except for CORM-2 (dissolved in DMSO; maximal DMSO 
concentration: 0.6%) and U46619 (dissolved in methylacetate). All concentrations are 
expressed as final molar concentrations in the organ baths. 
Chapter VI 
 
122 
VI.4.6 Data analysis and statistical procedures 
Data are presented as mean values ± SEM; N represents the number of preparations. The 
relaxations are expressed as the percentage decrease in contraction level. The level of NOR-
induced contraction is presented in mN. Statistical significance was evaluated using the 
Mann-Withney U test and Kruskal-Wallis test with Bonferroni corrected pairwise comparison 
when appropriate (SPSS, version 18; IBM Corporation, Armonk, NY, USA). Data were 
considered significant when P<0.05.  
 
VI.5 Results 
VI.5.1 Effect of ruthenium-containing compounds 
All tested ruthenium-compounds lowered, to some extent, NOR-induced tone of mice aortic 
rings (Fig. VI.1). Both RuCl3 and Ruthenium Red were able to elicit a strong relaxant effect 
(maximal effect RuCl3: 87.77% ± 3.63 – Ruthenium Red: 73.37% ± 6.49). The ruthenium-
based CO-releasing molecule [RuCl2(CO)3]2 (= CORM-2) also showed a concentration-
dependent vasorelaxation. However, its relaxant capacity was significantly lower as 
compared to RuCl3 (maximal effect [RuCl2(CO)3]2: 48.73% ± 5.83). In contrast, the CO-free 
ruthenium-complex RuCl2(DMSO)4 did only present a limited influence on the NOR-induced 
contraction level (maximal effect RuCl2(DMSO)4: 15.73% ± 8.96). Remarkably the lowest 
concentration of Ruthenium Red (30 µmol/L) induced a significant contractile effect (14.06% 
± 3.58), whereas the other ruthenium-compounds did not show any contractile effect at all. 
 
Figure VI.1: Cumulative concentration-responses to RuCl3, Ruthenium Red, [RuCl2(CO)3]2 (=CORM-2) and 
RuCl2(DMSO)4 in mice aortic ring segments precontracted with 5 µmol/L norepinephrine (NOR). Data are 
expressed as % relaxation of the NOR-induced tone (N = 5-7); *P<0.05 (as compared to RuCl3); **P<0.01 (as 
compared to RuCl3); #P<0.05(as compared to Ruthenium Red) and ##P<0.01 (as compared to Ruthenium Red). 
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VI.5.2 Effect of RuCl3 on different contractile agents 
RuCl3 almost completely relaxes NOR-contracted aortic rings. However when contraction 
was elicited using a K+-rich KRB-solution (K+30), RuCl3 did not seem to have any relaxant 
effect (Fig. VI.2 A). Also, when the aortic segments were contracted with serotonin, PGF2α or 
the thromboxane A2 mimetic U46619, RuCl3 did not show any vasorelaxation (Fig. VI.2 B-D). 
Even after contraction with phenylephrine RuCl3 did not induce relaxation (Fig. VI.2 E). 
 
Figure VI.2: The effect of RuCl3 on norepinephrine(NOR)-precontracted mice aortic ring segments compared to 
the RuCl3 response after contraction with K
+
30 (A); 1 µmol/L serotonin (B); 1.5 µmol/L PGF2α (C); 5 nmol/L 
U46619 (D) and 1 µmol/L phenylephrine (E). Data are expressed as % decrease in contractile tone (N = 4-7); 
*P<0.05 and #P<0.01 
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VI.5.3 Influence of ascorbic acid and N-acetyl L-cysteine 
NOR is susceptible to oxidative degradation by traces of heavy metals. This oxidation 
diminishes vascular reactivity which can be prevented by the addition of ascorbic acid [19]. 
We wondered if ascorbic acid would be able to influence the effect of RuCl3 on NOR-induced 
contraction. Incubation of aortic ring segments with 200 µmol/L RuCl3 for 20 minutes 
counteracted NOR-contraction. Although the aortic rings started to contract after addition of 
NOR, at some point the contraction level rapidly declined and the vessels returned to basal 
tone (Fig. VI.3 B). However, co-incubation with 100 µmol/L ascorbic acid prevented the 
RuCl3-induced loss of vascular tone (Fig. VI.3 C).  
 
Figure VI.3: Original tracings showing the contraction of mice aortic ring segments with 5 µmol/L 
norepinephrine (NOR) in the presence of vehicle (A), RuCl3 (200 µmol/L) (B), and RuCl3 (200 µmol/L) + ascorbic 
acid (100 µmol/L) (C).  
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Ascorbic acid also significantly diminished RuCl3-induced vasorelaxation of NOR-contracted 
aortic rings (Fig. VI.4 A). However, ascorbic acid as such has no influence on NOR-induced 
contraction (maximal contraction: without ascorbic acid: 10.48 mN ± 0.81 - with ascorbic 
acid: 9.01 mN ± 0.96; N = 8; p = 0.336). Moreover, the antioxidant N-acetyl L-cysteine  
(1 mmol/L) strongly blocked the vasorelaxing effect of RuCl3 after aortic contraction with 
NOR (Fig. VI.4 B). In another experiment, 200 µmol/L RuCl3 was left to react with 5 µmol/L 
NOR in KRB solution at 37 °C for 1 hour. In contrast to the control solution (KRB + NOR), 
changing the organ bath solution of the tissues by this RuCl3- and NOR-containing KRB 
solution did not result in contraction (maximal contraction without RuCl3:  
12.50 mN ± 1.32 – with RuCl3: 0.39 mN ± 0.20; N = 8). However, when RuCl3 is left to react 
with NOR in the presence of 100 µmol/L ascorbic acid, contraction does occur and is not 
significantly different from the contraction induced by the control solution (maximal 
contraction in the presence of RuCl3 and ascorbic acid: 8.95 mN ± 1.86; N = 8). 
 
Figure VI.4: Cumulative concentration-responses to RuCl3 in the absence or presence of ascorbic acid  
(100 µmol/L incubated during 20 minutes) (A) or N-acetyl L-cysteine (1 mmol/L incubated during 20 minutes) 
(B) in mice thoracic aorta contracted with 5 µmol/L norepinephrine (NOR). Data are expressed as % relaxation 
of the NOR-induced tone (N = 7); *P<0.05 and #P<0.01 
 
VI.5.4 Influence of ruthenium-containing compounds on NO-mediated relaxations 
For these incubation experiments we used a contractile agent which was not influenced by 
RuCl3, namely PGF2α. The presence of RuCl3 had an inhibitory effect on SNP- but not on  
ACh-induced relaxations (Fig. VI.5 A and B), whereas the ruthenium-complex RuCl2(DMSO)4 
had no influence on both ACh- and SNP-mediated relaxations (Fig. VI.5 C and D). In contrast, 
[RuCl2(CO)3]2 (= CORM-2) showed a strong inhibitory effect on ACh- as well as SNP-induced 
relaxations (Fig. VI.5 E and F). 
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Figure VI.5: The effect of incubation with 200 µmol/L RuCl3 (A), RuCl2(DMSO)4 (C) or [RuCl2(CO)3]2 (= CORM-2) 
(E) compared to vehicle control on acetylcholine-mediated relaxations in mice thoracic aorta. The effect of 
incubation with 200 µmol/L RuCl3 (B), RuCl2(DMSO)4 (D) or [RuCl2(CO)3]2 (= CORM-2) (F) compared to vehicle 
control on sodium nitroprusside-mediated relaxations in mice thoracic aorta. Data are expressed as  
% relaxation of the PGF2α-induced tone (N = 5-9); *P<0.05 and #P< 0.01 
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VI.6 Discussion 
This study showed that ruthenium as such and ruthenium-containing complexes can 
influence vascular tone. These compounds do not only counteract NOR-induced 
contractions, but can also impair NO-mediated relaxations. 
Organometallic complexes possess unique physico-chemical properties for drug 
development. They provide a great structural variety and rational ligand design offers 
control over its kinetic properties [20]. Hence, ruthenium-based molecules were developed 
delivering vasorelaxing CO and NO to the tissues in a controlled and safe way. However, the 
vasorelaxant effect of these ruthenium-complexes could not always be linked to their  
CO-/NO-release. Decaluwé et al. observed that part of the effects of the CO-releasing 
ruthenium-complex [RuCl2(CO)3]2 (= CORM-2) is unrelated to CO-release [12]. Therefore, we 
hypothesized that the ruthenium-core of CORM-2 could be (partially) responsible for the 
CORM-2 effects. Hence, the influence of various ruthenium-containing compounds on 
vascular tone was tested.  
We found that RuCl3 as well as Ruthenium Red strongly relaxed mice aorta. CORM-2 showed 
a less pronounced relaxation. RuCl3 is often used as “inactive” CO-free control for the  
CO-donor CORM-2 [8,21,22]. However, RuCl3 is perhaps not the best candidate to study the 
effects of the ruthenium-core of CORM-2. First of all the oxidation state of ruthenium differs 
in both molecules. Ruthenium is trivalent in RuCl3 whereas it is bivalent in CORM-2. 
Moreover, RuCl3 is an ionic compound in contrast to the ruthenium-based metal complex 
CORM-2. Another “inactive” CO-free control molecule for CORM-2 is the ruthenium-based 
metal complex RuCl2(DMSO)4 [23]. In contrast to RuCl3, RuCl2(DMSO)4 had only a limited 
influence on contractile tone. Therefore, it remains unclear to what extent the release of CO 
and the ruthenium-core is responsible for the CORM-2 relaxation. Whatsoever, all 
ruthenium-compounds studied somehow influence vascular tone. Hence the possible 
vascular effects of ruthenium should be taken into account when investigating ruthenium-
based compounds.  
Remarkable is the contractile effect induced by the lowest concentration of Ruthenium Red, 
what was not observed with the other ruthenium-compounds. Generally Ruthenium Red is 
used as an inhibitor of the ryanodine receptors localized on the smooth endoplasmic 
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reticulum releasing Ca2+ ions into the cytoplasm upon activation [24]. Hence, inhibition of 
this Ca2+-release would imply a lower cytoplasmic Ca2+-concentration and subsequent 
smooth muscle cell relaxation which is in contrast with the contractile effect in our results. 
However, activation of the ryanodine receptors can establish local increases of the  
Ca2+-concentration at the plasma membrane, leading to opening of Ca2+-activated  
K+-channels and hyperpolarization of the smooth muscle cell [25]. Thus it is possible that the 
low concentration of Ruthenium Red opposes the hyperpolarization due to ryanodine 
receptor activation and K+-channel opening, resulting in a contractile response. Moreover 
Ruthenium Red has shown to possess various nonspecific effects such as inhibition of 
voltage-gated Ca2+-channel activity, plasma membrane Ca2+-ATPase, Ca2+-activated  
K+-channels, IP3-mediated Ca
2+ release, mitochondrial Ca2+ uniporter and calmodulin activity. 
There are also important direct effects on myosin light chain kinase and myosin light chain 
phosphatase [24]. This wide range of possible effects of Ruthenium Red could all explain in 
their own way the relaxant as well as contractile responses seen on our aortic tissues.  
This study is the first to demonstrate a strong vasorelaxant effect of RuCl3. Only one study 
reported a vasoactive effect of RuCl3 namely a limited contractile effect on rat aortic rings 
[17]. This divergence could be due to species differences as already shown for CO and 
CORM-2 [12], but this is rather unlikely. Another possible explanation could be the 
difference in agents used to contract the aortic segments: NOR in our mouse vessels 
whereas phenylephrine in their rat experiments. This led us to test the effect of RuCl3 also 
after contraction with phenylephrine. Despite the fact that both vasoconstrictors are  
α1-adrenergic agonists, the large relaxant effect of RuCl3 after contraction with NOR was 
completely abolished when the tissues were contracted with phenylephrine. This surprising 
observation led us to investigate the response of RuCl3 after contraction with other 
vasoconstrictors. The relaxant effect of RuCl3 was not seen when contraction was induced by 
K+30, serotonin, PGF2α or the thromboxane A2 mimetic U46619. Thus the strong vasorelaxant 
effect of RuCl3 only occurs after contraction with NOR.  
This specificity of the RuCl3-effect after NOR-contraction cannot be explained by an (in)direct 
interaction with α1-adrenergic mechanisms since RuCl3-responses are absent after 
contraction with phenylephrine. Besides the specificity for NOR, another remarkable 
observation was that the RuCl3 relaxation showed a large variability. The potency of RuCl3 
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varied strongly from experiment to experiment and did not seem to be concentration-
dependent. It looked more like a mechanism that has been set in motion steadily and then 
leads to a complete relaxation. This cannot be explained by cell death as then it should occur 
after contraction with all contractile agents. Moreover, addition of another bolus dose of 
NOR after the RuCl3-induced relaxations was again able to elicit a strong contraction of the 
vessels (data not shown). Furthermore, preliminary TUNEL-staining experiments, tracing 
DNA fragmentation due to cell death, could not prove any sign of cell death under our 
experimental conditions (data not shown). Another hypothesis could be that RuCl3 gradually 
destroys NOR. In contrast to the more stable phenylephrine, NOR is quite sensitive to 
oxidative degradation by traces of heavy metals resulting in a loss of contraction [19]. To 
scavenge these metals, EDTA is routinely added to the KRB solution leading to stable 
contractions with NOR. However it is possible that RuCl3 somehow counteracts the chelation 
of heavy metals by EDTA or on itself stimulates oxidation of NOR. A higher concentration of 
EDTA (1 mmol/L) was added to the organ baths to test our hypothesis but unfortunately had 
no significant influence (data not shown). It has been shown that the antioxidant ascorbic 
acid is able to prevent the loss of vasoconstriction due to the oxidation ofNOR [19]. 
Therefore we analyzed the effect of ascorbic acid on RuCl3-induced responses. Ascorbic acid 
strongly diminished the relaxant effect of RuCl3 on NOR-contracted aortic rings. Moreover, 
ascorbic acid prevented the loss of contractile tone after incubation with RuCl3. Also the 
antioxidant N-acetyl L-cysteine was able to counteract the RuCl3 effect on NOR-contracted 
aortic rings. So, our data suggest that RuCl3 undermines NOR activity by oxidative 
degradation. Since NOR is one of the most important regulators of vascular tone in vivo, the 
counteracting effect of ruthenium/RuCl3 should be considered in future research of 
ruthenium-containing compounds. Furthermore, our data showed that this oxidative 
degradation of NOR by RuCl3 is independent of the presence of vascular tissue. After all, 
when RuCl3 is left to react with NOR for 1 hour before adding it to the aortic ring segments, 
no more contraction could be obtained. 
A ruthenium-core is not only present in CO- and NO-donors but also in compounds with NO 
scavenging capacities which are useful in various disease states that are characterized by  
NO-overproduction such as septic shock [13-15]. However, other diseases such as 
hypertension and erectile dysfunction are associated with impaired NO-production and  
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CO-(and NO-)releasing ruthenium-based molecules have been proposed as drugs to 
compensate for this lost NO-bioavailability. However, for these drugs, an additional NO 
scavenging effect of the ruthenium core can be regarded as an unwanted side effect limiting 
their therapeutic value. Marazioti et al. showed that CORM-2 diminishes NO donor-induced 
relaxations in rat aorta [16]. Furthermore, experiments on murine gastric fundus 
demonstrated that responses to exogenous NO were inhibited by CORM-2, whereas 
endogenous NO relaxations by electrical field stimulation were not affected. On the other 
hand RuCl3 only inhibited exogenous NO responses [26]. Also, CORM-3 attenuates ACh- but 
not SNP-induced relaxations in rat aorta while RuCl3 reduced both ACh- and SNP-effects [17]. 
We examined the effect of pre-incubation with RuCl3, RuCl2(DMSO)4 and [RuCl2(CO)3]2 (= 
CORM-2) on endogenous (ACh) as well as exogenous (SNP) NO-mediated relaxations. We 
used PGF2α as contractile agent since the contraction level of PGF2α is not altered by pre-
incubation with the ruthenium-containing compounds. We found that incubation of CORM-2 
had an inhibitory effect on exogenous NO-mediated relaxations, which is in accordance with 
former studies [16,26]. Moreover CORM-2 diminished also ACh-induced relaxations. A 
possible explanation for the latter effect could be an interaction between CO released from 
CORM-2 and the NO-signaling pathways. CO is able to stimulate as well as to inhibit NO 
synthase activity depending for instance on concentrations. For its inhibitory effect a CO 
concentration of 1 mmol/L seems to be needed [27-29]. Therefore NO synthase inhibition is 
unlikely to be responsible for the CORM-2 effect in our study. Moreover, if CO, released form 
CORM-2, causes NO synthase inhibition it could justify the decrease in ACh-induced 
relaxation, but inhibition of SNP responses would not be expected. Another hypothesis could 
be quenching of NO by the transition metal ruthenium-core. Indeed also RuCl3 altered the 
SNP-induced relaxation which is related to previous results [17,26]. In contrast, RuCl3 had no 
effect on ACh responses in mice aorta, whereas in rat aorta an inhibitory effect was proven 
[17]. Furthermore, the CO-free ruthenium-complex RuCl2(DMSO)4 did not modify ACh nor 
SNP responses which correlates with the lack of effect by incubation of CO-free inactive 
CORM-3 [17]. Although the results are not clear-cut, the possible unwanted effect of 
ruthenium-containing compounds on NO-mediated responses should not be 
underestimated.  
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VI.7 Conclusion 
In conclusion, this study shows for the first time that RuCl3 specifically relaxes aortic rings 
due to oxidative inactivation of NOR. Therefore the influence of ruthenium on vascular tone 
induced by NOR, being the most important physiological regulator of the cardiovascular 
system as neurotransmitter of the orthosympathetic nervous system, should be considered. 
Moreover, ruthenium-based molecules may alter NO-mediated relaxations. In future studies 
on ruthenium-containing compounds, their influence on vascular tone and their possible NO 
scavenging (side) effects should be kept in mind as this could limit their net therapeutic 
potential. 
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Nowadays, the (patho)physiological relevance of NO as a key signaling molecule has been 
well established. In the cardiovascular system, NO is the best known and most documented 
vasodilator. NO is continuously generated in vascular endothelial cells by basally expressed 
eNOS. These low levels of NO participate in the maintenance of basal vascular tone and 
regulation of blood pressure [1]. In the mechanism of penile erection, NO also acts as the 
principal mediator causing vasodilation of cavernous and helicine arteries and relaxation of 
trabecular smooth muscles [2]. Initiation of cavernosal relaxation is caused by NO liberated 
from parasympathetic nerve endings, whereas activation of eNOS may facilitate attainment 
and sustainment of penile erection [3]. In several disease states such as hypertension and 
erectile dysfunction (ED), (vascular) NO-mediated relaxations are impaired due to loss of 
(endothelial) NO production and/or unresponsiveness to NO [4]. Current cardiovascular 
therapy includes the use of organic nitrates, which release NO through metabolization, to 
compensate for this lost NO-bioavailability [5]. In patients suffering from ED,  
PDE type 5 inhibitors, which block the degradation of (NO-induced) cGMP, are still the first 
choice drugs [6]. However, the therapeutic value of both NO-related treatment strategies is 
limited by the development of tolerance, low bioavailability, unwanted side effects and the 
occurrence of a substantial number of non-responders [7-10]. As a result, the search for new 
better alternatives is still ongoing. 
 
VII.1 Oxime derivatives 
About a decade ago, a few studies proved the potential use of oxime derivatives as a new 
group of vasodilatory and blood pressure lowering compounds due to their NO-releasing 
capacities [11,12]. The presence of the oxime (C=NOH) functional group had aroused 
interest of researchers to explore the vasorelaxant effect of these compounds. After all,  
L-NOHA, which also bears a C=NOH group, had shown to induce endothelium-dependent 
relaxation of porcine coronary arteries by acting as a substrate for eNOS leading to enhanced 
NO concentrations [13]. Hence, various (non-)aromatic oximes were tested on their ability to 
relax vascular tissue and to elicit a decrease of blood pressure. Amongst them, formaldoxime 
(FAL) seemed to be the most potent compound in vitro whereas formamidoxime showed the 
most promising decline of blood pressure in vivo [11,12]. However, none of these 
compounds was studied in the context of penile erection and ED. 
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As a first goal of this thesis we tried to establish the ability of both FAL and FAM to relax 
mice corpora cavernosa (CC) as well as to elucidate the underlying mechanism(s) of their 
effect. To correlate our results with previous findings in literature and to explore the 
possible differences between vascular and corporal tissue, parallel experiments on mice 
aorta and femoral artery were performed. As expected from a former study on rat aorta, 
both FAL and FAM were able to concentration-dependently relax mice aorta and femoral 
artery [11]. However, it was for the first time that we could prove that both compounds also 
relax mice corporal tissue and thus could be of interest in the treatment of ED. 
Since sGC is the main target of NO, it is obvious that estimating the contribution of the  
sGC-cGMP pathway is the first step in determining the underlying molecular pathway(s) of 
any (new) NO donor and thus also of the oxime derivatives. For over twenty years now, ODQ 
has been widely used as potent inhibitor of sGC [14]. Irreversible oxidation of the prosthetic 
heme group of the sGC enzyme by ODQ results in a poor NO-sensitive ferric state [15]. 
Incubation of our mice aorta and femoral artery ring segments with ODQ leads to a 
substantial inhibition of the FAL-induced vasorelaxation and even completely abolished the 
FAM effect. On the contrary, ODQ was not able to alter corporal relaxation by FAL and had 
only a limited effect on the FAM-induced responses in the mice CC. However, the 
pharmacological application of ODQ as sGC inhibitor has a few drawbacks. It has been 
reported that ODQ also shows redox activity against other heme-containing proteins 
including haemoglobin and cytochrome P450 [16,17]. Moreover, high concentrations of NO 
seem to overcome the inhibitory effect of ODQ which implies that NO donor-induced effects 
in the presence of ODQ do not necessarily prove sGC independence [18]. Therefore, we 
defined the role of sGC in the FAL-/FAM-induced relaxations more accurately by using 
genetically modified mice. Furthermore, this genetic approach enabled us to distinguish the 
individual role of the different isoforms of sGC in the FAL-/FAM-responses. Despite the 
existence of two isoforms for each subunit of sGC, only the sGCα1β1 and sGCα2β1 
heterodimers are catalytically active and found in vivo [19]. A deletion in the catalytic 
domain of the α1 subunit selectively inactivates the sGCα1β1 isoform [20]. In these so called 
sGCα1
-/- mice, both FAL-/FAM-induced relaxations of aorta and femoral artery ring segments 
were significantly lower as compared to the wild-type control mice. In mice CC, the sGCα1β1 
isoform also seemed to mediate the FAM-effect but not the FAL-effect. Although sGCα1β1 is 
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the predominant form in most tissues, including the vascular and penile smooth muscle 
cells, residual activity of the sGCα2β1 isoform should not be underestimated [21]. Hence, 
genetically modified knock-in mice (sGCβ1
ki/ki) were developed in which mutation of the 
histidine 105 residue of sGCβ1 to phenylalanine results in the expression of heme-free  
NO-insensitive sGC which affects both heterodimeric isoforms [22]. The results of our 
FAL/FAM experiments in these sGCβ1
ki/ki mice are presented in supplementary figure 1. The 
even lower response of FAL and FAM in aorta and femoral artery of the sGCβ1
ki/ki mice in 
comparison with their effect in the sGCα1
-/- mice indicates that besides the sGCα1β1 isoform 
also the sGCα2β1 isoform is involved. However, in the CC no difference was observed in the 
FAM-induced relaxations of the sGCα1
-/- and sGCβ1
ki/ki mice suggesting that only the sGCα1β1 
isoform plays a role.In general we can say that both isoforms of sGC play an important role 
in the FAL-/FAM-mediated arterial relaxations whereas in the CC activation of the sGCα1β1 
isoform is primarily responsible for the FAM effect. In contrast, sGC does not appear to take 
part in the FAL-induced corporal relaxation. 
The lack of NO release in the absence of vascular tissue suggests that oxime-induced 
vasorelaxation unlikely results from spontaneous NO formation, but rather from 
metabolization within the tissue [11]. Our research has led to a proposed metabolization 
pathway underlying the FAL-/FAM-mediated vascular relaxation. We started with a broad, 
general approach by blocking non-specifically all flavoproteins with diphenyliodonium (DPI). 
After all, it has been reported that flavoproteins are involved in the vasorelaxant effect of 
the prototypic metabolic NO donor glyceryl trinitrate as well as some C=NOH bearing 
compounds [23-25]. Because DPI greatly blocked the FAL/FAM responses in our mice aorta 
and femoral artery ring segments to the same extent as ODQ, we assumed (a) flavoprotein(s) 
contribute(s) to their effects. Further stepwise inhibition of the different flavoproteins that 
could be involved in the FAL/FAM effect ruled out all irrelevant pathways. Taken together 
our results, we propose that (a) NADPH-CYP450 reductase-dependent mechanism(s) 
participates in the FAL-/FAM-induced relaxation of mice aorta and femoral artery which 
lead(s) to the biotransformation of the C=NOH function to NO or a NO-related compound 
subsequently activating the sGC-cGMP pathway. Recently, a similar pathway was suggested 
for the aromatic oxime derivative cinnamaldoxime [26]. However, the hypothesized pathway 
above does not fully explain the arterial oxime effect, especially not for FAL. It is possible 
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that these unexplained effects are related to (a) NO-independent mechanism(s). 
Unfortunately, we were also unable to elucidate the exact molecular mechanism(s) of FAL 
and FAM in the CC. Based on our results, we can already eliminate a possible contribution of 
NADPH oxidase, NADPH-dependent reductases, CYP450, AMP kinase, adenylate cyclase and 
K+ channels. In the CC, only a limited involvement of sGC in the FAM effect was 
demonstrated.  
Even though in literature SNP is the most frequently used comparator for research on 
exogenous NO sources, this NO donor does not relate well to our experiments. First of all, 
SNP does not only decompose into NO but also other substances such as cyanide, which can 
also influence smooth muscle tone [27]. More importantly, SNP generates NO rather 
spontaneously whereas oximes seem to undergo a metabolization step to release NO [28]. In 
a way this whole metabolization process of the oxime compounds is more comparable to the 
NO generation from GTN, a nitrovasodilator commonly used in cardiovascular diseases [5]. 
GTN has also proven to elicit relaxation of human CC strips [29,30]. Though there is no 
metabolization mechanism that can fully explain the vascular effect of GTN, several 
pathways appear to play a role including CYP450 [31], CYP450 reductase [32], glutathione  
S-transferase [33], xanthine oxidase [34] and aldehyde dehydrogenase [35].In accordance 
with our oxime results the flavoprotein inhibitor diphenyleneiodionum, an analog of DPI, 
blocked the enzymatic bioactivation of GTN [23,24]. Moreover, GTN-induced vasorelaxation 
is also sensitive to the CYP450 reductase inhibitor 7-ER, which also significantly alters the 
oxime responses [36,37]. However, while CYP450 seems to be important for GTN 
biotransformation, it does not take part in the oxime effect. A common side effect of GTN 
administration is the occurrence of tolerance upon prolonged use [7]. Chalupsky et al. 
demonstrated that pre-exposition of aortic ring segments to GTN decreased the relaxant 
effect of a subsequent addition of GTN confirming the existence of tolerance. Unlike GTN, 
FAL does not seem to be subjected to tolerance. In addition, no cross tolerance was 
observed between GTN and formaldoxime [11]. 
It is one thing to elicit vasorelaxation in normal physiological conditions, it is however 
another thing to be effective in pathological conditions. The C=NOH containing stable 
intermediate of endogenous NO production, L-NOHA, has proven to be a substrate of eNOS 
implicating the need for an intact endothelium to exert its effect [13]. However, many 
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(cardiovascular and erectile) disease states are characterized by endothelial dysfunction 
which often includes impairment of NOS activity [38]. Therefore it seemed interesting to 
explore the endothelium- and/or NOS-dependence of FAL and FAM. The NOS inhibitor  
L-NNA did not influence the FAL/FAM effect in the CC as well as the FAM-induced 
vasorelaxation. Surprisingly, the FAL response in the arteries was even more pronounced in 
the presence of L-NNA but an explanation for this enigmatic observation remains to be 
found. Although inhibition of NOS entails elimination of the most important endothelial 
signaling pathway, other pathways are preserved and should be taken into account [38]. 
Nevertheless, in correspondence with our L-NNA results, removal of the endothelium did not 
alter the FAM effect and even significantly enhanced FAL-induced vasorelaxation. These 
experiments in the presence of L-NNA as well as in endothelium-denuded tissue suggest that 
both FAL and FAM could be at least equally active in case of endothelial dysfunction-related 
pathologies as compared to normal physiological conditions. Various disease states, such as 
ED, are also associated with increased oxidative stress which can contribute to the 
endothelial dysfunction [39]. The excessive levels of reactive oxygen species, including 
superoxide anion, can quench NO by forming peroxynitrite which will (indirectly) lead to a 
lowered NO-bioavailability [40]. We used the superoxide generator hydroquinone in 
combination with the superoxide dismutase inhibitor DETCA to increase superoxide levels in 
the CC thus creating an in vitro model of oxidative stress. As expected, the combination of 
hydroquinone and DETCA impaired neuronal, endothelial and exogenous NO-induced 
corporal relaxations as it significantly blocked electrical field stimulation-, acetylcholine- and 
sodium nitroprusside responses respectively, which confirms our oxidative stress model. 
However, both FAL and FAM did not seem to be susceptible to the induced oxidative stress. 
Taken together, the NOS- and endothelium-independence as well as the resistance towards 
oxidative stress of both FAL and FAM offer some promising perspectives as alternative 
treatment strategies. 
In vitro tension measurements of vessel ring segments and corporal strips are an ideal, fast 
and cost-effective technique to unravel the molecular pathways underlying the contractile or 
relaxant effect of a wide range of compounds. Ion concentrations of the organ bath 
solutions, temperature and oxygen supply are adjusted to mimic the ‘real life’ conditions as 
much as possible. However, in these organ bath experiments not all interfering in vivo 
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factors can be taken into account. A vasorelaxant or corporal relaxant effect in vitro does not 
necessarily imply an in vivo, clinically relevant effect such as lowering of blood pressure or 
induction of erection respectively. Therefore, we performed some in vivo mice experiments 
in which blood pressure as well as intracavernosal pressure were monitored after 
intravenous or intracavernosal injection of FAL/FAM. It was already published that FAL and 
FAM induce a blood pressure drop in rats, but only after inhibition of endogenous NO 
production [12]. However, our results demonstrated a dose-dependent blood pressure 
decrease without the need for NOS inhibition. Furthermore, this blood pressure decrease 
was significantly lower in the sGCα1
-/- mice as compared to the wild-type control mice. This 
led us to conclude that the sGCα1β1 isoform of the sGC enzyme is, at least in part, involved in 
the FAL/FAM effect. More importantly, for the first time, our in vivo study could prove a 
dose-dependent increase of intracavernosal pressure after intracavernosal administration of 
both FAL and FAM. The FAM-induced increase of intracavernosal pressure was almost 
completely abolished in the sGCα1
-/- mice confirming the key role of the sGCα1β1 isoform 
which is in accordance with our in vitro results in the CC. To our surprise, sGC was also 
involved in the FAL-induced rise of intracavernosal pressure even though sGC did not seem 
to participate in the in vitro corporal relaxation by FAL. This ambiguous observation 
demonstrates that, despite the fact that our in vitro and in vivo results are more or less 
comparable, in vitro experiments do not always completely correlate with in vivo 
experiments. 
In the past, various other NO-donating compounds were already studied as potential 
treatment strategies for ED. Linsidomine chlorhydrate [41], GTN [42,43], SNP[44], and 
sodium nitrite [45] showed to induce penile erection. However, these compounds did not 
seem to present sufficient efficacy when compared to intracavernosal injection of 
papaverine or prostaglandin E1, which were used as a control condition [46-50]. So, it would 
be interesting to test whether our oxime compounds turn out to be inferior or superior to 
papaverine and/or prostaglandin E1. Besides poor efficacy, systemic hypotension is an 
undesired (side) effect that would limit the therapeutic value of NO donors in the treatment 
of ED. Since the oxime compounds are potent vasorelaxant agents with blood pressure 
lowering capacity, it is not unlikely that such a systemic hypotension could occur. However, 
local application of the oximes could possibly surpass the systemic blood pressure lowering 
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(side)effects. This local administration method was already tested for GTN in the form of an 
ointment or transcutaneous patch [42,43,48,51-54]. Quite recently, a new topical application 
method for erectogenic agents has been developed in which nanoparticles are used and 
applied as a gel to the glans and penile shaft [55]. This method has also been proven 
effective for the topical application of NO-releasing nanoparticles in a rat model of radical 
prostatectomy [56]. Maybe this method will make an excellent alternative or adjunct to oral 
medication in the future. 
Why did we study NO-donating oxime derivatives ? Is it not just another group of NO donors 
which will possibly present tolerance and side effects as seen with current NO-delivery 
strategies ? First of all, the apparent resemblance between the vasorelaxant mechanisms of 
oximes and current NO-therapy does not necessarily imply identical pharmacokinetic and 
pharmacodynamic properties. Moreover, the underlying molecular pathways do not 
completely correlate, so it will be required to address efficacy, effectiveness, efficiency and 
safety for each group or even each compound individually. Secondly, it was already 
published that the effect of subsequent addition of FAL in aortic rings, which were previously 
exposed to a high concentration of FAL, was not affected, suggesting that FAL is not 
subjected to tolerance. Furthermore, the effect of FAL was not altered in aortic rings pre-
exposed to GTN eliminating the possibility of cross tolerance [11]. Thirdly, oximes could offer 
some perspective for the creation of NO-hybrid molecules. Over the past few years, several 
NO-hybrid molecules were designed in which a NO donor moiety is coupled to a native  
well-known drug. The goal of such strategy is to develop a new compound which possesses 
NO activity in addition to the therapeutic effect of the original drug. In these molecules NO 
could improve the effect(s) of the native drug but could also present some complementary 
effects. Furthermore, the combination of NO and the original drug often results in a 
reduction of side effects [57]. Examples of such NO hybrids are a group of NO-releasing non-
steroidal anti-inflammatory drugs (NO-NSAIDs), including NO-aspirin and NO-diclofenac. 
These NO-NSAIDs maintain their original anti-inflammatory effects but, as an additional 
property, they present a marked reduction of NSAID-mediated gastric damage through the 
action of NO [58]. Likewise, NO-NSAIDs have shown to be far more potent in inhibiting 
cancer growth as compared with their native NSAID compounds due to the combined 
inhibition of proliferation, induction of cell death and inhibition of cell-cycle-phase 
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transitions [59]. It has also been reported that incorporation of a NO-moiety into statins 
significantly potentiates their cardiovascular-protective properties by enhancement of their 
non-lipid-lowering anti-inflammatory and antiproliferative effects [60]. More in line with our 
research focus, a NO-hybrid of the PDE type 5 inhibitor sildenafil, namely sildenafil nitrate 
(NCX-911), was tested in the context of ED [61]. In the past, a large number of placebo-
controlled, randomized, double blind trials had already shown that the native drug sildenafil 
can improve erections in men with ED, regardless of whether it originates form organic, 
psychogenic or mixed factors [62]. However, as stated before in the introduction, PDE type 5 
inhibitors need a critical amount of NO in order to work properly and therefore seemed to 
be less effective in certain patient groups, such as long-term diabetics and non-nerve sparing 
prostatectomy patients [63,64]. Hence, a NO-hybrid of sildenafil was developed to supply 
the necessary minimal dose of NO. In contrast to sildenafil, it was proven that sildenafil 
nitrate maintains its potency in the absence of endogenous NO confirming the potential use 
of NO-hybrid PDE type 5 inhibitors in (pathological) NO-deficient conditions [61]. Our results 
with the oxime derivatives FAL and FAM show that the C=NOH functional group could also 
be a plausible candidate as NO donor moiety for the design of NO-hybrid molecules. After 
all, oximes are capable of releasing NO independent from intact endothelium. In the context 
of penile erection and ED, oximes act (partially) through the activation of sGC leading to the 
formation of the required minimal amount of cGMP for effective PDE type 5 inhibitor 
therapy. Moreover, they seem to be resistant to oxidative stress which adds to their 
therapeutic value in pathological conditions.  
Although our results already suggest a significant effect of oxime derivatives in case of 
oxidative stress and in the absence of functional endothelium, their true therapeutic value 
should be further explored in the future, especially in the context of diseases. Just like 
various other pathologies, diabetes is associated with increased oxidative stress, especially in 
patients with poor glycemic control. Increased production of reactive oxygen species will 
affect vascular smooth muscle growth as well as endothelial function leading to a 
proinflammatory phenotype which contributes to the development of diabetic micro- and 
macrovascular complications [65]. Since diabetes is one of the biggest risk factors for the 
development of ED, as proven in numerous epidemiological studies, it would be interesting 
to study the efficacy of oximes in diabetic in vitro and in vivo models [66]. Though the 
Discussion 
 
145 
etiology of ED in diabetic patients is multifactorial, elevated oxidative stress levels seem to 
play an important role in its underlying pathophysiological mechanism [67]. It has been 
suggested that hyperglycemia-induced endothelial dysfunction, and therefore possibly also 
the associated vascular complications including ED, is most likely mediated by increased 
intracellular methylglyoxal levels [68]. Moreover, methylglyoxal, a highly reactive dicarbonyl 
metabolite produced during glucose metabolism, has been shown to impair endothelium-
dependent vasorelaxation in a pathway dependent on oxidative stress [69]. Hence, it would 
be of interest to test whether our oxime derivatives are still effective in in vitro diabetic 
mimicking conditions using methylglyoxal, high concentrations of glucose or even better a 
combination of both. Nevertheless, other diabetes-related factors have also been proven to 
be involved in the endothelial impairment such as Amadori glycosylation adducts and 
advanced glycosylation end products [70,71]. So in a next step, it would be appropriate to 
use diabetic mouse models for the in vitro as well as in vivo evaluation of the oximes. Mice 
with streptozotocin-induced hyperglycemia have shown to be a good model for type I 
diabetes-induced ED by presenting decreased endothelium-dependent dilatation and 
lowered in vivo erectile reactivity [72]. However, over the last decades, the impact of type II 
diabetes, and related obesity, on public health has been gradually increasing in our ageing 
population. To study type II diabetes-induced ED, leptin receptor mutated obese db/db mice 
can be used which exhibit lowered overall vasorelaxation and altered cavernosal 
vasoreactivity [73]. If these oxime experiments in diabetic conditions would present some 
promising results, it would strongly strengthen the therapeutic value of oximes. Moreover, 
these future experiments could offer some more insight in the potential use of the oxime 
functional group as NO donor moiety in NO-hybrid compounds. After all, some NO-
glibenclamide derivatives were already developed for the treatment of diabetes. In these 
molecules, the hypoglycemic activity, induced by the insulin secretagogue property of 
glibenclamide, is combined with the additional effects of NO including antiplatelet and 
antithrombic activities, vasorelaxation and cardioprotection [74]. Keeping this in mind, (a) 
beneficial effect(s) of oximes in our diabetic models could potentially imply a possible role in 
the future design of such antidiabetic NO-hybrids.  
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VII.2 Ruthenium-based metallocomplexes 
As mentioned in the introduction, ruthenium has drawn the attention of drug designers only 
recently. Its ability to exchange ligands, the range of accessible oxidation states and its 
relatively low toxicity make ruthenium a good candidate for the development of NO- and 
CO-donating metallocomplexes [75]. These compounds have been designed as an alternative 
treatment strategy for current NO-delivery therapies in pathological conditions 
characterized by impaired NO-bioavailability. One of these new ruthenium-based NO donors 
is the nitrosyl polypyridine complex [Ru(terpy)(bdq)NO]3+, which is abbreviated as TERPY. It 
has been published that the relaxation of endothelium-denuded vascular ring segments by 
TERPY relies on the release of both free radical NO and nitroxyl anions. Experiments on rat 
aorta and mesenteric resistance arteries have demonstrated that the TERPY-induced 
vasorelaxation mainly involves activation of sGC and K+ channels but also the sarcoplasmic 
reticulum Ca2+-ATPase can contribute to some extent [76,77]. Moreover, TERPY has shown 
to elicit an in vivo blood pressure lowering effect in normotensive as well as hypertensive 
rats [78,79]. Another NO-donating polypyridine ruthenium complex is the cis-
[Ru(bpy)2(py)NO2](PF6) compound (= RuBPY) which is composed of ruthenium, bipyridine 
ligands and a nitrite group. RuBPY-induced vasorelaxation seems to require metabolization 
and depends on the presence of tissue [80]. It has been hypothesized that conversion of the 
nitrite group into radicalar NO activates sGC and induces hyperpolarization of the cell 
membrane subsequently leading to vasodilation [81]. As yet, neither TERPY nor RuBPY is 
tested on their ability to elicit relaxation of CC. Hence, we received a small amount of both 
compounds from the laboratory of prof. Roberto Santana da Silva (Professor of Chemistry, 
Department of Physics and Chemistry, São Paulo University, Brazil) to perform some 
preliminary experiments on mice CC. Unfortunately, both TERPY and RuBPY were unable to 
significantly relax phenylephrine-contracted mice CC as shown in supplementary figures 2 
and 3. In contrast, TERPY and RuBPY did exhibit a pronounced vasorelaxant effect on mice 
aorta as well as femoral artery which is in line with the results on rat artery ring segments 
reported in literature [76,77]. 
Previous studies in our research department have tried to elucidate the underlying 
molecular pathways of the vasorelaxant and corporal relaxant effects induced by the  
CO-donating ruthenium compound CORM-2. Although CORM-2 was able to relax rat aorta, 
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mice aorta, mice femoral artery as well as mice CC, the mechanism(s) of effect seemed to 
differ. In rat aorta CORM-2 partially acted through activation of sGC and K+ channels. This 
was in correspondence with our results on mice aorta which also proved the participation of 
sGC and K+ channels, more specifically the voltage-dependent K+ channels. However, in mice 
femoral artery sGC did not seem to play a role and only the involvement of voltage-
dependent K+ channels could be demonstrated [82]. In addition, the underlying mechanism 
of CORM-2-induced corporal relaxation remained even unclear [83]. Nevertheless, these 
CORM-2 experiments have revealed some interesting findings. Despite the anatomical and 
physiological differences between the studied tissues, it was unexpected to observe such 
tissue-specific variations in the molecular pathways of CORM-2. An even more remarkable 
observation was the discrepancy between the vasorelaxant effect of CORM-2 and the 
vasorelaxant effect of CO as such [82]. First of all, CORM-2 seemed to be more potent as 
compared to the administration of a saturated CO gas solution. Secondly, mice aorta and 
femoral artery ring segments do not relax in response to this CO gas solution whereas they 
do so in response CORM-2. On the contrary, in rat aorta both CO and CORM-2 are able to 
elicit vasorelaxation showing that besides tissue differences also species differences seem to 
take place [82,83]. Taken together, these enigmatic observations made us wonder if the 
ruthenium-core of CORM-2 could be held responsible as it is the most apparent difference 
between CORM-2 and CO as such. 
So far, the influence of ruthenium on vascular tone had never been studied. Therefore we 
tested the vasorelaxant capacity of some ruthenium compounds in vitro. RuCl3, Ruthenium 
Red, CORM-2 and RuCl2(DMSO)4 all induced relaxation of mice aorta ring segments to some 
extent, though the potency of each compound varied greatly. Both RuCl3 and Ruthenium Red 
showed a pronounced vasorelaxing effect whereas the effect of RuCl2(DMSO)4 was quite 
limited. Because of the surprising marked vasorelaxation by RuCl3, we focused more on its 
effects in the following experiments. After all, only one other study had described a 
vasoactive effect of RuCl3, but in contrast to our results they reported that RuCl3 induced a 
limited contractile effect instead of a vasorelaxtion [84]. In the search for an explanation of 
these opposing observations, we noticed a difference in the experimental setup. Alshehri et 
al. used phenylephrine to contract the aortic ring segments whereas we used 
norepinephrine (NOR) in our in vitro model [84]. Although both vasoconstrictors are  
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α1-adrenergic agonist, this difference in contractile agents could possibly clarify the 
conflicting results. The large relaxant effect of RuCl3, which occurs when the tissues are 
contracted with NOR, appeared to be absent when contracting the mice aortic rings with 
phenylephrine. Moreover, the RuCl3-induced relaxation was also abolished when contraction 
was evoked by serotonin, PGF2α, the thromboxane A2 mimetic U46619 or a high K
+ 
concentration. This specificity of the RuCl3 effect towards NOR could not be explained by an 
alteration of the α1-adrenergic pathways nor by cell death mechanisms. However, NOR is 
known for its sensitivity to oxidative degradation by heavy metals. Gradual decomposition of 
NOR will affect its contractile capacity and thus will lead to vasorelaxation. It has also been 
demonstrated that antioxidants can prevent this oxidative degradation and subsequent loss 
of contraction [85]. Our data have shown that ascorbic acid as well as N-acetyl L-cysteine, 
both powerful antioxidants, are able to counteract the RuCl3 effect on NOR-contracted aorta 
ring segments confirming our hypothesis that RuCl3 undermines the contractile activity of 
NOR by oxidative degradation. Any change in NOR activity will alter the tightly regulated 
balance of vascular tone as it is the most important neurotransmitter of the 
orthosympathetic nervous system. Consequently, the detrimental influence of ruthenium on 
NOR-induced tone should be taken into account when studying ruthenium-based 
compounds. Nevertheless, future research will have to address to which extent these 
ruthenium effects take part in the effects of the various ruthenium complexes that are still 
designed, produced and tested nowadays. Hence, stability experiments will be necessary to 
determine ìf ruthenium is actually liberated during solubilization, degradation, ligand 
exchange, etc. and to what degree. 
As described before, various disease states are characterized by an impairment of  
NO-bioavailability. On the other hand, many other pathological conditions involve an 
overproduction of NO. High levels of NO can trigger both oxidative and nitrosative stress by 
formation of peroxynitrite and dinitrogen trioxide. Subsequently, these stress conditions will 
result in DNA damage and nitration of proteins which are responsible for the deleterious 
effects of excessive NO [86,87]. A number of neurodegenerative diseases such as 
Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and Huntington’s 
disease are believed to be caused in part by an increase in nitrosative stress in neurons [88]. 
Furthermore, an overproduction of NO has been associated with acute and chronic 
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inflammatory states such as septic shock [89,90]. While NOS inhibitors can be used to lower 
the synthesis of NO, an alternative therapeutic approach would be to remove or scavenge 
the excess NO [91]. An advantage of this strategy is that the rate of NO scavenging depends 
on both the concentration of NO and of the scavenger, meaning that for a given scavenger 
concentration scavenging occurs at a faster rate when the NO concentration is elevated. In 
contrast, NOS inhibitors alter NO production regardless of whether the NO production is 
high or low [92]. Ruthenium is able to form a stable interaction with NO creating nitrosyl 
complexes. Moreover, the broad coordination chemistry of ruthenium makes it perfectly 
suitable to modulate its properties to develop an effective NO scavenger. Some ruthenium 
polyaminocarboxylate complexes have already shown to be efficient and effective 
scavengers of NO [92-95]. Although NO removal is the goal in case of NO overproduction, 
this scavenging of NO would be an undesired side effect of therapeutics used in case of 
impaired NO-bioavailability, including ruthenium-based (NO- and) CO-donors. After all, these 
(NO- and) CO-donating molecules are applied to compensate the lost NO-bioavailability 
which means that scavenging of the remaining endogenous NO would seriously limit the 
therapeutic value of these drugs. It was already reported that CORM-2 lowers NO donor-
induced rat aorta relaxations which was partially explained through quenching of NO by the 
transition metal complex [96]. CORM-2 as well as RuCl3 have also shown to inhibit 
exogenous NO relaxations in murine gastric fundus, whereas endogenous NO responses by 
electrical field stimulation remained unaffected [97]. On the contrary, in rat aorta RuCl3 
seemed to attenuate both acetylcholine (ACh) and sodium nitroprusside(SNP) relaxations, 
while CORM-3 only reduced the ACh responses [84]. To get some more insight on the 
influence of ruthenium on NO-mediated relaxations, we examined the effect of RuCl3, 
RuCl2(DMSO)4 and [RuCl2(CO)3]2 (= CORM-2) on endogenous (ACh) as well as exogenous 
(SNP) NO-induced responses. Incubation with CORM-2 diminished both ACh- and SNP-
induced relaxations. In contrast, RuCl3 only altered the SNP effect, whereas RuCl2(DMSO)4 
had even no effect on the NO responses. Neither scavenging of NO by ruthenium nor other 
hypotheses such as partial agonism by CO and quenching of NO by formation of reactive 
oxygen species could fully explain these inconclusive results regarding the effect of 
ruthenium compounds on NO-induced relaxation. Nevertheless, it must be noted that in 
future research on ruthenium-based therapeutics this potentially unwanted side effect 
should be taken into account.  
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In general one could say that ruthenium seems to be a good candidate for the design of 
drugs, including NO- and CO-delivering agents. A wide range of ruthenium-based NO- and 
CO-containing compounds have already shown to exert a substantial (vaso)relaxant effect 
and therefore could be viewed as a possible therapeutic strategy for the treatment of 
cardiovascular diseases and/or ED. Although the results are promising, the path towards 
ruthenium-based NO and/or CO- therapy is long and many obstacles need to be overcome. 
Besides their proven efficacy, the effectiveness, safety and feasibility of these compounds 
need to be addressed. As can be concluded from our data, in future studies on ruthenium-
containing molecules, the influence on sympathetic vascular tone and the possible  
NO-scavenging (side) effects should always be kept in mind. Luckily, the unique physico-
chemical features of ruthenium-based metallocomplexes offer more control of their 
pharmacokinetic and pharmacodynamic properties. Moreover, due to their great structural 
variety, rational design of these compounds could potentially result in drugs which aim for 
specific (molecular) targets. This can be of interest for instance in the development of new 
treatments of ED. From compounds which relax corporal smooth muscles, it can be expected 
that they exert undesired cardiovascular (side) effects as a result of a generalized relaxation 
of vascular smooth muscles. Hence, modulation of these compounds in a way that they 
more specifically target erectile tissue would have a positive impact on efficacy as well as 
safety. Anyhow, to date ruthenium-based metallocomplexes still remain a hot topic. The 
search for new alternatives is still ongoing as each day more and more compounds are 
produced and tested.  
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VIII.1 Supplementary data of oximes in sGCβ1 knock-in mice 
 
Supplementary figure 1: The effect of formaldoxime (FAL) and formamidoxime (FAM) in thoracic aorta (A and 
B); in femoral artery (C and D) and in corpora cavernosa (E and F) from wild-type control (sGCβ1
+/+
) () and 
genetically modified knock-in (sGCβ1
ki/ki
) () mice. Data are expressed as % relaxation of the norepinephrine 
(NOR)-induced tone (N = 5-6); *P<0.05 and #P<0.01 
 
In the artery ring segments of sGCβ1
ki/ki mice, the FAL response is significantly reduced, 
whereas the FAM effect is even completely abolished (Suppl. fig. 1 A-D). The FAM effect is 
also diminished in sGCβ1
ki/ki corpora cavernosa but no difference was observed in the FAL 
relaxations of sGCβ1
ki/ki and sGCβ1
+/+ corpora cavernosa (Suppl. fig. 1 E-F). When comparing 
the result of the sGCβ1
ki/ki mice with our results in the genetically modified sGCα1
-/- mice, the 
FAL response is significantly lower in the sGCβ1
ki/ki mice both in aorta (maximal effect  
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sGCα1
-/-: 52.16 % ± 1.87 vs sGCβ1
ki/ki: 14.00 % ± 2.95; p = 0.011) and femoral artery (maximal 
effect sGCα1
-/-: 44.14 % ± 8.60 vs sGCβ1
ki/ki: 19.49 % ± 3.98; p = 0.033). Furthermore, also a 
significantly lower FAM effect is seen in aorta (maximal effect sGCα1
-/-: 21.87 % ± 2.20 vs 
sGCβ1
ki/ki: 1.79 % ± 0.63; p = 0.004) as well as femoral artery (maximal effect  
sGCα1
-/-: 41.25 % ± 2.74 vs sGCβ1
ki/ki: 18.29 % ± 3.13; p = 0.004) of the sGCβ1
ki/ki mice. In 
contrast, the FAL- and FAM-induced relaxations in the corpora cavernosa do not differ 
between sGCα1
-/- and sGCβ1
ki/ki mice. 
 
 
VIII.2 Supplementary data of ruthenium-based NO-donating molecules 
VIII.2.1 [Ru(terpy)(bdq)NO]3+ 
 
Supplementary figure 2: The effect of [Ru(terpy)(bdq)NO]
3+
 (=TERPY) () versus vehicle control () in thoracic 
aorta (A); in femoral artery (B) and in corpora cavernosa (C) from Swiss mice. Data are expressed as  
% relaxation of the phenylephrine-induced tone (N = 4-7); *P<0.05 and #P<0.01 
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TERPY strongly induces vasorelaxation of mice aorta ring segments with a maximal effect of  
85.71 % ± 3,36 at 10 µmol/L. Although less potent, TERPY also significantly relaxes mice 
femoral artery ring segments with a maximal effect of 65.09 % ± 7,82. In contrast, the effect 
of TERPY in the mice corpora cavernosa does not significantly differ from the vehicle control 
condition. 
 
VIII.2.2 5 Cis-[Ru(bpy)2(py)NO2](PF6) 
 
Supplementary figure 3: The effect of cis-[Ru(bpy)2(py)NO2](PF6) (= RuBPY) () versus vehicle control () in 
thoracic aorta (A); in femoral artery (B) and in corpora cavernosa (C) from Swiss mice. Data are expressed as  
% relaxation of the phenylephrine-induced tone (N = 4-7); *P<0.05 and #P<0.01 
 
As with TERPY, RuBPY induces a significant vasorelaxant effect in mice aorta ring segments 
with a maximal effect of 87.58 % ± 1,50 at 10 µmol/L. Furthermore, RuBPY elicits a 
pronounced vasorelaxant of mice femoral artery ring segments with a maximal effect of 
68.42 % ± 7,34. Surprisingly, in the mice corpora cavernosa also the effect of RuPBY does not 
significantly differ from the vehicle control condition. 
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Ever since nitric oxide (NO) was discovered as being the vascular endothelial-derived relaxing 
factor in the 1980s, an enormous amount of research has been done to enlarge our 
knowledge on this vital signaling molecule. Given the importance of NO in the normal human 
physiology, it is not surprising that several pathological conditions are characterized by an 
impairment of NO-bioavailability. A better understanding of the molecular pathways 
underlying the various physiological effects of NO has led to the unraveling of new 
therapeutic targets and the subsequent development of diverse treatment strategies. For 
instance, nitrates are being used as NO donating compounds for many years now to 
compensate the loss of NO functioning in some cardiovascular disorders. Likewise, 
phosphodiesterase (PDE) type 5 inhibitors are used as a treatment for erectile dysfunction 
(ED) to slow down the degradation of cGMP further downstream in the NO signal 
transduction cascade. This enables sufficient penile erection in case of lowered NO 
availability. Although in theory these therapies seem perfect, in reality their therapeutic 
value is limited by a few drawbacks. After long term usage of nitrates, a well-known 
attenuation of their effect occurs due to the development of tolerance. Moreover, even 
though efficacy and safety of PDE type 5 inhibitors have been proven in large clinical trials, 
up to 35 % of the patients fail to respond adequately. In this light, the urge for new and 
better alternatives still remains.  
 
Because of their NO-releasing capacities, oxime derivatives have been presented as a new 
group of vasodilatory compounds. As a first aim of this thesis we wanted to find out if these 
compounds were also able to elicit relaxation of corpora cavernosa (CC) besides their known 
vasorelaxing effect on arterial ring segments (Chapter IV). Formaldoxime (FAL) and 
formamidoxime (FAM), both non-aromatic oximes, concentration-dependently relaxed mice 
corporal tissue. In the search for the underlying mechanism(s), it became evident that the 
molecular pathways activated by FAL and FAM in the arteries clearly differ from those in the 
CC. For the FAL-/FAM-induced relaxation of mice aorta and femoral artery, we suggested the 
involvement of (a) NO synthase (NOS)- and endothelium-independent, but NADPH-CYP450 
reductase-dependent mechanism(s) with subsequent release of NO or a NO-related 
compound and activation of soluble guanylyl cyclase (sGC). However, in the CC only 
independence of NOS and the endothelium as well as a limited contribution of sGC was 
proven. 
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To further explore the role of sGC as well as the relative importance of the two active sGC 
isoforms in the FAL-/FAM-induced relaxations, we used genetically modified mice (Chapter V 
and supplementary data). A deletion in the catalytic domain of the sGCα1 subunit in the 
sGCα1
-/- knock-out mice selectively inactivates the sGCα1β1 isoform. In these mice, the effect 
of FAL and FAM was significantly lower as compared to their wild-type controls. The FAL and 
FAM response was even further diminished in the sGCβ1
ki/ki knock-in mice, in which a 
mutation of the histidine 105 residue alters both sGC isoforms. Thus, in addition to the 
sGCα1β1 isoform also the sGCα2β1 isoform seems to be involved in FAL-/FAM-induced 
relaxations. 
Besides their effect in normal physiological conditions, we also tested the effect of FAL and 
FAM in case of oxidative stress as it is often associated with various disease states including 
ED (Chapter V). In contrast to neuronal, endogenous and other exogenous NO-induced 
corporal relaxations, both FAL and FAM did not seem to be susceptible to oxidative stress. 
Taken together with the NOS- and endothelium-independence of their effect, FAL and FAM 
offer some promising perspectives as alternative ED treatment strategy. 
Although in vitro experiments try to mimic ‘real life’ conditions, in vitro efficacy does not 
necessarily imply effects in vivo. Therefore, we performed an in vivo study in which blood 
pressure and intracavernosal pressure were monitored after intravenous or intracavernosal 
injection of FAL/FAM (Chapter V). Our results showed that FAL and FAM dose-dependently 
decrease blood pressure. Moreover, both compounds elicit a distinct increase of 
intracavernosal pressure after intracavernosal injection. Furthermore, experiments with the 
sGCα1
-/- knock-out mice indicated that the effects of FAL/FAM on blood pressure and 
intracavernosal pressure are (partly) mediated by the sGCα1β1 isoform. 
Multiple studies have already suggested that ruthenium based NO- and carbon monoxide 
(CO)-releasing molecules (CORMs) could be suitable alternatives for current NO-related 
therapy. Because of its favorable features, ruthenium seemed to be a perfect candidate for 
the design of such NO- and CO-delivery agents. To date, the effect of ruthenium as such on 
vascular tone was not tested yet. Therefore we examined the influence of various 
ruthenium-containing compounds on contraction and NO-induced relaxation of aortic ring 
segments (Chapter VI). Of these ruthenium based molecules, RuCl3 presented the most 
Summary 
 
167 
marked vasorelaxing effect. However, this effect was limited to tissues contracted with 
norepinephrine (NOR) as RuCl3 did not alter contraction evoked by serotonin, PGF2α, U46619 
or a high K+ concentration. The specificity towards NOR was explained by the sensitivity of 
NOR for RuCl3-induced oxidative degradation which undermines its contractile activity. 
Furthermore we demonstrated that some ruthenium based compounds are able to diminish  
NO-mediated relaxations which can possibly be viewed as an undesired side effect of  
NO- and CO-releasing therapeutics.  
Conclusions. Although the exact mechanism(s) of the FAL-/FAM-induced effects in penile 
tissue remain(s) elusive, both our in vitro and in vivo experiments showed that FAL and FAM 
could be useful as alternative treatment for ED. However, future research will be necessary 
to fully explore their therapeutic potential. Furthermore we can conclude that ruthenium 
seems ideal for the design of drugs, including NO- and CO-releasing molecules. Nevertheless, 
it should always be kept in mind that ruthenium as such can exert an influence on 
sympathetic vascular tone and can present NO-scavenging (side) effects. 
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Sinds stikstofmonoxide (NO) ontdekt werd in de jaren ‘80 als de vasculaire relaxerende 
factor die door het endotheel wordt vrijgesteld, is reeds zeer veel onderzoek verricht om 
onze kennis omtrent deze essentiële signaalmolecule te vergroten. Gezien het belang van 
NO in de normale fysiologie van de mens, is het niet verwonderlijk dat verschillende 
pathologieën gekenmerkt worden door een verstoring in de biologische beschikbaarheid van 
NO. Een beter inzicht in de moleculaire mechanismen die aan de basis liggen van de talrijke 
fysiologische NO effecten heeft geleid tot het ontrafelen van nieuwe therapeutische doelen 
en de daaropvolgende ontwikkeling van diverse behandelingsstrategieën. Nitraten worden 
bijvoorbeeld al vele jaren gebruikt als NO-donerende componenten om het verlies aan  
NO functie in bepaalde cardiovasculaire aandoeningen te compenseren. Evenzo worden 
fosfodiësterase (PDE) type 5 inhibitoren gebruikt voor de behandeling van erectiele 
disfunctie (ED). Deze PDE type 5 inhibitoren remmen de afbraak van cGMP verderop in de 
NO signaal transductiecascade en zorgen op die manier voor voldoende erectie van de penis 
in geval van een verlaagde NO beschikbaarheid. Hoewel in theorie deze therapieën perfect 
lijken, is er in realiteit ook een keerzijde aan de medaille die hun therapeutische waarde 
limiteert. Na langdurig gebruik van nitraten treedt er immers vermindering op van hun effect 
door het ontwikkelen van tolerantie. Bovendien reageert tot 35 % van de patiënten 
onvoldoende op PDE type 5 inhibitoren, hoewel hun effect en veiligheid reeds aangetoond 
werd in grote klinische studies. In dit opzicht blijft het noodzakelijk om op zoek te gaan naar 
nieuwere en betere alternatieven. 
Omwille van hun vermogen om NO vrij te stellen, werden oxime derivaten voorgesteld als 
een nieuwe groep van vasodilaterende stoffen. Als eerste doel van deze thesis onderzochten 
we of deze moleculen, naast hun gekende vasorelaxerende effect op arteriële 
ringsegmenten, ook in staat zijn om relaxatie van de corpora cavernosa (CC) teweeg te 
brengen (Hoofdstuk IV). Formaldoxime (FAL) en formamidoxime (FAM), beide niet-
aromatische oximes, relaxeerden corporaal weefsel van de muis op een concentratie-
afhankelijke manier. In de zoektocht naar de onderliggende mechanismen werd het duidelijk 
dat de moleculaire mechanismen die geactiveerd worden door FAL en FAM in de arteriën in 
sterke mate verschillen van deze in de CC. Voor de FAL-/FAM-geïnduceerde relaxatie van 
muis aorta en femorale arterie suggereerden we de betrokkenheid van een NO synthase 
(NOS)- en endotheel-onafhankelijk, maar NADPH-CYP450 reductase-afhankelijk mechanisme 
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met daaropvolgend de vrijstelling van NO of een NO-gerelateerde component en de 
activatie van het oplosbaar guanylaat cyclase (sGC). In de CC daarentegen werd enkel 
onafhankelijkheid van NOS en van het endotheel aangetoond alsook een beperkte bijdrage 
van het sGC. 
Om verder de rol van het sGC alsook het relatieve belang van de twee actieve sGC isovormen 
in de FAL-/FAM-geïnduceerde relaxaties te onderzoeken, maakten we gebruik van genetisch 
gemodificeerde muizen (Hoofdstuk V en supplementaire data). Een deletie in het 
katalytische domein van de α1 subeenheid van sGC in de sGCα1
-/- knock-out muizen 
inactiveert selectief de sGCα1β1 isovorm. In deze muizen was het effect van FAL en FAM 
significant lager in vergelijking met hun wild-type controles. De FAL en FAM respons was 
bovendien in nog sterkere mate verminderd in de sGCβ1
ki/ki knock-in muizen bij dewelke 
beide isovormen beïnvloed worden door een mutatie van het histidine 105 residu. Bijgevolg 
lijkt niet alleen de sGCα1β1 isovorm maar ook de sGCα2β1 isovorm betrokken bij de  
FAL-/FAM-geïnduceerde relaxaties.  
Naast hun effect onder normale fysiologische omstandigheden hebben we ook het effect 
van FAL en FAM getest in geval van oxidatieve stress aangezien dit vaak geassocieerd wordt 
met verschillende ziektetoestanden waaronder ED (Hoofdstuk V). In tegenstelling tot de 
neuronale, endogene en andere exogene NO-geïnduceerde corporale relaxaties, leken zowel 
FAL als FAM niet gevoelig voor oxidatieve stress. In combinatie met de NOS- en 
endotheelonafhankelijkheid van hun effect bieden FAL en FAM enkele veelbelovende 
perspectieven als alternatieve behandelingsstrategie voor ED. 
Hoewel in vitro experimenten zoveel mogelijk de fysiologische omstandigheden trachten na 
te bootsen, impliceert werkzaamheid in vitro niet noodzakelijk effecten in vivo. Daarom 
voerden we een in vivo studie uit in dewelke bloeddruk en intracaverneuze druk werden 
gemeten na intraveneuze of intracaverneuze injectie van FAL/FAM (Hoofdstuk V). Onze 
resultaten wezen uit dat FAL en FAM de bloeddruk verlagen op een dosis-afhankelijke 
manier. Bovendien lokken beide componenten een uitgesproken toename uit van de 
intracaverneuze druk na intracaverneuze injectie. Verder toonden experimenten met de 
sGCα1
-/- knock-out muizen aan dat de effecten van FAL/FAM op bloeddruk en 
intracaverneuze druk (gedeeltelijk) gemedieerd zijn door de sGCα1β1 isovorm. 
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Meerdere studies hebben reeds aangegeven dat NO- en koolstofmonoxide (CO)-vrijstellende 
moleculen op basis van ruthenium geschikt kunnen zijn als alternatieve 
behandelingsstrategie voor huidige NO-gerelateerde therapie. Omwille van zijn gunstige 
eigenschappen bleek ruthenium een geschikte kandidaat te zijn voor het ontwikkelen van 
dergelijke NO- en CO-vrijstellende middelen. Tot op de dag van vandaag werd echter het 
effect van ruthenium zelf op de vasculaire tonus nog niet getest. Daarom bestudeerden we 
de invloed van verschillende componenten die ruthenium bevatten op de contractie en  
NO-geïnduceerde relaxatie van aorta ringsegmenten (Hoofdstuk VI). Van deze moleculen op 
basis van ruthenium vertoonde RuCl3 het meest uitgesproken vasorelaxerende effect. Dit 
effect was echter beperkt tot weefsels die gecontraheerd werden met norepinefrine (NOR), 
daar RuCl3 de contractie uitgelokt door serotonine, PGF2α, U46619 of een hoge K
+ 
concentratie niet beïnvloedde. Deze specificiteit ten opzichte van NOR werd verklaard door 
de gevoeligheid van NOR voor RuCl3-geïnduceerde oxidatieve degradatie dewelke zijn 
contractiecapaciteit ondermijnt. Daarnaast toonden we aan dat enkele stoffen gebaseerd op 
ruthenium in staat zijn om NO-gemedieerde relaxaties te verminderen wat mogelijks 
beschouwd kan worden als een ongewenst neveneffect van therapeutica die NO of CO 
vrijstellen. 
Conclusies. Ondanks het feit dat de exacte mechanismen van de FAL-/FAM-geïnduceerde 
effecten in de penis nog onbekend blijven, toonden zowel onze in vitro als in vivo 
experimenten aan dat FAL en FAM mogelijks nuttig kunnen zijn als alternatieve behandeling 
van ED. Toekomstig onderzoek zal echter noodzakelijk zijn om hun therapeutisch potentieel 
volledig op te helderen. Daarnaast kunnen we besluiten dat ruthenium geschikt lijkt voor het 
ontwikkelen van geneesmiddelen waaronder moleculen die NO of CO vrijstellen. 
Desalniettemin moet men er altijd rekening mee houden dat ruthenium zelf een invloed kan 
uitoefenen op de sympathische vasculaire tonus alsook NO-capterende (neven)werkingen 
kan vertonen. 
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